<SEC-DOCUMENT>0000320017-16-000152.txt : 20160915
<SEC-HEADER>0000320017-16-000152.hdr.sgml : 20160915
<ACCEPTANCE-DATETIME>20160915162013
ACCESSION NUMBER:		0000320017-16-000152
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20160915
DATE AS OF CHANGE:		20160915

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Caladrius Biosciences, Inc.
		CENTRAL INDEX KEY:			0000320017
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		IRS NUMBER:				222343568
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-206175
		FILM NUMBER:		161887369

	BUSINESS ADDRESS:	
		STREET 1:		106 ALLEN ROAD
		STREET 2:		FOURTH FLOOR
		CITY:			BASKING RIDGE
		STATE:			NJ
		ZIP:			07920
		BUSINESS PHONE:		908-842-0100

	MAIL ADDRESS:	
		STREET 1:		106 ALLEN ROAD
		STREET 2:		FOURTH FLOOR
		CITY:			BASKING RIDGE
		STATE:			NJ
		ZIP:			07920

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NeoStem, Inc.
		DATE OF NAME CHANGE:	20060906

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHASE III MEDICAL INC/DE
		DATE OF NAME CHANGE:	20030819

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CORNICHE GROUP INC /DE
		DATE OF NAME CHANGE:	19951117
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>prosuppseptember2016.htm
<DESCRIPTION>424B5 SEPTEMBER 2016
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s141A9C0606C433CDA74CCE2655152BDF"></a></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Filed Pursuant to Rule 424(b)(5)</font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Registration No. 333-206175</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PROSPECTUS SUPPLEMENT</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(To Prospectus dated </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">August&#160;28, 2015</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">847,458</font><font style="font-family:inherit;font-size:14pt;font-weight:bold;">&#32;Shares of Common Stock</font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:center;"><img src="caladriuslogoa03.jpg" alt="caladriuslogoa03.jpg" style="height:77px;width:200px;"></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to this prospectus supplement and the accompanying prospectus, we are offering up to </font><font style="font-family:inherit;font-size:10pt;">847,458</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock, at a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$4.72</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, to a single institutional investor. In a concurrent private placement, we are selling to certain accredited investors with whom we had a substantive, pre-existing relationship, including certain existing stockholders, up to </font><font style="font-family:inherit;font-size:10pt;">4,449,153</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock, at a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$4.72</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, in two tranches. The shares of common stock being offered in the concurrent private placement are not being registered under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), are not being offered pursuant to this prospectus supplement and the accompanying prospectus and are being offered pursuant to the exemption provided in Section&#160;4(a)(2) under the Securities Act and Rule 506 promulgated thereunder.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our common stock is listed on The NASDAQ Capital Market under the symbol &#8220;CLBS.&#8221; On September 13, 2016, the last reported sale price of our common stock was $4.72 per share.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of September 13, 2016, the aggregate market value of our outstanding common stock held by non-affiliates was approximately $34.9 million, based on 5,914,380&#160;shares of outstanding common stock, of which 385,777&#160;were held by affiliates, and a per share price of $6.31 based on the closing price of our common stock on August 4, 2016. During the prior twelve calendar month period that ends on the date of this prospectus supplement, and including this offering, we have offered securities with an aggregate market value of approximately $4.0 million&#160;pursuant to General Instruction I.B.6 on Form S-3.</font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Our business and an investment in our securities involve significant risks. See &#8220;Risk Factors&#8221; beginning on page S-5 of this prospectus supplement and page 3 of the accompanying prospectus to read about factors that you should consider before making an investment decision.</font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.5078125%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:52%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Offering price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000,001.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds to us, before expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.72</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000,001.76</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Delivery of the shares of common stock is expected to be made on or about </font><font style="font-family:inherit;font-size:10pt;">September&#160;14, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The date of this prospectus supplement is </font><font style="font-family:inherit;font-size:10pt;">September&#160;14, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><hr style="page-break-after:always"><div><a name="s00E1A204B5C7407E2E2FCE2655477062"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:86%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Page</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PROSPECTUS SUPPLEMENT</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">About this Prospectus Supplement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2D6C7EC7EFAFA837FF60CE26559AC30A">S - 1</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prospectus Supplement Summary</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5A477968AF48D1784798CE2655BB2F7F">S - 2</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk Factors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFE5BCE0A5A61D8638EC8CE2655EEBEEE">S - 5</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Special Note Regarding Forward-Looking Statements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6B48A5AC25DD603C750FCE26560F42B4">S - 8</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Use of Proceeds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4B43297C85CBDAA3C932CE2656426AD0">S - 9</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capitalization</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB79BB18B4D80D3369F0BCE2656635A8D">S - 10</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilution</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3AF76C2A4915C8211696CE26569778F6">S - 11</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Price Range of Common Stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB306F9DAB13A2266B7EBCE2656B567A7">S - 12</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Plan of Distribution</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s41EB28C95B84D28DE794CE2657091550">S - 13</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Private Placement Transaction</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2502ce5f605c4032b1d3e3c41fa8ac17">S - 14</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Legal Matters</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB555CD0F5E5E5DCDE68DCE26573B53EF">S - 15</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Experts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA41DBEAA00A11516E3D8CE26575CC230">S - 15</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Where You Can Find Additional Information</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3C0A447F6175815FBABCCE26578FE555">S - 15</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incorporation of Certain Documents by Reference</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s506EE702B808BD57A5A1CE2657AFAB1E">S - 15</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PROSPECTUS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">About this Prospectus</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-align:center;" href="#s5581A36842D65E8177F4CE2658032E02">1</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">About Caladrius</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-align:center;" href="#sAF3FD15235E89592DCD4CE2658355A95">2</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk Factors</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-align:center;" href="#s870EFA14731970BCD53DCE265856F63B">3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Special Note Regarding Forward-Looking Information</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-align:center;" href="#s0B6AEA4E36028BA1BD04CE2658887272">3</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Use of Proceeds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9C5AEAA27A0E3B1AA6DDCE2658A9CC30">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Securities We May Offer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8DEFA18E771732932DD8CE2658DC55B2">4</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Description of Capital Stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5D9EEA0F41B9D9C7C5A0CE2658FE4794">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Description of Debt Securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB9E8521609CD6DF3570FCE265950558B">18</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Description of Warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s35B54A6EEBE67EBA464CCE26599D1FEB">33</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Description of Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sADBD0914C3F91EFA8C03CE2659AAAFDF">34</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Plan of Distribution</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3BF366E811167E9F533CCE2659B494FA">35</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Legal Matters</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s70B8CEB53225FE292CA8CE2659D5DAD2">38</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Experts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCBEAD6294FCDF2870CFFCE2659F75A94">38</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incorporation of Certain Documents by Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1C79E160D21613661EA9CE265A297469">38</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Where You Can Find More Information</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5C11D9F2D7F5A02F8F76CE265A4A4652">39</a></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160; </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">- i -</font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sECCAFFFA8DBB589CFD5ECE265570C0E2"></a></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s2D6C7EC7EFAFA837FF60CE26559AC30A"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ABOUT THIS PROSPECTUS SUPPLEMENT </font></div><div style="line-height:120%;text-align:left;text-indent:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This document is in two parts. The first part is this prospectus supplement describes the specific terms of the offering and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement and the accompanying prospectus. The second part, the accompanying prospectus dated August 28, 2015, including the documents incorporated by reference, provides more general information. Generally, when we refer to this prospectus, we are referring to both parts of this document combined. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or in any document incorporated by reference that was filed with the Securities and Exchange Commission (the "SEC") before the date of this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement. If any statement in one of these documents is inconsistent with a statement in another document having a later date - for example, a document incorporated by reference in the accompanying prospectus - the statement in the document having the later date modifies or supersedes the earlier statement. You should read this prospectus supplement and the accompanying prospectus, including the information incorporated by reference and any free writing prospectus that we have authorized for use in connection with this offering, in their entirety before making an investment decision.</font></div><div style="line-height:120%;text-align:justify;text-indent:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">You should rely only on the information contained or incorporated by reference in this prospectus supplement and the accompanying prospectus, along with the information contained in any free writing prospectus that we have authorized for use in connection with this offering. If the description of the offering varies between this prospectus supplement and the accompanying prospectus, you should rely on the information in this prospectus supplement. We have not authorized anyone to provide you with different or additional information. You should assume that the information appearing in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference in this prospectus supplement and the accompanying prospectus, and in any free writing prospectus that we have authorized for use in connection with this offering, is accurate only as of the respective dates of those documents. Our business, financial condition, results of operations and prospects may have changed since those dates.</font></div><div style="line-height:120%;text-align:justify;text-indent:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference in this prospectus supplement or the accompanying prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties and covenants were accurate only as of the date when made; therefore, such representations, warranties and covenants should not be relied on as accurate representations of the current state of our affairs.</font></div><div style="line-height:120%;text-align:justify;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This prospectus supplement, the accompanying prospectus and the information incorporated by reference includes trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included or incorporated by reference into this prospectus supplement or the accompanying prospectus are the property of their respective owners.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S - 1</font></div></div><hr style="page-break-after:always"><div><a name="s5A477968AF48D1784798CE2655BB2F7F"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;PROSPECTUS SUPPLEMENT SUMMARY </font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">This summary highlights certain information about us, this offering and information appearing elsewhere in this prospectus supplement, in the accompanying prospectus and in the documents we incorporate by reference. This summary is not complete and does not contain all of the information that you should consider before making an investment decision. To fully understand this offering and its consequences to you, you should read this entire prospectus supplement and the accompanying prospectus carefully, including the factors described under the heading &#8220;Risk Factors&#8221; in this prospectus supplement beginning on page S-5 and page 3 of the accompanying prospectus, together with any free writing prospectus we have authorized for use in connection with this offering and the financial statements and all other information incorporated by reference in this prospectus supplement and the accompanying prospectus. When used in this prospectus supplement and the accompanying prospectus, except where the context otherwise requires, the terms &#8220;Caladrius,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Caladrius Biosciences, Inc. and its subsidiaries.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;About Caladrius Biosciences, Inc.</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Caladrius Biosciences, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; "our," &#8220;Caladrius&#8221; or the &#8220;Company&#8221;), through its subsidiary, PCT, LLC, a Caladrius Company</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM&#160;</sup></font><font style="font-family:inherit;font-size:10pt;">("PCT"), is a leading provider of development and manufacturing services to the cell and cell-based gene therapy industry. PCT has significant cell therapy-specific experience and expertise, an expansive list of noteworthy clients and significant revenue growth over the past two years. Notably, PCT and Hitachi Chemical Co. America, Ltd. and Hitachi Chemical Co., Ltd. (each independently or collectively referred to herein as "Hitachi Chemical") entered into a strategic collaboration to accelerate the creation of a global commercial cell therapy development and manufacturing enterprise with deep engineering expertise. Caladrius leverages both its internal specialized cell therapy clinical development expertise and PCT&#8217;s prowess to select and develop early-stage cell therapy candidates with the intention of partnering these candidates post proof-of-concept in man to both generate value for our shareholders and to expand PCT&#8217;s client base. Our current product candidate, CLBS03, is a T regulatory cell (&#8220;Treg&#8221;) clinical Phase 2 therapy targeting adolescents with recent-onset type 1 diabetes.</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cell Therapy Development and Manufacturing</font></div><div style="text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PCT is a leading cell therapy development and manufacturing provider (often called a contract development and manufacturing organization, or "CDMO"), specializing in cell and cell-based gene therapies. PCT offers high-quality development and manufacturing capabilities (e.g., current Good Manufacturing Practice (&#8220;cGMP&#8221;) manufacturing systems and facilities), quality systems, cell and tissue processing, logistics, storage and distribution and engineering solutions (e.g., process and assay development, optimization and automation) to clients with therapeutic candidates at all stages of development. PCT produces clinical supplies and ultimately, intends also to produce commercial product for its clients. PCT has worked with over&#160;100&#160;clients and produced over&#160;20,000&#160;cell therapy products since it was founded&#160;17&#160;years ago. PCT&#8217;s manufacturing services are designed to reduce the capital investment and time required by clients to advance their development programs compared to conducting the process development and manufacturing in-house. PCT has demonstrated regulatory expertise, including the support of over&#160;50&#160;U.S. and European Union ("EU") regulatory filings for clients and expertise across multiple cell types and therapeutic applications, including immunotherapy (e.g. CAR-T therapies), neuro/endocrine therapies, hematopoietic replacement and tissue repair/regeneration. PCT offers a complete development pathway for its clients, with services supporting preclinical through commercial phase, all underpinned by timely process optimization and automation support. We currently operate facilities qualified under cGMPs in each of Allendale, New Jersey and Mountain View, California, including EU-grade production suites. On March 11, 2016, PCT entered into a strategic collaboration and license agreement with Hitachi Chemical to accelerate the creation of a global commercial cell therapy development and manufacturing enterprise with deep engineering expertise. PCT is positioned to expand its capacity both in the United States and internationally, as needed. As the industry continues to mature and a growing number of cell therapy companies approach commercialization, we believe that PCT is well positioned to serve as an external manufacturing partner of choice for commercial-stage cell therapy companies.</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">CLBS03</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are developing, through the utilization of our core development and manufacturing expertise, a product candidate that is an innovative therapy for type 1 diabetes mellitus (&#8220;TID&#8221;). This therapy is based on a proprietary platform technology for immunomodulation. We have selected as an initial target the unmet medical need of pediatric patients who are newly diagnosed with T1D. This program is based on the use of Tregs to treat diseases caused by imbalances in an individual's immune system. This novel approach seeks to restore immune balance by enhancing Treg number and function. Tregs are a natural part of the human immune system and regulate the activity of T effector cells; the cells that are responsible for protecting the body from viruses and other foreign antigens. When Tregs function properly, only harmful foreign materials are attacked by T effector cells. In autoimmune disease, however, it is thought that deficient Treg activity and numbers permit the T effector cells to attack the body's own beneficial cells. In the case of T1D, there are currently no curative treatments, only lifelong insulin therapy, which often does not prevent serious co-morbidities. Two Phase 1 clinical trials of this technology in T1D patients demonstrated safety and tolerance, feasibility of manufacturing, an implied durability of effect and an early indication of efficacy through the preservation of beta cell function. In the first quarter of 2016 we commenced patient enrollment in the first of two cohorts in The Sanford Project: T-Rex Study, a Phase 2 prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate the safety and efficacy of our Treg product candidate, CLBS03, in adolescents with recent onset T1D. After the follow-up of the first cohort of 18 patients, which is expected by year end 2016, an initial safety analysis of the data and early analysis of immunological biomarkers will be undertaken. Satisfactory evaluation of the safety of the initial cohort as agreed by us, our independent Data Safety Monitoring Board and the U.S. Food and Drug Administration (&#8220;FDA&#8221;) will then prompt the enrollment of the remaining 93 patients. A subsequent interim analysis of efficacy is planned after approximately 50% of patients reach the six-month follow-up milestone.We entered into a strategic collaboration with Sanford Research to support the execution of this trial. Sanford Research is a U.S.-based non-profit research organization that supports an emerging translational research center focused on finding a cure for T1D. CLBS03 has been granted Fast Track and Orphan Drug designations from the FDA as well as Advanced Therapeutic Medicinal Product classification from the European Medicines Agency.</font></div><div style="padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Another of our pipeline programs is based on the use of Regulatory T Cells ("Tregs") to treat diseases caused by imbalances in an individual's immune system.&#160;This novel approach seeks to restore immune balance by enhancing Treg cell number and function.&#160; Tregs are a natural part of the human immune system and regulate the activity of T effector cells, the cells that are responsible for protecting the body from viruses and&#160;other foreign antigens. When Tregs function properly, only harmful&#160;foreign materials are attacked by T effector cells. In autoimmune disease, it is thought that deficient Treg activity permits the T effector cells to attack the body's own beneficial cells. We have entered into a strategic collaboration with Sanford Research with the goal of developing this therapy for the treatment of type 1 diabetes mellitus (&#8220;T1D&#8221;). Sanford Research is a non-profit research organization that is part of Sanford Health and supports an emerging translational research center focused on finding a cure for T1D. The initial focus of the collaboration will be the execution of a prospective, randomized, placebo-controlled, double-blind clinical trial (The Sanford Project: Trex Study) to evaluate the safety and efficacy of the Company&#8217;s Tregs product candidate, CLBS03, in adolescents with recent onset T1D. The Phase 2 study has an open and active investigational new drug application ("IND") in place and subject enrollment is expected to commence as early as the first quarter of 2016. An interim safety analysis of the data will occur after the treatment of the first 18 patients is completed, and an interim efficacy analysis is expected after the first 52 patients reach the 6 month follow-up milestone.</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S - 2</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:682px;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Additional Technology Platforms</font></div><div style="text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our broad intellectual property portfolio of cell therapy assets includes notable programs available for out-licensing and partnering in order to continue their clinical development. These include platforms using tumor cell/dendritic cell technology for immuno-oncology and CD34 technology for ischemic repair. Both have the benefit of promising Phase 2 clinical data and are applicable to multiple indications. The immuno-oncology platform is based on our extensive intellectual property portfolio and includes CLBS20, a candidate for metastatic melanoma which was investigated in two Phase 2 trials and recently in a discontinued Phase 3 clinical trial. With respect to our ischemic repair platform, we are actively exploring a program to develop CLBS12 (a candidate for critical limb ischemia &#8220;CLI&#8221;) under Japan's favorable regenerative medicine law and seeking to collaborate on CLBS 12 with development and/or manufacturing partners. In January 2016, we out-licensed our CD34 technology to SPS Cardio, LLC for chronic heart failure and acute myocardial infarction (candidate CLBS10) in India and other designated territories and non-major world markets outside the United States. In February 2016, we out-licensed a cell-derived dermatological product technology for topical skin application to AiVita Biomedical, Inc. ("AiVita"), which it intends to distribute through ALPHAEON Corporation. Furthermore, in May 2016, we out-licensed our tumor cell/dendritic cell technology to AiVita for ovarian cancer (candidate CLBS23) for worldwide use. Finally, our Treg immune modulation platform has potential applications across multiple autoimmune and allergic diseases beyond TID for which we are exploring partnering opportunities, including steroid-resistant asthma, multiple sclerosis, chronic obstructive pulmonary disease, inflammatory bowel disease, graft versus host disease, lupus and rheumatoid arthritis.</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our long term strategy focuses on advancing cell-based therapies to the market and assisting patients suffering from life-threatening medical conditions. Coupling our clinical development expertise with our process development and manufacturing capabilities, we believe we are positioned to realize potentially meaningful value increases within our own proprietary pipeline based on demonstration of proof-of-concept in man as well as process and manufacturing advancements.</font></div><div style="text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Developments - Reverse Stock Split</font></div><div style="text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 28, 2016, we implemented a one-for-ten reverse split of out issued and outstanding shares of common stock (the &#8220;Reverse Stock Split&#8221;), as authorized at the annual meeting of stockholders on June 22, 2016. The Reverse Stock Split became effective on July 27, 2016 and our common stock began trading on The NASDAQ Capital Market on a post-split basis at the open of business on July 28, 2016. As of July 28, 2016, every ten shares of our issued and outstanding common stock were combined into one share of our common stock, except to the extent that the Reverse Stock Split resulted in any of our stockholders owning a fractional share, which was rounded up to the next highest whole share. In connection with the Reverse Stock Split, there was no change in the nominal par value per share of $0.001. The Reverse Stock Split was effectuated in order to increase the per share trading price of our common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market.</font></div><div style="text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless otherwise noted, all references in this prospectus supplement to number of shares of common stock, price per share and weighted average shares of common stock have been adjusted to reflect the Reverse Stock Split on a retroactive basis for all periods presented.</font></div><div style="text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Caladrius Corporate Information</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our principal executive offices are located at 106 Allen Road, 4th Floor, Basking Ridge, New Jersey 07920, and our telephone number is (212) 584-4180. Our Common Stock is currently traded on The NASDAQ Capital Market under the symbol &#8220;CLBS.&#8221; We maintain a corporate website at</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;www.caladrius.com</font><font style="font-family:inherit;font-size:10pt;">. The contents of our website are not incorporated by reference into this prospectus supplement and should not be considered to be a part of this prospectus supplement or relied upon in connection herewith.</font></div><div style="text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Caladrius Biosciences, Inc. was incorporated under the laws of the State of Delaware in September 1980 under the name Fidelity Medical Services, Inc. and commenced operations in the adult stem cell collection, processing and storage services business in January 2006.</font></div><div style="text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all amendments to those reports, as well as other documents we file with the SEC, are available free of charge through the Investors section of our website as soon as reasonably practicable after such material is electronically filed with or furnished to the SEC. The public can obtain documents that we file with the SEC at&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">www.sec.gov</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This prospectus supplement includes the following trademarks, service marks and trade names owned by us: Caladrius</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, Amorcyte</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, Athelos</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;">, and PCT, LLC</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;">. These trademarks, service marks and trade names are the property of Caladrius and its affiliates. This prospectus supplement also includes other trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and traded names included herein are the property of their respective owners.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S - 3</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:6%;"></td><td style="width:31%;"></td><td style="width:3%;"></td><td style="width:55%;"></td><td style="width:5%;"></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">THE OFFERING</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares of common stock offered</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">847,458</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock outstanding prior to this offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,914,380</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock to be outstanding after this offering (including the Concurrent Private Placement)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,210,990</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Use of proceeds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We estimate that the net proceeds from this offering will be approximately $3.9 million.&#160;&#160;We intend to use the net proceeds from this offering for advancement of the Company's development of CLBS03 clinical trial, payment of our loan to Oxford Finance, LLC in the ordinary course and working capital and general corporate purposes. See &#8220;Use of Proceeds&#8221; on page S-9 of this prospectus supplement.</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk factors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See &#8220;Risk Factors&#8221; beginning on page S-5 of this prospectus supplement and page 3 of the accompanying prospectus for a discussion of the risks you should carefully consider before deciding to invest in our securities.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NASDAQ Capital Market symbol</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CLBS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Concurrent Private Placement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In a concurrent private placement, we are selling to certain accredited investors (the &#8220;Investors&#8221;) with whom we had a substantive, pre-existing relationship, including certain existing stockholders, up to 4,449,153 share of our common stock, at a purchase price of $4.72 per share, in two tranches. </font></div><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The shares of our common stock to be issued in the concurrent private placement are not being offered pursuant to this prospectus supplement and the accompanying prospectus and are being offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and Rule 506 promulgated thereunder. See &#8220;Private Placement Transaction.&#8221;</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless otherwise stated, all information in this prospectus supplement is based on 5,914,380 shares of common stock outstanding as of September 13, 2016 and assumes no issuance of the shares being purchased in the concurrent private placement, and does not include the following as of that date:</font></div><div style="padding-left:18px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="padding-left:42px;text-indent:-18px;font-size:10pt;"><font style="font-family:Wingdings;font-size:4pt;">l   </font><font style="font-family:inherit;font-size:10pt;">687,913 shares of common stock issuable upon the exercise of outstanding options to common stock at a weighted average exercise price of $5.50 per share;</font></div><div style="padding-left:42px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="padding-left:42px;text-indent:-18px;font-size:10pt;"><font style="font-family:Wingdings;font-size:4pt;">l   </font><font style="font-family:inherit;font-size:10pt;">369,131 shares of common stock which were reserved for future equity awards that may be granted in the future under our equity incentive plans;</font></div><div style="padding-left:42px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="padding-left:42px;text-indent:-18px;font-size:10pt;"><font style="font-family:Wingdings;font-size:4pt;">l   </font><font style="font-family:inherit;font-size:10pt;">362,650 shares of common stock issuable upon the exercise of outstanding warrants to purchase common stock at a weighted average exercise price of $85.41 per share;</font></div><div style="padding-left:42px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="padding-left:42px;text-indent:-18px;font-size:10pt;"><font style="font-family:Wingdings;font-size:4pt;">l   </font><font style="font-family:inherit;font-size:10pt;">any shares of common stock which may become issuable by us in lieu of cash milestone payments upon achievement of specified business milestones pursuant to the agreement governing our acquisition of California Stem Cell;</font></div><div style="padding-left:42px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="padding-left:42px;text-indent:-18px;font-size:10pt;"><font style="font-family:Wingdings;font-size:4pt;">l   </font><font style="font-family:inherit;font-size:10pt;">100 shares of common stock issuable upon conversion of our outstanding Series B Convertible Redeemable Preferred Stock;</font></div><div style="padding-left:42px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="padding-left:42px;text-indent:-18px;font-size:10pt;"><font style="font-family:Wingdings;font-size:4pt;">l   </font><font style="font-family:inherit;font-size:10pt;">any additional shares of our common stock that we may issue from time to time in connection with draw-downs pursuant to our Purchase Agreements with Aspire Capital Fund, LLC.</font></div><div style="padding-left:42px;text-indent:-18px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="padding-left:42px;text-indent:-18px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="padding-left:42px;text-indent:-18px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S - 4</font></div></div><hr style="page-break-after:always"><div><a name="sFE5BCE0A5A61D8638EC8CE2655EEBEEE"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RISK FACTORS</font></div><div style="line-height:120%;text-align:left;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investing in our securities involves a high degree of risk. This prospectus supplement does not describe all of those risks. You should consider the risk factors described in this prospectus supplement under the caption &#8220;Risks Related to This Offering and Our Securities&#8221; below, as well as the those described under the caption "Risk Factors" in the documents incorporated by reference herein, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 filed with the SEC on March 15, 2016 (our &#8220;2015 Form 10-K&#8221;) and the Quarterly Reports we filed thereafter, together with the other information contained or incorporated by reference in this prospectus supplement and the accompanying prospectus, and in any free writing prospectus that we have authorized for use in connection with this offering, before making an investment decision.</font></div><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If any of these risks occur, our business, financial condition, results of operations and future prospects would likely be materially and adversely affected. In these circumstances, the market price of our common stock would likely decline and you may lose all or part of your investment. Share information set forth in these risk factors is as of the dates set forth herein or therein and unless otherwise indicated, does not give effect to the issuance of the securities in connection with this offering.</font></div><div style="line-height:100%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Risks Related to This Offering and Our Securities</font></div><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We anticipate that we will need substantial additional financing in the future to continue our operations. If we are unable to raise additional capital as and when needed, or on acceptable terms, we may be forced to delay, reduce or eliminate one or more of our product development programs or expansion of our contract and manufacturing operations and our business will be harmed.</font></div><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We anticipate that we will require substantial additional capital to fund our current operating plan, including, among other things, the continued development of our cell therapy product candidates and the operation, enhancement and expansion of our contract development and manufacturing operations to support our customers and clinical development activities and could require additional funding to not only expand our current business units but those we may obtain through strategic transactions.&#160;</font></div><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The amount and timing of our future capital requirements also will likely depend on many other factors, including:</font></div><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:10pt;padding-left:34px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the scope, progress, results, costs, timing and outcomes of our other cell therapy research and development programs and product candidates;</font></div></td></tr></table><div style="line-height:100%;text-align:justify;padding-left:65px;text-indent:-31px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:10pt;padding-left:34px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to enter into any collaboration agreements with third parties for our other product candidates and the timing and terms of any such agreements;</font></div></td></tr></table><div style="line-height:100%;text-align:justify;padding-left:65px;text-indent:-31px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:10pt;padding-left:34px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the costs associated with the consummation of one or more strategic transactions;</font></div></td></tr></table><div style="line-height:100%;text-align:justify;padding-left:65px;text-indent:-31px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:10pt;padding-left:34px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the timing of and the costs involved in obtaining regulatory approvals for our product candidates, a process which could be particularly lengthy or complex given the FDA's limited experience with marketing approval for cell therapy products;</font></div></td></tr></table><div style="line-height:100%;text-align:justify;padding-left:65px;text-indent:-31px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:10pt;padding-left:34px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the costs of maintaining, expanding and protecting our intellectual property portfolio, including potential litigation costs and liabilities; and</font></div></td></tr></table><div style="line-height:100%;text-align:justify;padding-left:65px;text-indent:-31px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:10pt;padding-left:34px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the cost of expansion of our contract development and manufacturing operations, including but not limited to the costs of expanded facilities, equipment costs, engineering and innovation initiatives and personnel.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To both fund our clinical studies and support our future operations, we would likely seek to raise capital through a variety of different public and/or private financings vehicles. This could include, but not be limited to, use of our Purchase Agreement with Aspire Capital, option exercises, issuances of other debt or equity securities in public or private financings, and/or sale of assets. If we raise capital through the sale of equity, or securities convertible into equity, it would result in dilution to our then existing stockholders. Servicing the interest and principal repayment obligations under debt facilities could divert funds that would otherwise be available to support research and development, clinical or commercialization activities. In certain cases, we also may seek funding through collaborative arrangements, that would likely require us to relinquish certain rights to our technology or product candidates and share in the future revenues associated with the partnered product.</font></div><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our future cash requirements may vary materially from those currently anticipated because of expenses relating to marketing, advertising, sales, distribution, research and development and regulatory affairs (including the expenses related to clinical trials), as well as the costs of maintaining, expanding and protecting our intellectual property portfolio, including potential litigation costs and liabilities. Ultimately, we may be unable to raise capital or enter into collaborative relationships on terms that are acceptable to us, if at all. Our inability to obtain necessary capital or financing to fund our future operating needs could adversely affect our business, results of operations and financial condition.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have a right to sell up to a maximum of 5,000 Purchase Shares per day under our Purchase Agreement with Aspire Capital, which total may be increased by mutual agreement up to an additional 200,000 Purchase Shares per day. In addition, under certain circumstances we also have the right to sell to Aspire Capital an amount of stock equal to up to 30% of the aggregate shares of the Company&#8217;s Common Stock traded on NASDAQ on the next business day, subject to a maximum </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S - 5</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">number of shares determined by the Company. The extent to which we rely on Aspire Capital as a source of funding will depend on a number of factors, including the prevailing market price of our common stock and the extent to which we are able to secure working capital from other sources. The aggregate number of shares that we can sell to Aspire Capital under the Purchase Agreement may in no case exceed 1,101,928 shares of our common stock (which is equal to approximately 19.9% of the common stock outstanding on the date of the Purchase Agreement, including the 84,270 Commitment Shares (the &#8220;Exchange Cap&#8221;), unless (i) shareholder approval is obtained to issue more, in which case the Exchange Cap will not apply, or (ii) stockholder approval has not been obtained and at any time the Exchange Cap is reached and at all times thereafter the average price paid for all shares issued under the Purchase Agreement (including the Commitment Shares) is equal to or greater than $13.50 (the &#8220;Minimum Price&#8221;), a price equal to the closing sale price of our common stock immediately preceding the time we entered into the Purchase Agreement.</font></div><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Management will have broad discretion as to the use of the proceeds from this offering, and we may not use the proceeds effectively.</font></div><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our management will have broad discretion in the application of the proceeds from sales of our common stock offered by this prospectus supplement, and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. Our failure to apply these funds effectively could have a material adverse effect on our business, delay the development of our product candidates and cause the price of our common stock to decline.</font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Investors will incur an immediate dilution from the public offering price.</font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because the price per share being offered is substantially higher than the book value per share of our ordinary shares, you will suffer substantial dilution in the net tangible book value of the ordinary shares you purchase in this offering. Based on the offering price of </font><font style="font-family:inherit;font-size:10pt;">$4.72</font><font style="font-family:inherit;font-size:10pt;">, if you purchase shares of common stock in this offering, you will suffer immediate and substantial dilution of </font><font style="font-family:inherit;font-size:10pt;">$1.13</font><font style="font-family:inherit;font-size:10pt;">&#32;per share in the net tangible book value of the shares, as of June 30, 2016. See &#8220;Dilution&#8221; for a more detailed discussion of the dilution you will incur in this offering.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our stock price has been, and will likely continue to be, highly volatile.</font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The market price of our common stock has been and in the future may continue to be highly volatile. The market price for our common stock is highly dependent on, among other things, our clinical development efforts the profitability and growth of our cell therapy services business and the growth of our business in general, the amount of our available cash and investments and our level of cash utilization. Future events could increase the volatility seen in our common stock and ultimately cause a significant decline in the price of our common stock and ultimately impact our ability to raise additional capital in the future. These events could include the following, among others:</font></div><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">low levels of trading volume for our shares;</font></div></td></tr></table><div style="line-height:100%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">capital-raising or other transactions that are, or may in the future be, dilutive to existing stockholders or that involve the issuance of debt securities;</font></div></td></tr></table><div style="line-height:100%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delays in our clinical trials, negative clinical trial results or adverse regulatory decisions relating to our product candidates;</font></div></td></tr></table><div style="line-height:100%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adverse fluctuations in our revenues or operating results or financial results that otherwise fall below the market's expectations;</font></div></td></tr></table><div style="line-height:100%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">disappointing developments concerning our cell therapy services clients or other collaborators for our product candidates; and</font></div></td></tr></table><div style="line-height:100%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">legal challenges, disputes and/or other adverse developments impacting our patents or other proprietary rights that protect our products.</font></div></td></tr></table><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, broader external events, such as news concerning economic or market conditions in the general economy or within our industry, the activities of our competitors, changes (or the threat of changes) in U.S. or foreign government regulations impacting the life sciences industry or the movement of capital into or out of our industry, are likely to affect the price of our common stock. There can be no assurance that the market price of our common stock will not continue to fluctuate or decline significantly in the future.</font></div><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">In addition to potential dilution associated with future fundraising transactions, we currently have significant numbers of securities outstanding that are exercisable for our common stock, and potential milestone payment obligations, which could result in significant additional dilution and downward pressure on our stock price.</font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">5,914,380</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock outstanding. In addition, as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, there were outstanding stock options and warrants representing the potential issuance of an additional </font><font style="font-family:inherit;font-size:10pt;">1,152,252</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock, excluding the shares to be issued in our concurrent private placement. The issuance of these shares in the future would result in significant dilution to our current stockholders and could adversely affect the price of our common stock and the terms on which we could raise additional capital. In addition, the issuance and subsequent trading of shares could cause the supply of our common stock available for purchase in the market to exceed the purchase demand for our common stock. Such supply in excess of demand could cause the market price of our common stock to decline.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S - 6</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Sales of our common stock to Aspire Capital may cause substantial dilution to our existing stockholders and the sale of the shares of our common stock acquired by Aspire Capital could cause the price of our common stock to decline.</font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We previously registered $30.0 million worth of our common stock that we may issue and sell to Aspire Capital from time to time pursuant to a Purchase Agreement, together with 84,270 Commitment Shares. It is anticipated that shares offered to Aspire Capital will be sold over a period of up to 24 months commencing on November 5, 2015. The number of shares ultimately offered for sale to Aspire Capital is dependent upon the number of shares we elect to sell to Aspire Capital under the Purchase Agreement. Depending upon market liquidity at the time, sales of shares of our common stock under the Purchase Agreement may cause the trading price of our common stock to decline.</font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aspire Capital may ultimately purchase all or some of the $30.0 million of our common stock together with the 84,270 Commitment Shares. After Aspire Capital has acquired shares under the Purchase Agreement, it may sell all or some of those shares. As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, Aspire Capital has purchased 25,000 shares of our common stock pursuant to the Purchase Agreement for aggregate gross proceeds of $0.3 million. Sales to Aspire Capital by us pursuant to the Purchase Agreement may result in substantial dilution to the interests of other holders of our common stock. The sale of a substantial number of shares of our common stock to Aspire Capital, or anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales. In addition, under certain circumstances, we may be able to sell additional shares of common stock to Aspire Capital under two prior purchase agreements. </font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Future sales of a significant number of our shares of common stock in the public markets, or the perception that such sales could occur, could depress the market price of our shares of common stock.</font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales of a substantial number of our shares of common stock in the public markets, or the perception that such sales could occur, could depress the market price of our shares of common stock and impair our ability to raise capital through the sale of additional equity securities. A substantial number of shares of common stock are being offered by this prospectus supplement, and we cannot predict if and when Aspire Capital may sell shares purchased pursuant to the Purchase Agreement in the public markets.</font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we fail to maintain the listing of our common stock with a U.S. national securities exchange, the liquidity of our common stock could be adversely affected.</font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If our common stock is delisted by NASDAQ, our common stock may be eligible to trade on the OTC Bulletin Board, OTC QB or another over-the-counter market.&#160;Any such alternative would likely result in it being more difficult for us to raise additional capital through the public or private sale of equity securities and for investors to dispose of, or obtain accurate quotations as to the market value of, our common stock.&#160;In addition, there can be no assurance that our common stock would be eligible for trading on any such alternative exchange or markets.</font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We do not anticipate declaring any cash dividends on our common stock</font></div><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have never declared or paid cash dividends on our common stock and do not plan to pay any cash dividends in the near future. Our current policy is to retain all funds and earnings for use in the operation and expansion of our business.</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S - 7</font></div></div><hr style="page-break-after:always"><div><a name="s6B48A5AC25DD603C750FCE26560F42B4"></a></div><div><br></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></div><div style="line-height:100%;text-align:justify;padding-left:24px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This prospectus contains &#8220;forward-looking&#8221; statements within the meaning of the Private Securities Litigation Reform Act of 1995, as well as historical information. When used in this prospectus, statements that are not statements of current or historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words &#8220;plan,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;continue&#8221; or similar expressions or other variations or comparable terminology are intended to identify such forward-looking statements, although some forward-looking statements are expressed differently. We remind readers that forward-looking statements are merely predictions and therefore inherently subject to uncertainties and other factors and involve known and unknown risks that could cause the actual results, performance, levels of activity or our achievements or industry results, to be materially different from any future results, performance, levels of activity or our achievements or industry results expressed or implied by such forward-looking statements. Factors that could cause our actual results to differ materially from anticipated results expressed or implied by forward-looking statements include, among others:</font></div><div style="line-height:100%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to obtain sufficient capital or strategic business arrangements to fund our operations and expansion plans, including meeting our financial obligations under various licensing and other strategic arrangements, the funding of our clinical trials for product candidates, and the commercialization of the relevant technology;</font></div></td></tr></table><div style="line-height:100%;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to build and maintain the management and human resources infrastructure necessary to support the growth of our business;</font></div></td></tr></table><div style="line-height:100%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to integrate our acquired businesses successfully and grow such acquired businesses as anticipated, including expanding our PCT business;</font></div></td></tr></table><div style="line-height:100%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">whether a market is established for our cell-based products and services and our ability to capture a meaningful share of this market;</font></div></td></tr></table><div style="line-height:100%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">scientific and medical developments beyond our control;</font></div></td></tr></table><div style="line-height:100%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to obtain and maintain, as applicable, appropriate governmental licenses, accreditations or certifications or comply with healthcare laws and regulations or any other adverse effect or limitations caused by government regulation of our business;</font></div></td></tr></table><div style="line-height:100%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">whether any of our current or future patent applications result in issued patents, the scope of those patents and our ability to obtain and maintain other rights to technology required or desirable for the conduct of our business; and our ability to commercialize products without infringing the claims of third party patents;</font></div></td></tr></table><div style="line-height:100%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">whether any potential strategic or financial benefits of various licensing agreements will be realized;</font></div></td></tr></table><div style="line-height:100%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the results of our development activities;</font></div></td></tr></table><div style="line-height:100%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to complete our other planned clinical trials (or initiate other trials) in accordance with our estimated timelines due to delays associated with enrolling patients due to the novelty of the treatment, the size of the patient population and the need of patients to meet the inclusion criteria of the trial or otherwise; </font></div></td></tr></table><div style="line-height:100%;text-align:justify;padding-left:24px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to satisfy our obligations under our loan agreement; and</font></div></td></tr></table><div style="line-height:100%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">other factors discussed in "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 15, 2016 (our "2015 Form 10-K").</font></div></td></tr></table><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The factors discussed herein, including those risks described in &#8220;Item 1A. Risk Factors&#8221; and elsewhere in our 2015 Form 10-K and in our other periodic filings with the SEC, which are available for review at</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;www.sec.gov, </font><font style="font-family:inherit;font-size:10pt;">could cause actual results and developments to be materially different from those expressed or implied by such statements. All forward-looking statements attributable to us are expressly qualified in their entirety by these and other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they were made. Except as required by law, we undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.</font></div><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S - 8</font></div></div><hr style="page-break-after:always"><div><a name="s4B43297C85CBDAA3C932CE2656426AD0"></a></div><div><br></div><div style="line-height:120%;text-align:center;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">USE OF PROCEEDS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We estimate that the net proceeds from the sale of the securities offered under this prospectus, after deducting estimated offering expenses payable by us will be </font><font style="font-family:inherit;font-size:10pt;">$3.9 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We anticipate that the net proceeds from the sale of the securities under this prospectus supplement will be used for advancement of the Company's development of CLBS03 clinical trial, payment of our loan to Oxford Finance, LLC in the ordinary course, working capital and general corporate purposes and any other purposes that we may specify in any prospectus supplement. We will have discretion in the use of any net proceeds. Investors will be relying on the judgment of our management regarding the application of the proceeds of any sale of the securities. </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have not determined the amounts we plan to spend on any of the areas listed above or the timing of these expenditures. As a result, our management will have broad discretion to allocate the net proceeds from this offering. Pending application of the net proceeds as described above, we expect to invest the net proceeds in short-term, interest-bearing, investment-grade securities pursuant to our investment policy.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S - 9</font></div></div><hr style="page-break-after:always"><div><a name="sB79BB18B4D80D3369F0BCE2656635A8D"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CAPITALIZATION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth our capitalization as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">on an actual basis; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">on an as adjusted basis to reflect the sale of&#160;</font><font style="font-family:inherit;font-size:10pt;">847,458</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock and </font><font style="font-family:inherit;font-size:10pt;">4,449,153</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock in the concurrent private placement,  after deducting estimated offering expenses payable by us.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This capitalization table should be read in conjunction with management's discussion and analysis of results of operations and our consolidated financial statements and related notes included in our Form 10-Q for the fiscal quarter ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:78%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of June 30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Actual</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As Adjusted</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and Cash Equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,699.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,599.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,813.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,813.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,400.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,400.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholder's equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock, par value $0.01, 20,000,000 shares authorized, 10,000 shares of Series B convertible redeemable preferred stock issued and outstanding actual and pro forma, as adjusted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock, par value $0.001, 500,000,000 shares authorized, 5,926,749 shares issued and outstanding, actual and 11,223,359 shares issued and outstanding, as adjusted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional paid in capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">398,700.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">423,594.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Treasury stock, at cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(707.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(707.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(391,948.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(391,948.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total shareholders' equity</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,050.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,950.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total capitalization</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,263.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,163.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">__________</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding shares of common stock as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;excludes as of such date:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">692,205</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock issuable upon the exercise of outstanding options to common stock at a weighted average exercise price of </font><font style="font-family:inherit;font-size:10pt;">$55.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">351,665</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock which were reserved for future equity awards that may be granted in the future under our equity incentive plans;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">460,047</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock issuable upon the exercise of outstanding warrants to purchase common stock at a weighted average exercise price of </font><font style="font-family:inherit;font-size:10pt;">$97.90</font><font style="font-family:inherit;font-size:10pt;">&#32;per share;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any shares of common stock which may become issuable by us in lieu of cash milestone payments upon achievement of specified business milestones pursuant to the agreement governing our acquisition of California Stem Cell;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100 shares of common stock issuable upon conversion of our outstanding Series B Convertible Redeemable Preferred Stock; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any additional shares of our common stock that we may issue from time to time in connection with draw-downs pursuant to our Purchase Agreements with Aspire Capital Fund, LLC.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S - 10</font></div></div><hr style="page-break-after:always"><div><a name="s3AF76C2A4915C8211696CE26569778F6"></a></div><div><br></div><div style="line-height:120%;text-align:center;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DILUTION</font></div><div style="line-height:120%;text-align:left;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If you invest in our common stock, your interest will be diluted to the extent of the difference between the price per share you pay in this offering and the net tangible book value per share of our common stock immediately after this offering. Our net tangible book value as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;was approximately $</font><font style="font-family:inherit;font-size:10pt;">15.4 million</font><font style="font-family:inherit;font-size:10pt;">, or $</font><font style="font-family:inherit;font-size:10pt;">2.60</font><font style="font-family:inherit;font-size:10pt;">&#32;per share of common stock. Net tangible book value per share of common stock is calculated by subtracting our total liabilities from our total tangible assets, which is total assets less intangible assets, and dividing this amount by the number of shares of common stock outstanding.</font></div><div style="line-height:120%;text-align:justify;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">After giving effect to the sale of </font><font style="font-family:inherit;font-size:10pt;">847,458</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock in this offering at a public offering price of </font><font style="font-family:inherit;font-size:10pt;">$4.72</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;per share, and </font><font style="font-family:inherit;font-size:10pt;">4,449,153</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock in the concurrent private placement, and after estimated offering expenses payable by  us, our net tangible book value as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;would have been approximately </font><font style="font-family:inherit;font-size:10pt;">$40.3 million</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">$3.59</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;per share of common stock based on </font><font style="font-family:inherit;font-size:10pt;">11,223,360</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock outstanding on a pro forma basis at that time. This represents an immediate increase in net tangible book value of </font><font style="font-family:inherit;font-size:10pt;">$0.99</font><font style="font-family:inherit;font-size:10pt;">&#32;per share to our existing stockholders and immediate dilution of approximately </font><font style="font-family:inherit;font-size:10pt;">$1.13</font><font style="font-family:inherit;font-size:10pt;">&#32;per share to new investors participating in this offering, as illustrated by the following table: </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:86%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Offering price per share of common stock</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;Net tangible book value per share of common stock as of June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.60</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Increase in net tangible book value per share of common stock attributable to the offering</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.99</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">As adjusted net tangible book value per share of common stock as of June 30, 2016 after giving effect to the offering</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.59</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Dilution in net tangible book value per share of common stock to new investors in the offering</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.13</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;The above discussion and table are based on </font><font style="font-family:inherit;font-size:10pt;">5,915,750</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock outstanding as of the close of business on </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">. This number excludes the following:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">692,205</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock issuable upon the exercise of outstanding options to common stock at a weighted average exercise price of </font><font style="font-family:inherit;font-size:10pt;">$55.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">351,665</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock which were reserved for future equity awards that may be granted in the future under our equity incentive plans;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">460,047</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock issuable upon the exercise of outstanding warrants to purchase common stock at a weighted average exercise price of </font><font style="font-family:inherit;font-size:10pt;">$97.90</font><font style="font-family:inherit;font-size:10pt;">&#32;per share;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any shares of common stock which may become issuable by us in lieu of cash milestone payments upon achievement of specified business milestones pursuant to the agreement governing our acquisition of California Stem Cell;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100 shares of common stock issuable upon conversion of our outstanding Series B Convertible Redeemable Preferred Stock;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any additional shares of our common stock that we may issue from time to time in connection with draw-downs pursuant to our Purchase Agreements with Aspire Capital Fund, LLC.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The above illustration of dilution per share to investors participating in this offering assumes no exercise of outstanding options to purchase our common stock or outstanding warrants to purchase shares of our common stock. The exercise of outstanding options and warrants having an exercise price less than the offering price will increase dilution to new investors.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S - 11</font></div></div><hr style="page-break-after:always"><div><a name="sB306F9DAB13A2266B7EBCE2656B567A7"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PRICE RANGE OF CURRENT STOCK</font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our common stock trades on The NASDAQ Capital Market under the symbol &#8220;CLBS.&#8221; The following table sets forth the high and low sales prices of our common stock for each quarterly period presented, as reported by The NASDAQ Capital Market.</font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.03125%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:56%;"></td><td style="width:22%;"></td><td style="width:22%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">High</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Low</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">First Quarter</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$13.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.00</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Second Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$7.80</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.50</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third Quarter (through September 13, 2016)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$6.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.41</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.03125%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:56%;"></td><td style="width:22%;"></td><td style="width:22%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">High</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Low</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">First Quarter</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$42.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$25.30</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Second Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$34.70</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$18.00</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third Quarter</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$20.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$11.00</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fourth Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$15.60</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$10.10</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.03125%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:57%;"></td><td style="width:21%;"></td><td style="width:22%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">High</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Low</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third Quarter</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$66.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$51.00</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fourth Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$72.20</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$30.80</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;">September&#160;13, 2016</font><font style="font-family:inherit;font-size:10pt;">, the last reported sale price of our common stock was $</font><font style="font-family:inherit;font-size:10pt;">4.72</font><font style="font-family:inherit;font-size:10pt;">&#32;per share.</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Holders</font></div><div style="line-height:100%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of&#160;</font><font style="font-family:inherit;font-size:10pt;">September&#160;13, 2016</font><font style="font-family:inherit;font-size:10pt;">, there were approximately </font><font style="font-family:inherit;font-size:10pt;">1,398</font><font style="font-family:inherit;font-size:10pt;">&#32;stockholders of record of our common stock. The number of record holders was determined from the records of our transfer agent and does not include beneficial owners of our common stock whose shares are held in the names of various security brokers, dealers, and registered clearing agencies.</font></div><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dividend Policy </font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have not paid cash dividends on our common stock during the periods set forth in the stock price table that appears above. The holders of our common stock are each entitled to receive dividends when and if declared by the board of directors out of funds legally available therefor, subject to the terms of any outstanding series of preferred stock. We intend to retain any future earnings to fund the development and growth of our business, and therefore we do not anticipate paying any cash dividends on our common stock in the foreseeable future.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S - 12</font></div></div><hr style="page-break-after:always"><div><a name="s41EB28C95B84D28DE794CE2657091550"></a></div><div><br></div><div style="line-height:120%;text-align:center;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PLAN OF DISTRIBUTION</font></div><div style="line-height:120%;text-align:center;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are selling </font><font style="font-family:inherit;font-size:10pt;">847,458</font><font style="font-family:inherit;font-size:10pt;">&#32;of our shares of common stock offered under this prospectus supplement directly to a single institutional investor in a privately negotiated transaction in which no party is acting as an underwriter or placement agent. Subject to the terms of a securities purchase agreement dated the date of this prospectus supplement, the purchaser has agreed to purchase and we have agreed to sell to the purchaser an aggregate of </font><font style="font-family:inherit;font-size:10pt;">847,458</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$4.72</font><font style="font-family:inherit;font-size:10pt;">&#32;per share of common stock. We determined the common stock price per share through negotiations with the purchasers. We expect to deliver the shares of common stock through the book entry facilities of The Depository Trust Company against payment of the aggregate purchase price for the shares of common stock purchased.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Trading Market</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our common stock is listed on The NASDAQ Capital Market under the symbol &#8220;CLBS.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S - 13</font></div></div><hr style="page-break-after:always"><div><a name="s2502ce5f605c4032b1d3e3c41fa8ac17"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PRIVATE PLACEMENT TRANSACTION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In a concurrent private placement on September 14, 2016, we entered into securities purchase agreements (each, a &#8220;Private Placement Purchase Agreement&#8221; and collectively, the &#8220;Private Placement Purchase Agreements&#8221;) with certain accredited investors (the &#8220;Investors&#8221;) with whom we had a substantive, pre-existing relationship, including certain existing stockholders, for the sale by us of an aggregate of 4,449,153 shares of Common Stock, at a purchase price of $4.72 per share. The investments will be placed in two tranches: (i) up to $12.6 million upon an initial closing (the &#8220;Initial Closing&#8221;), and (ii) up to $8.4 million, subject to certain conditions, including the enrollment of 70 subjects in the Company&#8217;s Phase 2 CLBS03 clinical trial, in a second closing (the &#8220;Second Closing&#8221;). The Initial Closing is expected to occur on September 19, 2016 and the Second Closing shall occur within ten days after the satisfaction of the certain conditions outlined in the Private Placement Purchase Agreements. The aggregate gross proceeds for the sale of the shares of Common Stock in the private placement are expected to be approximately $21.0 million.</font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the concurrent private placement, we entered into a Registration Rights Agreement on September 14,  2016, with each of the Investors (the &#8220;Registration Rights Agreement&#8221;), which requires us to file a registration statement with the SEC, covering the resale of the shares of Common Stock issued in the private placement, and use our commercially reasonable efforts to cause such registration statement to be declared effective by the SEC within 90 days of the Initial Closing (or 120 days in the event such registration statement is reviewed by the SEC). Failure to do so or meet various other deadlines set forth in the Registration Rights Agreement will give rise to liquidated damages of 1% per month, up to a maximum of 3% so long as the event giving rise to the damages remains uncured, all as set forth in the Registration Rights Agreement.</font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Investors also agreed to enter into lock-up agreements ranging from 90 to 180 days.</font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, one of the investors in the private placement, with an expected investment of up to $5.0 million, will have a limited right to have a board observer (with no voting rights) for a period commencing on the date of the Initial Closing and ending on the second anniversary of the Initial Closing.</font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The shares of our common stock issuable pursuant to the Placement Purchase Agreement are not being registered under the Securities Act of 1933, as amended, and are not being offered pursuant to this prospectus supplement and the accompanying prospectus and will be issued pursuant to the exemption provided in Section&#160;4(a)(2) under the Securities Act and Rule 506 promulgated thereunder. </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S - 14</font></div></div><hr style="page-break-after:always"><div><a name="sB555CD0F5E5E5DCDE68DCE26573B53EF"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LEGAL MATTERS</font></div><div style="line-height:120%;text-align:left;text-indent:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The validity of the shares of common stock offered hereby will be passed upon for us by Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., New York, New York. </font></div><div><a name="sA41DBEAA00A11516E3D8CE26575CC230"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXPERTS </font></div><div style="line-height:120%;text-align:left;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The financial statements and management&#8217;s assessment of the effectiveness of internal control over financial reporting incorporated by reference in this prospectus and elsewhere in the registration statement have been so incorporated by reference in reliance upon the reports of Grant Thornton LLP, independent registered public accountants, upon the authority of said firm as experts in accounting and auditing.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s3C0A447F6175815FBABCCE26578FE555"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WHERE YOU CAN FIND MORE INFORMATION </font></div><div style="line-height:100%;text-align:left;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This prospectus supplement is part of a registration statement on Form S-3 that we filed with the SEC. The registration statement that contains this prospectus supplement, including the exhibits to the registration statement, contains additional information about us and the shares of common stock offered by this prospectus supplement.</font></div><div style="line-height:100%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy any document we file with the SEC at the SEC&#8217;s Public Reference Room at 100 F Street, N.E. Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the Public Reference Room. Our public filings, including reports, proxy and information statements, are also available on the SEC's web site at</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;http://www.sec.gov</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s506EE702B808BD57A5A1CE2657AFAB1E"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE </font></div><div style="line-height:100%;text-align:left;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The SEC allows us to &#8220;incorporate by reference&#8221; the information contained in documents that we file with the SEC, which means that we can disclose important information to you by referring to those documents. The information incorporated by reference is considered to be part of this prospectus supplement. Information in this prospectus supplement modifies or supersedes information incorporated by reference that we filed with the SEC prior to the date of this prospectus supplement, and information that we file later with the SEC also will automatically update and supersede this information.</font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We incorporated by reference into this prospectus supplement, the documents listed below and any documents that we file in the future with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, after the date of this prospectus supplement:</font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:10pt;padding-left:22px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, as amended filed with the SEC on March 15, 2016 and April 29, 2016;</font></div></td></tr></table><div style="line-height:100%;text-align:justify;padding-left:65px;text-indent:-43px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:10pt;padding-left:22px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Quarterly Reports on Form 10-Q, as amended, filed with the SEC on May 5, 2016, May 6, 2016 and August 9, 2016;</font></div></td></tr></table><div style="line-height:100%;text-align:justify;padding-left:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:10pt;padding-left:22px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Current Reports on Form 8-K filed with the SEC on January 6, 2016, January 11, 2016, February 26, 2016, March 14, 2016 (two reports), March 17, 2016, May 5, 2016, June 23, 2016, June 27, 2016, July 27, 2016, August 9, 2016 and September 15, 2016 (excluding any information deemed furnished pursuant to Item 2.02 or Item 7.01 of any Current Report on Form 8-K); </font></div></td></tr></table><div style="line-height:100%;text-align:justify;padding-left:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:10pt;padding-left:22px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Definitive Proxy Statement on Schedule 14A filed with the SEC on May 10, 2016;</font></div></td></tr></table><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;padding-left:65px;text-indent:-43px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:10pt;padding-left:22px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The description of our common stock set forth in our Registration Statement on Form 8-A, filed with the SEC on August 2, 2013 (including any amendment or report filed with the SEC for the purpose of updating such description); and </font></div></td></tr></table><div style="line-height:100%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:10pt;padding-left:22px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">all reports and other documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of this prospectus supplement and prior to the termination or completion of the offering of securities under this prospectus supplement shall be deemed to be incorporated by reference in this prospectus supplement and the accompanying prospectus and to be a part hereof from the date of filing such reports and other documents.</font></div></td></tr></table><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless otherwise noted, the SEC file number for each of the documents listed above is 001-33650.</font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To the extent that any statement in this prospectus supplement is inconsistent with any statement that is incorporated by reference and that was made on or before the date of this prospectus supplement, the statement in this prospectus supplement shall supersede such incorporated statement. The incorporated statement shall not be deemed, except as modified or superseded, to constitute a part of this prospectus supplement, the accompanying prospectus or the registration statement. Statements contained in this prospectus supplement as to the contents of any contract or other document are not necessarily complete and, in each instance, we refer you to the copy of each contract or document filed as an exhibit to the registration statement.</font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will furnish without charge to you, upon written or oral request, a copy of any or all of the documents incorporated by reference, including exhibits to these documents. You should direct any requests for documents to:</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S - 15</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Caladrius Biosciences, Inc.</font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">420 Lexington Avenue, Suite 350</font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New York, New York 10170</font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(212) 584-4180</font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Attention: Todd Girolamo, Esq., General Counsel</font></div><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibits to the filings will not be sent, however, unless those exhibits have specifically been incorporated by reference in this document.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S - 16</font></div></div><hr style="page-break-after:always"><div><a name="s63043F96553B7D69328ECE2657E21CB4"></a></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PROSPECTUS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$150,000,000</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CALADRIUS BIOSCIENCES, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Preferred Stock</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Debt Securities</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrants</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Units</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may from time to time offer and sell common stock, preferred stock, debt securities, warrants and units, having an aggregate offering price of up to $150,000,000.  We may offer and sell these securities separately or together in any combination.  We may offer and sell these securities to or through underwriters, directly to investors or through agents.  We will specify the terms of the securities, and the names of any underwriters or agents and their respective compensation, in supplements to this prospectus.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our common stock is traded on the The NASDAQ Capital Market under the symbol &#8220;CLBS.&#8221; On </font><font style="font-family:inherit;font-size:10pt;">August&#160;5, 2015</font><font style="font-family:inherit;font-size:10pt;">, the last reported sale price of our common stock on the The NASDAQ Capital Market was $</font><font style="font-family:inherit;font-size:10pt;">1.58</font><font style="font-family:inherit;font-size:10pt;">&#32;per share.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investing in our securities involves risks.  See &#8220;Risk Factors&#8221; at page&#160;4 of this prospectus.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus.  Any representation to the contrary is a criminal offense.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This prospectus may not be used to consummate sales of securities unless it is accompanied by a prospectus supplement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The date of this prospectus is August 28, 2015.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><hr style="page-break-after:always"><div><a name="s5581A36842D65E8177F4CE2658032E02"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ABOUT THIS PROSPECTUS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, using a &#8220;shelf&#8221; registration process.  Under this shelf process, we may sell any combination of the securities described in this prospectus in one or more offerings up to a total dollar amount of $150,000,000.  We have provided to you in this prospectus a general description of the securities we may offer.  Each time we sell securities under this shelf registration process, we will provide a prospectus supplement that will contain specific information about the terms of the offering.  We may also add, update or change any of the information contained in this prospectus in the prospectus supplement or any &#8220;free writing prospectus&#8221; we may authorize to be delivered to you.  To the extent there is a conflict between the information contained in this prospectus and the prospectus supplement or any free writing prospectus we may authorize to be delivered to you, you should rely on the information in the prospectus supplement or free writing prospectus, as the case may be, provided that if any statement in one of these documents is inconsistent with a statement in another document having a later date-for example, a document incorporated by reference in this prospectus or any prospectus supplement-the statement in the document having the later date modifies or supersedes the earlier statement.  This prospectus, together with the applicable prospectus supplements and any free writing prospectus we may authorize to be delivered to you, includes all material information relating to a particular offering.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">An investment in our securities involves certain risks that should be carefully considered by prospective investors.  See &#8220;Risk Factors.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">You should read this prospectus and any prospectus supplement as well as additional information described under &#8220;Incorporation of Certain Documents by Reference&#8221; and &#8220;Where You Can Find More Information&#8221; on pages 39 and 39, respectively.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><a name="sAF3FD15235E89592DCD4CE2658355A95"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ABOUT CALADRIUS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Overview</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Caladrius Biosciences, Inc. (&#8220;we,&#8221; &#8220;us&#8221;, "our", &#8220;Caladrius&#8221; or the &#8220;Company&#8221;) is among the first of a new breed of immunotherapy companies with proven expertise and unique experience in cell process optimization, development, and manufacturing. Caladrius is a company combining a leading cell therapy service provider with a development pipeline including late-stage clinical programs based on proprietary platform technology for immuno-oncology, as well as additional platform technologies for ischemic repair and immunomodulation. This integrated approach supports the industry in bringing significant life-improving medical treatments to market. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our most advanced clinical program is based on our tumor cell/dendritic cell technology. It is focused on the development of an innovative cancer treatment (</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">i.e.</font><font style="font-family:inherit;font-size:10pt;">, vaccine) that is designed to target the cells responsible for tumor growth and metastasis, known as cancer- or tumor-initiating cells ("CICs"), using purified CICs from a patient&#8217;s own tumor as an antigen source to induce or enhance an anti-tumor immune response in the patient. CLBS20, our lead product candidate based on this platform technology, targets malignant melanoma.  CLBS20 is being studied in patients with recurrent Stage III or Stage IV metastatic melanoma. The program has been granted Fast Track and Orphan designation by the Food and Drug Administration (the "FDA") as well as Advanced Therapeutic Medicinal Product classification by the European Medicines Agency (the "EMA").  The protocol for the Phase 3 study, known as the Intus study, is the subject of a Special Protocol Assessment ("SPA") by the FDA. Our SPA letter states that our Phase 3 clinical trial is adequately designed to provide the necessary data that, depending on outcome, could support a Biologics License Application ("BLA") seeking marketing approval of CLBS20. The Intus Study is the subject of a $17.7 million grant from the California Institute for Regenerative Medicine, announced in May 2015. The study protocol calls for randomizing 250 patients.  Patient screening began in the first quarter of 2015 and randomization of the first patient was announced in April 2015.  An interim analysis is planned after 99 trial events (i.e., deaths) and is expected to occur during the fourth quarter of 2017. We are also evaluating other clinical indications for which we may advance this program, including ovarian, liver, colon, kidney, brain and lung cancers. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are also developing therapies that are designed to utilize CD34 cells to regenerate tissue impacted by ischemia. Ischemia occurs when the supply of oxygenated blood in the body is restricted, causing local tissue distress and death. Ischemia can lead to conditions such as chronic heart failure ("CHF") and critical limb ischemia ("CLI"). We seek to improve oxygen delivery to affected tissues through the development and formation of new blood vessels. The ischemic repair program is supported by data from the clinical study of CLBS10, a product candidate designed to prevent heart failure and major adverse cardiac events following a severe heart attack (known as an ST segment elevation myocardial infarction ("STEMI")). After a thorough review, the Company has set the future direction for its ischemic repair program. Based on an analysis of the available Phase 2 data from the PreSERVE-AMI trial, an updated commercial assessment considering all major potential relevant cardiovascular indications and consultation with the Company&#8217;s new cardiovascular scientific advisory board and the Science and Technology Committee of the Board of Directors, Caladrius has decided that it will not pursue further development of CLBS10 upon completion of the ongoing PreSERVE-AMI Phase 2 clinical study. However, we believe that the positive suggestion of safety and therapeutic activity seen to date in the CLBS10 study supports the underlying platform technology and enables the Company&#8217;s exploration of what we believe to be more commercially viable indications of chronic heart failure (CLBS14) and/or critical limb ischemia (CLBS12) as targets for further development. In the case of CLI, we are actively exploring a program to develop CLBS12 in Japan under Japan&#8217;s regenerative medicine law. Japan&#8217;s regenerative medicine law enables an expedited path to conditional approval for regenerative medicine products that show sufficient safety evidence and signals of efficacy in a phase 2 study. This program is supported by three previous studies of autologous CD34 cells in no-option CLI patients. These other indications are early stage opportunities, and would require external funding and/or partnerships to proceed to the next step in clinical development. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are also developing a therapy that is designed to utilize Regulatory T Cells ("Tregs") to treat diseases caused by imbalances in an individual's immune system.&#160;This novel approach seeks to restore immune balance by enhancing Treg cell number and function.&#160; Tregs are a natural part of the human immune system and regulate the activity of T effector cells, the cells that are responsible for protecting the body from viruses and&#160;other foreign antigens. When Tregs function properly, only harmful&#160;foreign materials are attacked by T effector cells. In autoimmune disease, it is thought that deficient Treg activity permits the T effector cells to attack the body's own tissues.  We have received FDA concurrence that we may proceed to a Phase 2 study (the "Trutina study") of CLBS03, a Treg-based therapeutic being developed to treat type 1 diabetes mellitus ("T1DM") in adolescents. We are evaluating other clinical indications into which we may advance this program, including steroid-resistant asthma, multiple sclerosis, chronic obstructive pulmonary disease, inflammatory bowel disease, graft versus host disease, lupus, and rheumatoid arthritis. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that cell-based therapies have the potential to create a paradigm change in the treatment for a variety of diseases and conditions and we are evaluating other programs that we view as holding particular promise, including an aesthetics program for a topical skin application and a very small embryonic like ("VSEL</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM"</sup></font><font style="font-family:inherit;font-size:10pt;">) stem cell program for the treatment of retinal </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">degeneration, bone restoration and wound healing.  We have also received recent grants to support early stage research for retinal disease using human-induced pluripotent stem cells. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Through our wholly owned subsidiary, PCT, LLC, a Caladrius company ("PCT"), we are recognized as a world industry leader in providing high-quality innovative and reliable manufacturing capabilities and engineering solutions (</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">e.g.</font><font style="font-family:inherit;font-size:10pt;">, process and assay development, optimization and automation) in the development of cell-based therapies.  We currently operate three facilities qualified under Good Manufacturing Practices ("cGMPs") in Allendale, NJ, Mountain View, CA and Irvine, CA, and are positioned to expand our capacity both in the United States and internationally, as needed. In addition to leveraging this core expertise in the development of our own products, we partner opportunistically with other industry leaders who recognize our unique ability to significantly improve their manufacturing processes and supply clinical and commercial material.  </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We look forward to further advancement of our cell-based therapies to the market and to helping patients suffering from life-threatening medical conditions. Coupling our development expertise with our strong process development and manufacturing capability, we believe the stage is set for us to realize meaningful clinical development of our own proprietary platform technologies and manufacturing advancements, further positioning Caladrius as a leader in the immuno-oncology field and the cell therapy industry.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Caladrius Corporate Information</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Caladrius&#8217; offices are located at&#160;106 Allen Road, Fourth Floor, Basking Ridge, New Jersey 07920, and our telephone number is (908) 842-0100.  Our Common Stock is currently traded on the The Nasdaq Capital Market under the symbol &#8220;CLBS.&#8221;  We maintain a corporate website at</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;www.caladrius.com</font><font style="font-family:inherit;font-size:10pt;">.  The contents of our website are not incorporated by reference into this prospectus and should not be considered to be a part of this prospectus or relied upon in connection herewith.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Caladrius Biosciences, Inc. was incorporated under the laws of the State of Delaware in September&#160;1980 under the name Fidelity Medical Services, Inc. and commenced operations in the adult stem cell collection, processing and storage services business in January&#160;2006.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This prospectus and the information incorporated herein by reference includes trademarks, service marks and trade names owned by us or other companies.  All trademarks, service marks and trade names included or incorporated by reference into this prospectus are the property of their respective owners.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s870EFA14731970BCD53DCE265856F63B"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RISK FACTORS</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investing in our securities involves risk.  Please see the risk factors set forth under the heading &#8220;Risk Factors&#8221; beginning on page&#160;30 of our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2014 filed with the Securities and Exchange Commission (the "SEC") on March 2, 2015 (our "2014 Form 10-K"), which document is on file with the Securities and Exchange Commission and incorporated by reference into this prospectus.  Before making an investment decision, you should carefully consider these risks as well as other information we include or incorporate by reference in this prospectus and any prospectus supplement.  The risks and uncertainties we have described are not the only ones facing our Company.  Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our business operations.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s0B6AEA4E36028BA1BD04CE2658887272"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SPECIAL NOTE REGARDING FORWARD-LOOKING INFORMATION</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This prospectus, any prospectus supplement and the documents we incorporate by reference in this prospectus contain forward-looking statements within the meaning of Section&#160;27A of the Securities Act of&#160;1933, as amended (the &#8220;Securities Act&#8221;), and Section&#160;21E of the Securities Exchange Act of&#160;1934, as amended (the &#8220;Exchange Act&#8221;).  All statements, other than statements of historical facts, that we include in this prospectus, any prospectus supplement, and in the documents we incorporate by reference in this prospectus, may be deemed forward-looking statements for purposes of the Securities Act and the Exchange Act.  We use the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions to identify forward-looking statements, although not all forward-looking statements contain these identifying words.  We cannot guarantee that we actually will achieve the plans, intentions or expectations disclosed in our forward-looking statements and, accordingly, you should not place undue reliance on our forward-looking statements.  There are a number of important factors that could cause actual results or events to differ materially from anticipated results expressed or implied by such forward-looking statements, including among others: </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to obtain sufficient capital or strategic business arrangements to fund our operations and expansion plans, including meeting our financial obligations under various licensing and other strategic arrangements, the funding of our </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-left:48px;text-align:justify;"><font style="font-family:inherit;font-size:10pt;">clinical trials for product candidates in our development programs for our Immuno-oncology Program, our Ischemic Repair Program and our Immune Modulation Program, and the commercialization of the relevant technology; </font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to build and maintain the management and human resources infrastructure necessary to support the growth of our business; </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to integrate our acquired businesses successfully and grow such acquired businesses as anticipated, including expanding our PCT business; </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">whether a market is established for our cell-based products and services and our ability to capture a meaningful share of this market; </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">scientific and medical developments beyond our control; </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to obtain and maintain, as applicable, appropriate governmental licenses, accreditations or certifications or comply with healthcare laws and regulations or any other adverse effect or limitations caused by government regulation of our business;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">whether any of our current or future patent applications result in issued patents, the scope of those patents and our ability to obtain and maintain other rights to technology required or desirable for the conduct of our business; and our ability to commercialize products without infringing the claims of third party patents; </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">whether any potential strategic or financial benefits of various licensing agreements will be realized; </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the results of our development activities, including the results of our Intus Phase 3 clinical trial of CLBS20, being developed to treat metastatic melanoma;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to complete our other planned clinical trials (or initiate other trials) in accordance with our estimated timelines due to delays associated with enrolling patients due to the novelty of the treatment, the size of the patient population and the need of patients to meet the inclusion criteria of the trial or otherwise;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to satisfy our obligations under our loan agreement; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">other factors discussed in "Risk Factors" in our  2014 Form 10-K,</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">You should read these factors and the other cautionary statements made in the documents we incorporate by reference as being applicable to all related forward-looking statements wherever they appear in this prospectus, any prospectus supplement, and any document incorporated by reference.  We caution you that we do not undertake any obligation to update forward-looking statements made by us, except as required by law.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s9C5AEAA27A0E3B1AA6DDCE2658A9CC30"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">USE OF PROCEEDS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless otherwise provided in the applicable prospectus supplement, we intend to use the net proceeds from the sale of the securities under this prospectus for working capital, including research and development of cell therapeutic product candidates, expansion of our business, strategic transactions and other general corporate purposes.  We will set forth in the prospectus supplement our intended use for the net proceeds received from the sale of any securities.  Pending the use of the net proceeds, we may use the net proceeds to invest in investment&#8209;grade, interest-bearing securities.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s8DEFA18E771732932DD8CE2658DC55B2"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">THE SECURITIES WE MAY OFFER</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The descriptions of the securities contained in this prospectus, together with the applicable prospectus supplements, summarize all the material terms and provisions of the various types of securities that we may offer.  We will describe in the applicable prospectus supplement relating to any securities the particular terms of the securities offered by that prospectus supplement.  If we indicate in the applicable prospectus supplement, the terms of the securities may differ from the terms we have summarized below.  We will also include in the prospectus supplement information, where applicable, about material United States </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">federal income tax considerations relating to the securities, and the securities exchange, if any, on which the securities will be listed.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may sell from time to time, in one or more offerings:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">common stock;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">preferred stock;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">debt securities;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">warrants to purchase any of the securities listed above; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">units consisting of any combination of the securities listed above.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In this prospectus, we refer to the common stock, preferred stock, debt securities, warrants and units collectively as &#8220;securities.&#8221;  The total dollar amount of all securities that we may sell will not exceed $150,000,000.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we issue debt securities at a discount from their original stated principal amount, then, for purposes of calculating the total dollar amount of all securities issued under this prospectus, we will treat the initial offering price of the debt securities as the total original principal amount of the debt securities.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This prospectus may not be used to consummate a sale of securities unless it is accompanied by a prospectus supplement.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s5D9EEA0F41B9D9C7C5A0CE2658FE4794"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DESCRIPTION OF CAPITAL STOCK</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of all material characteristics of our capital stock as set forth in our certificate of incorporation and bylaws, and our outstanding warrants.  The summary does not purport to be complete and is qualified in its entirety by reference to our certificate of incorporation and bylaws and the Class&#160;D warrants, the warrants issued in our November&#160;2010 Common Stock Offering and in our November&#160;2010 Preferred Stock Offering, the warrants issued in connection with our merger (the &#8220;PCT Merger&#8221;) with Progenitor Cell Therapy, LLC ("PCT") and our merger (the "Amorcyte Merger") with Amorcyte, Inc. ("Amorcyte"), the Series NA Warrants, the warrants issued in our March&#160;2012 underwritten offering, the warrants issued in our May-July&#160;2012 Private Placement, the July&#160;2012 New Warrants issued upon exercise of certain of our May-July&#160;2012 Private Placement Warrants, and the warrants issued in our August&#160;2012 private placement themselves, all of which are incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and to the provisions of the General Corporation Law of the State of Delaware, as amended.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Common Stock</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are authorized to issue&#160;500,000,000 shares of common stock, par value $0.001&#160;per share (&#8220;Common Stock&#8221;).  Holders of our Common Stock are entitled to one vote per share in the election of directors and on all other matters on which stockholders are entitled or permitted to vote.  Holders of our Common Stock are not entitled to cumulative voting rights.  Therefore, holders of a majority of the shares voting for the election of directors can elect all of the directors.  Subject to the terms of any outstanding series of preferred stock, the holders of our Common Stock are entitled to dividends in the amounts and at times as may be declared by the Board of Directors out of funds legally available.  Upon liquidation or dissolution, holders of our Common Stock are entitled to share ratably in all net assets available for distribution to stockholders after payment of any liquidation preferences to holders of our preferred stock.  Holders of our Common Stock have no redemption, conversion or preemptive rights.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">August&#160;5, 2015</font><font style="font-family:inherit;font-size:10pt;">, we had&#160;</font><font style="font-family:inherit;font-size:10pt;">55,349,712</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Common Stock issued and outstanding, exclusive of existing convertible preferred stock, options and warrants and the shares and warrants to be issued pursuant to the registration statement of which this prospectus is a part.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Preferred Stock</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are authorized to issue up to&#160;20,000,000 shares of preferred stock, par value $0.01&#160;per share, with such designations, rights, and preferences as may be determined from time to time by our Board of Directors.  Accordingly, our Board of Directors is empowered, without stockholder approval, to issue preferred stock with dividend, liquidation, conversion, voting, or other rights that could adversely affect the voting power or other rights of the holders of our Common Stock.  The issuance of preferred stock </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">could have the effect of restricting dividends on our Common Stock, diluting the voting power of our Common Stock, impairing the liquidation rights of our Common Stock, or delaying or preventing a change in control of our company, all without further action by our stockholders.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">August&#160;5, 2015</font><font style="font-family:inherit;font-size:10pt;">, there were 10,000 shares of our Series B Convertible Redeemable Preferred Stock, $0.01 par value per share (&#8220;Series B Preferred Stock&#8221;), issued and outstanding.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Series B Preferred Stock</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Series B Preferred Stock ranks pari passu with our Common Stock with respect to the payment of dividends and to the distribution of assets upon liquidation, dissolution or winding up.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">So long as any shares of the Series B Preferred Stock are outstanding, no dividend shall be declared or paid or set aside for payment or other distribution declared or made upon our Common Stock or upon any other stock ranking junior to, or on a parity with, the Series B Preferred Stock as to dividends or upon liquidation, dissolution or winding up, unless, in the case of our preferred stock, the same dividend is declared, paid or set aside for payment on all outstanding shares of the Series B Preferred Stock or in the case of our Common Stock, ten times such dividend per share is declared, paid or set aside for payment on each outstanding share of the Series B Preferred Stock.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Except as otherwise provided by law, each share of the Series B Preferred Stock has the same voting rights as ten shares of our Common Stock and the holders of the Series B Preferred Stock and the Common Stock shall vote together as one class on all matters.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The holder of any share of Series B Preferred Stock has the right, at such holder&#8217;s option, to convert such share into one fully paid and non-assessable share of our Common Stock, subject to adjustment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the event of any voluntary or involuntary dissolution, liquidation or winding up of our Company, after any distribution of assets is made to the holders of any other class or series of stock that ranks prior to the Series B Preferred Stock in respect of distributions upon the liquidation of the Company, the holder of each share of Series B Preferred Stock then outstanding shall be entitled to be paid out of our assets available for distribution to our stockholders, an amount on a pari passu basis equal to ten times the amount per share distributed to the holders of our Common Stock.  After payment of the full amount of the distribution to which they are entitled, the holders of shares of the Series B Preferred Stock will not be entitled to any further participation in any distribution of assets by the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares of Series B Preferred Stock issued and reacquired by us shall have the status of authorized and unissued shares of preferred stock, undesignated as to series, subject to later issuance.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Holders of shares of Series B Preferred Stock are not entitled to any preemptive or subscription rights in respect of any securities of the corporation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">August&#160;5, 2015</font><font style="font-family:inherit;font-size:10pt;">, we had outstanding options to purchase an aggregate of&#160;</font><font style="font-family:inherit;font-size:10pt;">6,584,965</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our Common Stock with exercise prices ranging from </font><font style="font-family:inherit;font-size:10pt;">$2.12</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$100.00</font><font style="font-family:inherit;font-size:10pt;">&#160;per share, with an approximate weighted average exercise price of </font><font style="font-family:inherit;font-size:10pt;">$6.91</font><font style="font-family:inherit;font-size:10pt;">&#160;per share.  The shares of our Common Stock underlying all such options are registered with the SEC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrants</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">August&#160;5, 2015</font><font style="font-family:inherit;font-size:10pt;">, we had outstanding warrants to purchase an aggregate of&#160;</font><font style="font-family:inherit;font-size:10pt;">3,518,952</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our Common Stock with exercise prices ranging from </font><font style="font-family:inherit;font-size:10pt;">$3.60</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$50.00</font><font style="font-family:inherit;font-size:10pt;">, with an approximate weighted average exercise price of $</font><font style="font-family:inherit;font-size:10pt;">14.07</font><font style="font-family:inherit;font-size:10pt;">&#160;per share.  The shares of Common Stock underlying the vast majority of such warrants have been registered for resale.  The exercise prices, the number of shares or units sold and the number of shares that can be acquired on the exercise of the warrants disclosed in this section have been adjusted to take into account the Company's one-for-ten reverse stock split on July 16, 2013.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Class&#160;D Warrants</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;">April&#160;9, 2009</font><font style="font-family:inherit;font-size:10pt;">, we issued 880,000 Class D warrant in a private placement. Each Class&#160;D warrant entitles the holder to purchase one share of our Common Stock at an exercise price per share of </font><font style="font-family:inherit;font-size:10pt;">$25.00</font><font style="font-family:inherit;font-size:10pt;">.  The exercise price per share of each Class&#160;D warrant is subject to adjustment upon the occurrence of certain events as provided in the Class&#160;D warrant certificate and summarized </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">below.  The Class&#160;D warrants may be exercised at any time during their five year term, or eight year term in the case of a Class&#160;D warrant to purchase an aggregate of&#160;</font><font style="font-family:inherit;font-size:10pt;">400,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares held by RimAsia Capital Partners, L.P., a Cayman Islands exempted limited partnership and an affiliate of Caladrius (&#8220;RimAsia&#8221;), unless redeemed.  The Class&#160;D warrants which have not been previously exercised will expire at the end of their respective term.  A Class&#160;D warrant holder will not be deemed to be a holder of the underlying Common Stock for any purpose until the Class&#160;D warrant is exercised.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the event our Common Stock is trading at a per share price equal to or exceeding the redemption threshold of $35.00, or $50.00 in the case of the Class&#160;D warrant held by RimAsia, for twenty consecutive trading days, we have the option to call the Class&#160;D warrants.  If the holders of Class&#160;D warrants have not exercised the Class&#160;D Warrants within&#160;30&#160;days of the written notice to call, we may redeem the Class&#160;D warrants at $0.001&#160;per warrant.  We will send the written notice of call by first class mail to Class&#160;D warrant holders at their last known addresses appearing on the registration records maintained by the transfer agent of the Class&#160;D warrants.  No other form of notice by publication or otherwise will be required.  If we call any Class&#160;D Warrants for redemption, they will be exercisable until close of business on the business day next preceding the specified redemption date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The exercise price and redemption price of the Class&#160;D warrants are subject to adjustment in specified circumstances, including in the event we declare any stock dividend to stockholders or effect any split or reverse split with respect to our Common Stock after the issuance thereof.  Therefore, if we effect any stock split or reverse split with respect to our Common Stock, the exercise price in effect immediately prior to such stock split or reverse split will be proportionately reduced or increased, respectively.  Any adjustment of the exercise price will also result in an adjustment of the number of shares purchasable upon exercise of a Class&#160;D warrant or, if we elect, an adjustment of the number of Class&#160;D warrants outstanding.  The Class&#160;D warrants do not contain provisions protecting against dilution resulting from the sale of additional shares of our Common Stock for less than the exercise price of the Class&#160;D warrants or the current market price of our Common Stock.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Until exercised, the Class&#160;D warrants will have no voting, dividend or other stockholder rights.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Warrants Issued in Our November&#160;2010 Common Stock Offering</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November&#160;19, 2010, in connection with a public offering of our Common Stock and certain warrants, we issued (i) 633,798 shares of our Common Stock and (ii)&#160;warrants to purchase up to&#160;316,899 shares of our Common Stock (the &#8220;November&#160;2010 Common Stock Offering&#8221;).  The material terms and provisions of the warrants issued in connection with our November&#160;2010 Common Stock Offering are summarized below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Term; Exercise Price and Exercisability</font><font style="font-family:inherit;font-size:10pt;">.  In our November&#160;2010 Common Stock Offering we issued warrants representing the rights to purchase up to an aggregate of&#160;316,889 shares of our Common Stock (with&#160;</font><font style="font-family:inherit;font-size:10pt;">282,419</font><font style="font-family:inherit;font-size:10pt;">&#32;of such warrants remaining outstanding as of </font><font style="font-family:inherit;font-size:10pt;">August&#160;5, 2015</font><font style="font-family:inherit;font-size:10pt;">).  Each warrant has an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$18.50</font><font style="font-family:inherit;font-size:10pt;">&#160;per share, becoming exercisable six months after issuance and expiring five years from the date of issuance.  The number of warrant shares that may be acquired by any holder upon any exercise of the warrant will be limited to the extent necessary to insure that, following such exercise (or other issuance), the total number of shares of our Common Stock then beneficially owned by such holder and its affiliates and any other persons whose beneficial ownership of common stock would be aggregated with the holder&#8217;s for purposes of Section&#160;13(d) of the Exchange Act does not exceed&#160;4.99% of the total number of issued and outstanding shares of our Common Stock (including for such purpose the shares of our Common Stock issuable upon such exercise), which is referred to as the &#8220;beneficial ownership limitation.&#8221; The holder may elect to change this beneficial ownership limitation from&#160;4.99% to&#160;9.99% of the total number of issued and outstanding shares of our Common Stock (including for such purpose the shares of our Common Stock issuable upon such exercise) upon providing us with not less than&#160;61&#160;days&#8217; prior written notice.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Call Provision</font><font style="font-family:inherit;font-size:10pt;">.  Subject to certain exceptions, while the warrants are outstanding, if the volume weighted average price of a share of our Common Stock for each of&#160;20 consecutive Trading Days (the &#8220;Measurement Period,&#8221; which&#160;20 consecutive Trading Day period shall not have commenced until after the Initial Exercise Date) exceeds $37.00 (subject to adjustment), (i)&#160;the average daily volume for such Measurement Period exceeds $100,000&#160;per Trading Day (subject to adjustment) and (ii)&#160;the holder is not in possession of any information that constitutes, or might constitute, material non-public information which was provided by us, then we may, within&#160;1 Trading Day of the end of such Measurement Period, upon notice, call for cancellation of all or any portion of the warrants (a &#8220;Call&#8221;).  To exercise this right, we must send a Call notice indicating the portion of unexercised portion of the warrant to which the notice applies.  If the holders of the warrants have not exercised their warrants within 10 trading days after the date of the Call notice, then the warrants will be cancelled at 6:30 p.m. on the 10</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;trading after the date of the Call notice for consideration equal to $0.001 per share.  Our right to Call the warrants shall be exercised ratably among the holders based on each holder&#8217;s initial purchase of warrants from us.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fundamental Transaction</font><font style="font-family:inherit;font-size:10pt;">.  If, at any time while the warrants are outstanding, (1)&#160;we consolidate or merge with or into another corporation, (2)&#160;we sell, lease, license, assign, transfer, convey or otherwise dispose of all or substantially all of our assets, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3)&#160;any purchase offer, tender offer or exchange offer (whether by us or another individual or entity) is completed pursuant to which holders of our Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of&#160;50% or more of our outstanding Common Stock or (4)&#160;we effect any reclassification or recapitalization of our Common Stock or any compulsory share exchange pursuant to which our Common Stock is converted into or exchanged for other securities, cash or property (each, a &#8220;Fundamental Transaction&#8221;), then upon any subsequent exercise of the warrants, each holder thereof will have the right to receive the same amount and kind of securities, as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the number of warrant shares then issuable upon exercise of the warrant, and any additional consideration payable as part of the Fundamental Transaction;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;&#32;provided, however</font><font style="font-family:inherit;font-size:10pt;">, that in the event of a change of control transaction (as defined in the warrant) other than one in which the successor entity is a publicly traded corporation whose stock is listed or quoted for trading on the New York Stock Exchange, NASDAQ markets or the NYSE MKT and results in the warrants being exercisable for publicly traded common stock of such successor entity, at the request of a holder of a warrant delivered before the&#160;90th calendar day after consummation of such change of control transaction, we (or the successor entity) will purchase the warrant by paying to the holder, cash in an amount equal to the Black Scholes value, as described in the warrant, of the remaining unexercised portion of the warrant on the date of consummation of such change of control transaction.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Certain Adjustments</font><font style="font-family:inherit;font-size:10pt;">.  The exercise price and the number of shares of our Common Stock purchasable upon the exercise of the warrants are subject to adjustment upon the occurrence of specific events, including stock dividends, stock splits, combinations and reclassifications of our Common Stock.  Additionally, the exercise price of the warrants issued to the investors is subject to certain adjustments if we (i)&#160;issue rights, options or warrants to all holders of our Common Stock (and not to the warrant holder) entitling them to subscribe for or purchase shares of our Common Stock at a price per share less than the volume weighted average price (the &#8220;VWAP&#8221;) of our Common Stock on the record date for the determination of stockholders entitled to receive such rights, options or warrants, or (ii)&#160;distribute to all holders of our Common Stock (and not to the warrant holder) evidences of our indebtedness or assets (including cash and cash dividends) or rights or warrants to purchase any security.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fractional Shares</font><font style="font-family:inherit;font-size:10pt;">.  No fractional shares or scrip representing fractional shares shall be issued upon the exercise of the warrants.  As to any fraction of a share which the holder would otherwise be entitled to purchase upon such exercise, we will, at our election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the exercise price or round up to the next whole share.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Exchange Listing</font><font style="font-family:inherit;font-size:10pt;">.  We do not plan on making an application to list the warrants on the The Nasdaq Capital Market or any other national securities exchange or recognized trading system.  Our Common Stock underlying the warrants is listed on the The Nasdaq Capital Market.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The description of the warrants contained herein does not purport to be complete and is qualified in its entirety by reference to the form of warrant, which was filed as Exhibit&#160;4.1 to our Current Report on Form&#160;8-K filed with the SEC on November&#160;16, 2010 in connection with the November&#160;2010 Common Stock Offering.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">PCT Merger Warrants</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the closing of the PCT Merger on January&#160;19, 2011 (and in addition to the Common Stock consideration for the PCT Merger which we deposited into an escrow account at such time), we issued seven-year warrants to purchase an aggregate&#160;3,000,000 shares of our Common Stock (collectively, the &#8220;PCT Merger Warrants&#8221;).  The PCT Merger Warrants were delivered in book entry form to the former members of PCT after receipt by us of an appropriate letter of transmittal from the respective former member.  The PCT Merger Warrants are divided into three series as follows:  (i)&#160;warrants to purchase an aggregate&#160;1,000,000 shares of our Common Stock at an exercise price of $30.00&#160;per share (the &#8220;$30.00 Warrants&#8221;); (ii)&#160;warrants to purchase an aggregate&#160;1,000,000 shares of our Common Stock at an exercise price of $50.00&#160;per share (the &#8220;$50.00 Warrants&#8221;); and (iii)&#160;warrants to purchase an aggregate&#160;1,000,000 shares of our Common Stock at an exercise price of $70.00&#160;per share, which are now expired.  The material terms and provisions of the PCT Merger Warrants are summarized below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">$30.00 Warrants and $50.00 Warrants</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">General</font><font style="font-family:inherit;font-size:10pt;">.  Each $30.00 Warrant and $50.00 Warrant entitles the holder to purchase one share of Common Stock at an exercise price per share of $30.00 and $50.00, respectively.  The exercise price per share of each $30.00 Warrant and $50.00 Warrant is subject to adjustment upon the occurrence of certain events as provided in the applicable warrant certificate and summarized below.  The $30.00 Warrants and $50.00 Warrants may be exercised at any time during their seven year term, unless redeemed.  The $30.00 Warrants and $50.00 Warrants which have not been previously exercised will expire at the expiration date.  Holders of the warrants will not be deemed to be a holder of the underlying Common Stock for any purpose until such warrant is </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">exercised.  As described below, the Warrants are redeemable in certain circumstances.  Transfer of the shares issuable upon exercise of the Warrants had been restricted until the one year anniversary of the closing date of the PCT Merger.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Redemption</font><font style="font-family:inherit;font-size:10pt;">.  In the event Common Stock is trading at a per share price equal to or exceeding the redemption threshold of $50.00 with respect to the $30.00 Warrant or $70.00 with respect to the $50.00 Warrant for twenty (20)&#160;out of thirty (30)&#160;consecutive trading days, Caladrius has the option to call the applicable warrant.  If the warrant holders have not exercised the warrants within&#160;14&#160;days of the redemption notice, Caladrius may redeem the warrants at $0.001&#160;per warrant.  Caladrius will send the redemption notice by first class mail to warrant holders at their last known addresses appearing on the registration records maintained by the transfer agent of the warrants.  No other form of notice by publication or otherwise will be required.  If Caladrius calls any warrants for redemption, they will be exercisable until close of business on the business day next preceding the specified redemption date.  Notwithstanding the foregoing, Caladrius may not redeem the Warrants unless (i)&#160;Caladrius waives the lock-up provisions in the applicable Warrant and (ii)&#160;the issuance of the shares underlying the Warrants is covered by an effective registration statement or there is an effective resale registration statement available to the holders of the Warrants with respect to the shares underlying the Warrants.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Adjustments of Exercise Price</font><font style="font-family:inherit;font-size:10pt;">.  The exercise price and redemption price of the warrants are subject to adjustment in specified circumstances, including in the event (i)&#160;there is a merger or consolidation and Caladrius is not the surviving corporation; (ii)&#160;there is subdivision, combination or reclassification of securities, recapitalization, automatic conversion, or other similar event affecting the number or character of outstanding shares of Common Stock; or (iii)&#160;Caladrius declares any stock dividend to stockholders or effects any split or reverse split with respect to the Common Stock after the issuance thereof.  The warrants do not contain provisions protecting against dilution resulting from the sale of additional shares of Common Stock for less than the exercise price of the warrants or the current market price of the Common Stock.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">No Voting and Dividend Rights</font><font style="font-family:inherit;font-size:10pt;">.  Until exercised, the holders of the warrants will have no voting, dividend or other stockholder rights.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Registration Rights</font><font style="font-family:inherit;font-size:10pt;">.  Caladrius has agreed to use its commercially reasonable efforts to maintain the effectiveness of a registration statement covering the shares underlying the Warrants at any time that both (a)&#160;the Warrants are exercisable and (b)&#160;the exercise price of the Warrants is less than&#160;105% of the price at which the Common Stock is trading on the NYSE MKT (or, such other stock exchange on which the Common Stock trades).  Under certain limited circumstances, if a registration statement is not effective or a prospectus supplement is not available during the last&#160;20 business days prior to the expiration date of the Warrants, the exercise period of the Warrants would be extended for a period of&#160;20 business days following such effectiveness or availability.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The above description of the PCT Merger Warrants does not purport to be complete and is qualified in its entirety by reference to the Warrant Agreement (with the forms of $30.00 Warrant and $50.00 Warrant attached thereto), which was filed as Exhibit&#160;4.1 to our Current Report on Form&#160;8-K filed with the SEC on January&#160;24, 2011 in connection with the closing of the PCT Merger.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Series NA Warrants</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Background</font><font style="font-family:inherit;font-size:10pt;">.  On </font><font style="font-family:inherit;font-size:10pt;">July&#160;22, 2011</font><font style="font-family:inherit;font-size:10pt;">, we completed an underwritten offering of&#160;1,375,000 units, with each unit consisting of one share of our Common Stock and a warrant to purchase&#160;0.75 of a share of our Common Stock (each, a &#8220;Series NA Warrant&#8221;).  The Series NA Warrants issued in connection with the July&#160;2011 underwritten offering covered, in the aggregate, up to&#160;</font><font style="font-family:inherit;font-size:10pt;">1,031,250</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our Common Stock (with Series NA Warrants covering&#160;</font><font style="font-family:inherit;font-size:10pt;">976,500</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our Common Stock remaining outstanding as of </font><font style="font-family:inherit;font-size:10pt;">August&#160;5, 2015</font><font style="font-family:inherit;font-size:10pt;">).  The material terms and provisions of the Series NA Warrants are summarized below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Warrant Agreement</font><font style="font-family:inherit;font-size:10pt;">.  Pursuant to the terms of the underwriting entered into in connection with the July&#160;2011 offering, the Series NA Warrants may be issued through DTC and evidenced by a &#8220;Global Warrant&#8221; or may be delivered in physical or other appropriate form.  The Series NA Warrants are governed by a warrant agreement (the &#8220;Warrant Agreement&#8221;), dated as of July&#160;22, 2011, between us and Continental Stock Transfer &amp; Trust Company, as our agent in respect of the Series NA Warrants.  Book-entry form&#160;Series NA Warrants may be exercised by notifying a broker who is a DTC participant prior to the expiry of such warrants and providing payment of the exercise price for the number of shares of our Common Stock for which such warrants are being exercised.  The following description of the terms of the Warrant Agreement is subject to the detailed provisions of such Warrant Agreement, the form of which is filed as Exhibit&#160;4.1 to our Current Report on Form&#160;8-K filed with the SEC on July&#160;20, 2011.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Term; Exercise Price and Exercisability</font><font style="font-family:inherit;font-size:10pt;">.  Series NA Warrants representing the rights to purchase up to an aggregate of&#160;</font><font style="font-family:inherit;font-size:10pt;">976,500</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our Common Stock remain outstanding as of </font><font style="font-family:inherit;font-size:10pt;">August&#160;5, 2015</font><font style="font-family:inherit;font-size:10pt;">.  Each warrant has an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$14.50</font><font style="font-family:inherit;font-size:10pt;">&#160;per share, was immediately exercisable upon issuance, and will expire on July&#160;18, 2016.  The number of warrant shares that may be acquired by any holder upon any exercise of the warrant will be limited to the extent necessary to insure that, following such </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">exercise (or other issuance), the total number of shares of our Common Stock then beneficially owned by such holder and its affiliates and any other persons whose beneficial ownership of our Common Stock would be aggregated with the holder&#8217;s for purposes of Section&#160;13(d) of the Exchange Act, does not exceed&#160;4.99% of the total number of issued and outstanding shares of our Common Stock (including for such purpose the shares of our Common Stock issuable upon such exercise), or beneficial ownership limitation.  The holder may elect to change this beneficial ownership limitation from&#160;4.99% to&#160;9.99% of the total number of issued and outstanding shares of our Common Stock (including for such purpose the shares of our Common Stock issuable upon such exercise) upon providing us with not less than&#160;61&#160;days&#8217; prior written notice.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Manner of Exercise</font><font style="font-family:inherit;font-size:10pt;">.  Holders of the Series NA Warrants may exercise their Series NA Warrants to purchase shares of our Common Stock on or before the expiration date by delivering (i)&#160;notice of exercise, appropriately completed and duly signed, and (ii)&#160;if such holder is not utilizing the cashless exercise provisions with respect to the warrants, payment of the exercise price by wire transfer or cashier&#8217;s check drawn on a United States bank, for the number of shares with respect to which the warrant is being exercised.  Series NA Warrants may be exercised in whole or in part, but only for full shares of our Common Stock.  We provide certain buy-in rights to a holder if we fail to deliver the shares of our Common Stock underlying the Series NA Warrants by the second trading day after the date on which delivery of the stock certificate is required by the Series NA Warrant.  The buy-in rights apply if after the second trading day on which delivery of the stock is required by the Series NA Warrant, the holder purchases (in an open market transaction or otherwise) shares of our Common Stock to deliver in satisfaction of a sale by the holder of the warrant shares that the holder anticipated receiving from us upon exercise of the Series NA Warrant.  In such event, we will:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">pay in cash to the holder the amount equal to the excess (if any) of the buy-in price (including brokerage commissions, if any) over the product of (A)&#160;the number of warrant shares that we were required to deliver to the holder in connection with the exercise at issue, times (B)&#160;the price at which the sell order giving rise to holder&#8217;s purchase obligation was executed; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">at the election of holder, either (A)&#160;reinstate the portion of the Series NA Warrant as to such number of shares of our Common Stock for which such exercise was not honored, or (B)&#160;deliver to the holder such number of shares of our Common Stock that would have been exercised had we timely complied with our exercise and delivery obligations.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the holder of a Series NA Warrant desires to exercise its warrant and sell the shares issuable upon exercise of its warrant and there is no effective registration statement registering, or no current prospectus available for, the issuance or resale of the shares of our Common Stock underlying such warrants, in lieu of exercising its warrant by payment of a wire transfer or cashier&#8217;s check, the holder may elect to receive shares equal to the value of such holder&#8217;s warrant by surrender of the warrant to us, together with a properly endorsed notice of exercise.  The number of shares to be issued would be determined by a formula based on the total number of shares with respect to which the warrant is being exercised, the volume weighted average price for the shares of our Common Stock on the trading day immediately prior to the date of exercise and the applicable exercise price of the Series NA Warrants.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The shares of our Common Stock issuable on exercise of the Series NA warrants will be, when issued and paid for in accordance with the Series NA Warrants, duly authorized, validly issued and fully paid and non-assessable.  We have authorized and reserved at least that number of shares of our Common Stock equal to the number of shares of our Common Stock issuable upon exercise of all outstanding Series NA Warrants.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fundamental Transaction</font><font style="font-family:inherit;font-size:10pt;">.  If, at any time while the Series NA Warrants are outstanding, (1)&#160;we consolidate or merge with or into another corporation, (2)&#160;we sell, lease, license, assign, transfer, convey or otherwise dispose of all or substantially all of our assets, (3)&#160;any purchase offer, tender offer or exchange offer (whether by us or another individual or entity) is completed pursuant to which holders of our Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of&#160;50% or more of our outstanding Common Stock or (4)&#160;we effect any reclassification or recapitalization of our Common Stock or any compulsory share exchange pursuant to which our Common Stock is converted into or exchanged for other securities, cash or property (or the occurrence of any analogous proceeding) affecting us (each, a &#8220;Fundamental Transaction&#8221;), then upon any subsequent exercise of the Series NA Warrants, the holders thereof will have the right to receive the same amount and kind of securities, as they would have been entitled to receive upon the occurrence of such Fundamental Transaction if they had been, immediately prior to such Fundamental Transaction, the holder of the number of warrant shares then issuable upon exercise of the Series NA Warrant, and any additional consideration payable as part of the Fundamental Transaction;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;&#32;provided, however</font><font style="font-family:inherit;font-size:10pt;">, that in the event of a change of control transaction (as defined in the warrant) other than one in which the successor entity is a publicly traded corporation whose stock is listed or quoted for trading on the New York Stock Exchange, NASDAQ markets or the NYSE MKT and results in the Series NA Warrants being exercisable for publicly traded common stock of such successor entity, at the request of a holder of a warrant delivered before the&#160;90th calendar day after </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">consummation of such change of control transaction, we (or the successor entity) will purchase the warrant by paying to the holder, cash in an amount equal to the Black Scholes value, as described in the warrant, of the remaining unexercised portion of the warrant on the date of consummation of such change of control transaction.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Certain Adjustments</font><font style="font-family:inherit;font-size:10pt;">.  The exercise price and the number of shares of our Common Stock purchasable upon the exercise of the Series NA Warrants are subject to adjustment upon the occurrence of specific events, including stock dividends, stock splits, combinations and reclassifications of our Common Stock.  Additionally, the exercise price of the Series NA Warrants is subject to certain adjustments if we (i)&#160;issue rights, options or warrants to all holders of our Common Stock (and not to the warrant holder) entitling them to subscribe for or purchase shares of our Common Stock at a price per share less than the volume weighted average price (the &#8220;VWAP&#8221;) of our Common Stock on the record date for the determination of stockholders entitled to receive such rights, options or warrants, or (ii)&#160;distribute to all holders of our Common Stock (and not to the warrant holder) evidences of our indebtedness or assets (including cash and cash dividends) or rights or warrants to purchase any security.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Delivery of Certificates</font><font style="font-family:inherit;font-size:10pt;">.  Upon the holder&#8217;s exercise of a Series NA Warrant, we will promptly, but in no event later than three business days after the exercise date (referred to as the &#8220;warrant share delivery date&#8221;), issue and deliver, or cause to be issued and delivered, a certificate for the shares of our Common Stock issuable upon exercise of the Series NA Warrant.  In addition, we will, if the holder provides the necessary information to us, issue and deliver the shares electronically through The Depository Trust Corporation through its Deposit Withdrawal Agent Commission System (DWAC)&#160;or another established clearing corporation performing similar functions.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Notice of Corporate Action</font><font style="font-family:inherit;font-size:10pt;">.  We will provide prior notice to holders of the Series NA Warrants in advance of certain record or effective dates (as specified below) in connection with the following corporate events, to provide the holders of the Series NA Warrants with the opportunity to exercise their warrants and hold our Common Stock:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if we declare a dividend (or any other distribution in whatever form) on our Common Stock;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if we declare a special nonrecurring cash dividend on or a redemption of our Common Stock;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if we authorize the granting to all holders of our Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if the approval of any of our stockholders shall be required in connection with any reclassification of our Common Stock, any consolidation or merger to which we are a party, any sale or transfer of all or substantially all of our assets, or any compulsory share exchange whereby our Common Stock is converted into other securities, cash or property; or</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if we authorize the voluntary or involuntary liquidation or winding up of the affairs of our Company, </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">then, in each case, we will mail to the holders of the Series NA Warrants a notice stating:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of our Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined, or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of record of our Common Stock will be entitled to exchange their shares of Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subject to applicable law, the holder will be provided a reasonable opportunity (which shall be not less than eight calendar days notice) to exercise the Series NA Warrant prior to the effective date of the event triggering such notice.  No holders of the Series NA Warrants will possess any rights as a stockholder under those warrants until the holder exercises those warrants.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Transferability</font><font style="font-family:inherit;font-size:10pt;">.  The Series NA Warrants may be transferred independent of the Common Stock they were issued with, on a form of assignment, subject to all applicable laws.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fractional Shares</font><font style="font-family:inherit;font-size:10pt;">.  No fractional shares or scrip representing fractional shares shall be issued upon the exercise of the Series NA Warrants.  As to any fraction of a share which the holder would otherwise be entitled to purchase upon such exercise, we will, at our election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the exercise price or round up to the next whole share.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Exchange Listing</font><font style="font-family:inherit;font-size:10pt;">.  We do not plan on making an application to list the Series NA Warrants on the The Nasdaq Capital Market or any other national securities exchange or recognized trading system.  Our Common Stock underlying the Series NA Warrants is listed on the The Nasdaq Capital Market.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The description of the Series NA Warrants contained herein does not purport to be complete and is qualified in its entirety by reference to the Warrant Agreement and the Form of Warrant Certificate, which are filed as Exhibit&#160;4.1 to our Current Report on Form&#160;8-K filed with the SEC on July&#160;20, 2011.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Series AMO Warrants</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">General</font><font style="font-family:inherit;font-size:10pt;">.  Upon closing the Amorcyte Merger on October&#160;17, 2011, as a portion of the merger consideration we issued Series AMO Warrants to purchase an aggregate of&#160;</font><font style="font-family:inherit;font-size:10pt;">188,100</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our Common Stock (the &#8220;Series AMO Warrants&#8221;).  The Series AMO Warrants are evidenced by a &#8220;Global Warrant&#8221; and were delivered in book entry form to the former stockholders of Amorcyte.  Each Series AMO Warrant entitles the holder to purchase one share of our Common Stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$14.66</font><font style="font-family:inherit;font-size:10pt;">&#32;per share.  The exercise price per share of each Warrant will be subject to adjustment upon the occurrence of certain events as provided in the form of global warrant certificate and summarized below.  The Series AMO Warrants may be exercised at any time during their seven year term, unless redeemed; provided, however, that transfer of any shares of our Common Stock issuable upon exercise of the Series AMO Warrants was restricted until the one year anniversary of the closing date of the Amorcyte Merger.  The Series AMO Warrants which have not been previously exercised will expire at the end of their seven-year term.  A Series AMO Warrant holder will not be deemed to be a holder of the underlying Common Stock for any purpose until the Series AMO Warrant is exercised.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Redemption</font><font style="font-family:inherit;font-size:10pt;">.  In the event our Common Stock is trading at a per share price equal to or exceeding the redemption threshold of </font><font style="font-family:inherit;font-size:10pt;">$34.66</font><font style="font-family:inherit;font-size:10pt;">&#160;per share for twenty (20)&#160;out of thirty (30)&#160;consecutive trading days, we have the option to call the Series AMO Warrants.  If the holders of Series AMO Warrants have not exercised their warrants within&#160;14&#160;days of the redemption notice, we may redeem the Series AMO Warrants at $0.0001&#160;per warrant.  We will send the redemption notice by first class mail to Series AMO Warrant holders at their last known addresses appearing on the registration records maintained by the transfer agent of the Series AMO Warrants.  No other form of notice by publication or otherwise will be required.  If we call any Series AMO Warrants for redemption, they will be exercisable until close of business on the business day next preceding the specified redemption date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Adjustments of Exercise Price</font><font style="font-family:inherit;font-size:10pt;">.  The exercise price and redemption price of the Series AMO Warrants is subject to adjustment in specified circumstances, including in the event (i)&#160;there is a merger or consolidation and we are not the surviving corporation; (ii)&#160;there is subdivision, combination or reclassification of securities, recapitalization, automatic conversion, or other similar event affecting the number or character of outstanding shares of our Common Stock; or (iii)&#160;we declare any stock dividend to stockholders or effect any split or reverse split with respect to our Common Stock.  The Series AMO Warrants do not contain provisions protecting against dilution resulting from the sale of additional shares of our Common Stock for less than the exercise price of the Series AMO Warrants or the current market price of our Common Stock.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">No Voting and Dividend Rights</font><font style="font-family:inherit;font-size:10pt;">.  Until exercised, the Series AMO Warrants have no voting, dividend or other stockholder rights.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Registration Rights</font><font style="font-family:inherit;font-size:10pt;">.  We shall use commercially reasonable efforts to maintain the effectiveness of the Registration Statement on Form&#160;S-4 which covers the shares of our Common Stock underlying the Series AMO Warrants or file and maintain the effectiveness of another registration statement covering the shares of our Common Stock issuable upon exercise of the Series AMO Warrants at any time that both (a)&#160;the Series AMO Warrants are exercisable and (b)&#160;the exercise price of the Series AMO Warrants is less than&#160;105% of the price at which our Common Stock is trading on the NYSE MKT (or if our Common Stock is no longer trading on the NYSE MKT, such other stock exchange on which such shares trade).  In no event will any holder of a Series AMO Warrant be entitled to receive a &#8220;net cash settlement&#8221; in lieu of physical settlement in shares of our Common Stock regardless of whether we comply with our obligation described in the preceding sentence.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The description of the Series AMO Warrants contained herein does not purport to be complete and is qualified in its entirety by reference to the Warrant Agreement and the Form of Global Series AMO Warrant attached thereto, which is filed as Exhibit&#160;4.1 to our Current Report on Form&#160;8-K filed with the SEC on October&#160;17, 2011.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Warrants Issued in Our March&#160;2012 Underwritten Offering</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with a public offering of our Common Stock and certain warrants which closed as to&#160;1,500,000 units on March&#160;30, 2012 (and which closed with respect to an exercise of the underwriter&#8217;s over-allotment option to the extent of an additional&#160;200,000 units on April&#160;4, 2012) (the &#8220;March&#160;2012 Underwritten Offering&#8221;), we issued warrants to purchase up to an aggregate of&#160;1,700,000 shares of our Common Stock.  The material terms and provisions of the warrants issued in connection with our March&#160;2012 Underwritten Offering are summarized below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Term; Exercise Price and Exercisability</font><font style="font-family:inherit;font-size:10pt;">.  The warrants issued in our March&#160;2012 Underwritten Offering provided for the purchase of up to&#160;1,700,000 shares of our Common Stock in the aggregate (with&#160;</font><font style="font-family:inherit;font-size:10pt;">507,500</font><font style="font-family:inherit;font-size:10pt;">&#32;of such warrants remaining outstanding as of </font><font style="font-family:inherit;font-size:10pt;">August&#160;5, 2015</font><font style="font-family:inherit;font-size:10pt;">).  Each warrant has an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$5.10</font><font style="font-family:inherit;font-size:10pt;">&#160;per share, became exercisable in April&#160;2012 (the Company having waived the six-month waiting period to exercise the warrants), and will expire five years from the date of issuance.  The number of warrant shares that may be acquired by any holder upon any exercise of the warrant will be limited to the extent necessary to insure that, following such exercise (or other issuance), the total number of shares of Common Stock then beneficially owned by such holder and its affiliates and any other persons whose beneficial ownership of Common Stock would be aggregated with the holder&#8217;s for purposes of Section&#160;13(d) of the Securities Exchange Act of&#160;1934, as amended, does not exceed&#160;4.99% of the total number of issued and outstanding shares of Common Stock (including for such purpose the shares of Common Stock issuable upon such exercise), or beneficial ownership limitation.  The holder may elect to change this beneficial ownership limitation from&#160;4.99% to&#160;9.99% of the total number of issued and outstanding shares of Common Stock (including for such purpose the shares of Common Stock issuable upon such exercise) upon providing us with not less than&#160;61&#160;days&#8217; prior written notice.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Manner of Exercise</font><font style="font-family:inherit;font-size:10pt;">.  Holders of the warrants may exercise their warrants to purchase shares of our Common Stock at any time on or after the Initial Exercise Date and on or before the expiration date by delivering (i)&#160;notice of exercise, appropriately completed and duly signed, and (ii)&#160;payment of the exercise price by wire transfer or cashier&#8217;s check drawn on a United States bank, for the number of shares with respect to which the warrant is being exercised.  Warrants may be exercised in whole or in part, but only for full shares of Common Stock.  We provide certain buy-in rights to a holder if we fail to deliver the shares of Common Stock underlying the warrants by the date on which delivery of the warrant shares is required by the warrant.  The buy-in rights apply if after the day on which delivery of the warrant shares is required by the warrant, the holder purchases (in an open market transaction or otherwise) shares of our Common Stock to deliver in satisfaction of a sale by the holder of the warrant shares that the holder anticipated receiving from us upon exercise of the warrant.  In such event, we will:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">pay in cash to the holder the amount equal to the excess (if any) of the buy-in price (including brokerage commissions, if any) over the product of (A)&#160;the number of warrant shares that we were required to deliver to the holder in connection with the exercise at issue, times (B)&#160;the price at which the sell order giving rise to holder&#8217;s purchase obligation was executed; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">at the election of holder, either (A)&#160;reinstate the portion of the warrant as to such number of shares of Common Stock for which such exercise was not honored, or (B)&#160;deliver to the holder such number of shares of Common Stock that would have been issued had we timely complied with our exercise and delivery obligations.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the holder of a warrant desires to exercise its warrant and there is no effective registration statement registering, or no current prospectus available for, the issuance of the shares of Common Stock underlying the warrants, in lieu of exercising its warrant by payment of a wire transfer or cashier&#8217;s check, the holder may elect to receive shares equal to the value of such holder&#8217;s warrant by surrender of the warrant to us, together with a properly endorsed notice of exercise.  The number of shares to be issued would be determined by a formula based on the total number of shares with respect to which the warrant is being exercised, the volume weighted average price for the shares of our Common Stock on the trading day immediately prior to the date of exercise and the applicable exercise price of the warrants.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The shares of Common Stock issuable on exercise of the warrants will be, when issued and paid for in accordance with the warrants, duly authorized, validly issued and fully paid and non-assessable.  We will authorize and reserve at least that number of shares of Common Stock equal to the number of shares of Common Stock issuable upon exercise of all outstanding warrants.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Call Provision</font><font style="font-family:inherit;font-size:10pt;">.  Subject to certain exceptions, while the warrants are outstanding and following the Initial Exercise Date, if the volume weighted average price of a share of our Common Stock for each of&#160;10 consecutive Trading Days (the &#8220;Measurement Period,&#8221; which&#160;10 consecutive Trading Day period shall not have commenced until after the Initial Exercise Date) exceeds $15.30 (subject to adjustment), then we may, within&#160;1 Trading Day of the end of such Measurement Period, upon notice, call for cancellation of all or any portion of the warrants (a &#8220;Call&#8221;) for consideration equal to $0.001&#160;per Share.  Our right to Call the warrants shall be exercised ratably among the holders based on each holder&#8217;s initial purchase of warrants from us.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fundamental Transaction</font><font style="font-family:inherit;font-size:10pt;">.  If, at any time while the warrants are outstanding, (1)&#160;we consolidate or merge with or into another corporation, (2)&#160;we sell, lease, license, assign, transfer, convey or otherwise dispose of all or substantially all of our assets for consideration which is distributed to the holders of all our Common Stock, (3)&#160;any purchase offer, tender offer or exchange offer (whether by us or another individual or entity) is completed pursuant to which holders of our Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of&#160;50% or more of our outstanding Common Stock, (4)&#160;we effect any reclassification or recapitalization of our Common Stock or any compulsory share exchange pursuant to which our Common Stock is converted into or exchanged for other securities, cash or property or (5)&#160;we consummate a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another individual, entity or group whereby such other individual, entity or group acquires more than&#160;50% of our outstanding stock (or the occurrence of any analogous proceeding) affecting our company (each, a &#8220;Fundamental Transaction&#8221;), then upon any subsequent exercise of the warrants, the holders thereof will have the right to receive the same amount and kind of securities, as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the number of warrant shares then issuable upon exercise of the warrant, and any additional consideration payable as part of the Fundamental Transaction;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;&#32;provided, however,</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;that in the event of a Fundamental Transaction that is (1)&#160;an all cash transaction, (2)&#160;a &#8220;Rule&#160;13e-3 transaction&#8221; as defined in Rule&#160;13e-3 under the Exchange Act, or (3)&#160;a Fundamental Transaction (other than as described solely in clause&#160;(5) above) involving a person or entity not traded on a national securities exchange, including, but not limited to, the New York Stock Exchange, the NYSE MKT, The Nasdaq Global Select Market, The Nasdaq Global Market, or The Nasdaq Capital Market, we or any Successor Entity (as defined below) shall, at the holder&#8217;s option, exercisable at any time concurrently with, or within&#160;30&#160;days after, the consummation of the Fundamental Transaction, purchase the warrant from the holder by paying to the holder an amount of cash equal to the Black Scholes Value (as defined in the warrant) of the remaining unexercised portion of the warrant on the date of the consummation of such Fundamental Transaction, and we shall cause any successor entity in a Fundamental Transaction in which we are not the survivor (the &#8220;Successor Entity&#8221;) to assume in writing all of our obligations under the warrant prior to such Fundamental Transaction and shall, at the option of the holder, deliver to the holder in exchange for the warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to the warrants which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of the warrants (without regard to any limitations on the exercise of the warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price under the warrant to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of the warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the holder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Certain Adjustments</font><font style="font-family:inherit;font-size:10pt;">.  The exercise price and the number of shares of Common Stock purchasable upon the exercise of the warrants are subject to adjustment upon the occurrence of specific events, including stock dividends, stock splits, combinations and reclassifications of our Common Stock.  Additionally, the exercise price of the warrants issued to the investors is subject to certain adjustments if we (i)&#160;issue rights, options or warrants to all holders of Common Stock (and not to the warrant holder) entitling them to subscribe for or purchase shares of Common Stock at a price per share less than the volume weighted average price (the &#8220;VWAP&#8221;) of the Common Stock on the record date for the determination of stockholders entitled to receive such rights, options or warrants, or (ii)&#160;distribute to all holders of Common Stock (and not to the warrant holder) evidences of our indebtedness or assets (including cash and cash dividends) or rights or warrants to purchase any security.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Delivery of Warrant Shares</font><font style="font-family:inherit;font-size:10pt;">.  Upon the holder&#8217;s exercise of a warrant, we will promptly, but in no event later than three business days after the exercise date (referred to as the &#8220;exercise share delivery date&#8221;), issue and deliver, or cause to be issued and delivered, the shares of Common Stock issuable upon exercise of the warrant.  If the holder provides the necessary information to us, we will issue and deliver the shares electronically through The Depository Trust Corporation through its Deposit Withdrawal Agent Commission System (DWAC)&#160;or another established clearing corporation performing similar functions.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Notice of Corporate Action</font><font style="font-family:inherit;font-size:10pt;">.  We will provide prior notice to holders of the warrants in advance of certain record or effective dates (as specified below) in connection with the following corporate events, to provide the holders of the warrants with the opportunity to exercise their warrants and hold Common Stock:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if we declare a dividend (or any other distribution in whatever form) on our Common Stock;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if we declare a special nonrecurring cash dividend on or a redemption of Common Stock;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if we authorize the granting to all holders of our Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if the approval of any of our stockholders shall be required in connection with any reclassification of our Common Stock, any consolidation or merger to which our Company is a party, any sale or transfer of all or substantially all of our assets, or any compulsory share exchange whereby our Common Stock is converted into other securities, cash or property; or</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if we authorize the voluntary or involuntary liquidation or winding up of the affairs of the Company,</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">then, in each case, we will mail to the holders of the warrants a notice stating:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of our Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined, or</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of record of our Common Stock will be entitled to exchange their shares of Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subject to applicable law, the holder will be provided a reasonable opportunity to exercise the warrant prior to the effective date of the event triggering such notice.  No holders of the warrants will possess any rights as a stockholder under those warrants until the holder exercises those warrants.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Transferability</font><font style="font-family:inherit;font-size:10pt;">.  The warrants may be transferred independent of the Common Stock they were issued with, on a form of assignment, subject to all applicable laws.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fractional Shares</font><font style="font-family:inherit;font-size:10pt;">.  No fractional shares or scrip representing fractional shares shall be issued upon the exercise of the warrants.  As to any fraction of a share which the holder would otherwise be entitled to purchase upon such exercise, we will, at our election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the exercise price or round up to the next whole share.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Exchange Listing</font><font style="font-family:inherit;font-size:10pt;">.  We do not plan on making an application to list the warrants on the The Nasdaq Capital Market or any other national securities exchange or recognized trading system.  The Common Stock underlying the warrants is listed on the The Nasdaq Capital Market.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The above description of the warrants issued in our March&#160;2012 Underwritten Offering does not purport to be complete and is qualified in its entirety by reference to the form of warrant, which was filed as Exhibit&#160;4.1 to our Current Report on Form&#160;8-K filed with the SEC on March&#160;29, 2012 in connection with the March&#160;2012 Underwritten Offering.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Warrants Issued in Connection With Our May-July&#160;2012 Private Placement</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">May-July&#160;2012 Private Placement Warrants</font><font style="font-family:inherit;font-size:10pt;">.  In closings occurring from May through August&#160;2012, we issued in a private placement an aggregate of&#160;</font><font style="font-family:inherit;font-size:10pt;">534,583</font><font style="font-family:inherit;font-size:10pt;">&#32;units, with each unit consisting of (i)&#160;one share of our Common Stock and (ii)&#160;a warrant to purchase one share of our Common Stock at an exercise price of $5.10&#160;per share, exercisable during the five-year period following the date of issuance (our board of directors having waived the six month waiting period provided for in the form of warrant) (each, a &#8220;May-July&#160;2012 Private Placement Warrant&#8221;).  As of </font><font style="font-family:inherit;font-size:10pt;">August&#160;5, 2015</font><font style="font-family:inherit;font-size:10pt;">, May-July&#160;2012 Private Placement Warrants covering an aggregate of&#160;</font><font style="font-family:inherit;font-size:10pt;">25,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our Common Stock remained outstanding.  In the event the average closing price of our Common Stock equals or exceeds $10.00&#160;per share for&#160;20 out of&#160;30 consecutive trading days, we have the option to call the May-July&#160;2012 Private Placement Warrants by mailing a notice to the registered holders thereof at least&#160;10 business days prior to the date fixed by us for redemption (the &#8220;Redemption Date&#8221;).  Any May-July&#160;2012 Private Placement Warrants not exercised by&#160;5:00 p.m. on the business day immediately preceding the Redemption Date shall terminate, with the holder of such terminated warrants having no further rights except to receive, upon surrender of the warrants, the redemption price of $.0001&#160;per warrant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">July&#160;2012 New Warrants</font><font style="font-family:inherit;font-size:10pt;">.  In July&#160;2012, an aggregate of&#160;</font><font style="font-family:inherit;font-size:10pt;">280,814</font><font style="font-family:inherit;font-size:10pt;">&#32;of the May-July&#160;2012 Private Placement Warrants were exercised, and in consideration for such exercises, we issued to each exercising holder a new five-year warrant (each, a &#8220;July&#160;2012 New Warrant&#8221;) to purchase the identical number of shares of our Common Stock as had been covered by such portion of the old </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May-July&#160;2012 Private Placement Warrant as had been exercised.  Each July&#160;2012 New Warrant is exercisable for five years and is subject to substantially the same terms as the old May-July&#160;2012 Private Placement Warrants that were exercised, except that the per share exercise price of each July&#160;2012 New Warrant is between </font><font style="font-family:inherit;font-size:10pt;">$6.60</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$6.90</font><font style="font-family:inherit;font-size:10pt;">, the closing price of our Common Stock on the date the old May-July&#160;2012 Private Placement Warrant was exercised. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Warrants Issued in Connection With Our August&#160;2012 Private Placement</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In an August&#160;2012 private placement, we issued an aggregate of&#160;</font><font style="font-family:inherit;font-size:10pt;">295,438</font><font style="font-family:inherit;font-size:10pt;">&#32;units, with each Unit consisting of (a)&#160;one share of common stock and (b)&#160;a warrant (each, an &#8220;August&#160;2012 Private Placement Warrant&#8221;) to purchase one share of Common Stock at an exercise price ranging from </font><font style="font-family:inherit;font-size:10pt;">$7.00</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$7.40</font><font style="font-family:inherit;font-size:10pt;">, expiring five years from the date of issuance and are exercisable immediately upon issuance (with August 2012 Private Placement Warrants covering </font><font style="font-family:inherit;font-size:10pt;">217,720</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our Common Stock remaining outstanding as of August 5, 2015). In the event the average closing price of our Common Stock equals or exceeds </font><font style="font-family:inherit;font-size:10pt;">$15.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share for 20 out of 30 consecutive trading days, we have the option to redeem these warrants by mailing a notice to the registered holders thereof at least 10 business days prior to the date fixed by us for redemption (the &#8220;Redemption Date&#8221;). Any August 2012 Private Placement Warrants not exercised by 5:00 p.m. on the business day immediately preceding the Redemption Date shall terminate, with the holder of such terminated warrants having no further rights except to receive, upon surrender of the warrants, the redemption price of $.0001 per warrant. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Anti-Takeover Effects of Certain Provisions of Delaware Law and Our Certificate of Incorporation and Bylaws</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Amended and Restated Certificate of Incorporation and bylaws contain some provisions that could make our acquisition by means of a tender or exchange offer, a proxy contest or otherwise more difficult.  These provisions are summarized below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Special Meetings</font><font style="font-family:inherit;font-size:10pt;">.  Our bylaws provide that special meetings of our stockholders may, unless otherwise prescribed by law, be called by our Chairman of the Board (if any), our Board of Directors or our Chief Executive Officer and shall be held at such place, on such date and at such time as shall be fixed by our Board of Directors or the person calling the meeting.  Business transacted at any special meeting shall be limited to matters relating to the purpose or purposes stated in the notice of the meeting.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Undesignated Preferred Stock</font><font style="font-family:inherit;font-size:10pt;">.  The ability to authorize undesignated preferred stock makes it possible for our Board of Directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to acquire us.  The ability to issue preferred stock may have the effect of deferring hostile takeovers or delaying changes in control or management of our company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Delaware Anti-Takeover Statute</font><font style="font-family:inherit;font-size:10pt;">.  We are subject to the provisions of Section&#160;203 of the Delaware General Corporation Law regulating corporate takeovers.  In general, Section&#160;203 prohibits a publicly held Delaware corporation from engaging in a business combination with an interested stockholder for a period of three years following the date the person became an interested stockholder unless:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the stockholder owned at least&#160;85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (1)&#160;shares owned by persons who are directors and also officers and (2)&#160;shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">on or subsequent to the date of the transaction, the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least&#160;66 2/3% of the outstanding voting stock which is not owned by the interested stockholder.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Generally, a business combination includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder.  An interested stockholder is a person who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, owned&#160;15% or more of a corporation&#8217;s outstanding voting securities.  We expect the existence of this provision to have an anti-takeover effect with respect to transactions our Board of Directors does not approve in advance.  We also anticipate that Section&#160;203 may discourage attempted acquisitions that might result in a premium over the market price for the shares of our Common Stock held by stockholders.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The provisions of Delaware law, our Amended and Restated Certificate of Incorporation and our bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our Common Stock that often result from actual or rumored hostile takeover attempts.  These provisions may also have the effect of preventing changes in our management.  It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Potential Effects of Authorized but Unissued Stock</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have shares of Common Stock and preferred stock available for future issuance without stockholder approval.  We may utilize these additional shares for a variety of corporate purposes, including future public offerings to raise additional capital, to facilitate corporate acquisitions or payment as a dividend on the capital stock.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The existence of unissued and unreserved Common Stock and preferred stock may enable our Board of Directors to issue shares to persons friendly to current management or to issue preferred stock with terms that could render more difficult or discourage a third-party attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise, thereby protecting the continuity of our management.  In addition, the Board of Directors has the discretion to determine designations, rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences of each series of preferred stock, all to the fullest extent permissible under the Delaware General Corporation Law and subject to any limitations set forth in our certificate of incorporation.  The purpose of authorizing the Board of Directors to issue preferred stock and to determine the rights and preferences applicable to such preferred stock is to eliminate delays associated with a stockholder vote on specific issuances.  The issuance of preferred stock, while providing desirable flexibility in connection with possible financings, acquisitions and other corporate purposes, could have the effect of making it more difficult for a third party to acquire, or could discourage a third party from acquiring, a majority of our outstanding voting stock.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Limitations of Director Liability and Indemnification of Directors, Officers and Employees</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section&#160;145 of the Delaware General Corporation Law, permits indemnification of directors, officers, agents and controlling persons of a corporation under certain conditions and subject to certain limitations.  Section&#160;145 empowers a corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding whether civil, criminal, administrative or investigative, by reason of the fact that he or she is or was a director, officer or agent of the corporation or another enterprise if serving at the request of the Company.  Depending on the character of the proceeding, a corporation may indemnify against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding if the person indemnified acted in good faith and in a manner he or she reasonably believed to be in or not opposed to, the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.  In the case of an action by or in the right of the corporation, no indemnification may be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine that despite the adjudication of liability such person is fairly and reasonably entitled to indemnity for such expenses which the court shall deem proper.  Section&#160;145 further provides that to the extent a present or former director or officer of a corporation has been successful in the defense of any action, suit or proceeding referred to above or in the defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys&#8217; fees) actually and reasonably incurred by such person in connection therewith.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Litigation Forum Selection Clause</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our bylaws provides that, unless we consent in writing to the selection of an alternative forum, the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Company to the Company or its stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law or our certificate of incorporation or our bylaws or (iv) any action asserting a claim governed by the internal affairs doctrine shall be the Court of Chancery in the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Indemnification Agreements</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into indemnification agreements with each of our Chief Executive Officer, Chief Financial Officer, General Counsel, certain other employees and each of our directors pursuant to which we have agreed to indemnify such party to the full extent permitted by law, subject to certain exceptions, if such party becomes subject to an action because such party is our director, officer, employee, agent or fiduciary.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Transfer Agent</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The transfer agent and registrar for our Common Stock is Continental Stock Transfer &amp; Trust Company.  Its address is&#160;17 Battery Place, New York, New York, 10004 and its telephone number is (212) 509-4000.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The Nasdaq Capital Market</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Common Stock is traded on the The Nasdaq Capital Market under the symbol &#8220;CLBS.&#8221;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sB9E8521609CD6DF3570FCE265950558B"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DESCRIPTION OF DEBT SECURITIES</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We summarize below some of the provisions that will apply to the debt securities unless the applicable prospectus supplement provides otherwise.  This summary may not contain all information that is important to you.  The complete terms of the debt securities will be contained in the applicable notes.  The notes will be included or incorporated by reference as exhibits to the registration statement of which this prospectus is a part.  You should read the provisions of the notes.  You should also read the prospectus supplement, which will contain additional information and which may update or change some of the information below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">General</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This prospectus describes certain general terms and provisions of the debt securities.  The debt securities will be issued under an indenture between us and a trustee to be designated prior to the issuance of the debt securities.  When we offer to sell a particular series of debt securities, we will describe the specific terms of the securities in a supplement to this prospectus.  The prospectus supplement will also indicate whether the general terms and provisions described in this prospectus apply to a particular series of debt securities.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may issue, from time to time, debt securities, in one or more series, that will consist of either our senior debt (&#8220;senior debt securities&#8221;), our senior subordinated debt (&#8220;senior subordinated debt securities&#8221;), our subordinated debt (&#8220;subordinated debt securities&#8221;) or our junior subordinated debt (&#8220;junior subordinated debt securities&#8221; and, together with the senior subordinated debt securities and the subordinated debt securities, the &#8220;subordinated securities&#8221;).  Debt securities, whether senior, senior subordinated, subordinated or junior subordinated, may be issued as convertible debt securities or exchangeable debt securities.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have summarized herein certain terms and provisions of the form of indenture (the &#8220;indenture&#8221;).  The summary is not complete and is qualified in its entirety by reference to the actual text of the indenture.  The indenture is an exhibit to the registration statement of which this prospectus is a part.  You should read the indenture for the provisions which may be important to you.  The indenture is subject to and governed by the Trust Indenture Act of&#160;1939, as amended.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The indenture does not limit the amount of debt securities which we may issue.  We may issue debt securities up to an aggregate principal amount as we may authorize from time to time which securities may be in any currency or currency unit designated by us.  The terms of each series of debt securities will be established by or pursuant to (a)&#160;a supplemental indenture, (b)&#160;a resolution of our board of directors, or (c)&#160;an officers&#8217; certificate pursuant to authority granted under a resolution of our board of directors.  The prospectus supplement will describe the terms of any debt securities being offered, including:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the title of the debt securities;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the limit, if any, upon the aggregate principal amount or issue price of the debt securities of a series;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ranking of the specific series of debt securities relative to other outstanding indebtedness, including any debt of any of our subsidiaries;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the price or prices at which the debt securities will be issued;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the designation, aggregate principal amount and authorized denominations of the series of debt securities;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the issue date or dates of the series and the maturity date of the series;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">whether the securities will be issued at par or at a premium over or a discount from their face amount;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the interest rate, if any, and the method for calculating the interest rate and basis upon which interest shall be calculated;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the right, if any, to extend interest payment periods and the duration of the extension;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the interest payment dates and the record dates for the interest payments;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any mandatory or optional redemption terms or prepayment, conversion, sinking fund or exchangeability or convertibility provisions;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the currency of denomination of the securities;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the place where we will pay principal, premium, if any, and interest, if any, and the place where the debt securities may be presented for transfer;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if payments of principal of, premium, if any, or interest, if any, on the debt securities will be made in one or more currencies or currency units other than that or those in which the debt securities are denominated, the manner in which the exchange rate with respect to these payments will be determined;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if other than denominations of $1,000 or multiples of $1,000, the denominations the debt securities will be issued in;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">whether the debt securities will be issued in the form of global securities or certificates;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the applicability of and additional provisions, if any, relating to the defeasance of the debt securities;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the portion of principal amount of the debt securities payable upon declaration of acceleration of the maturity date, if other than the entire principal amount;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the currency or currencies, if other than the currency of the United States, in which principal and interest will be paid;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the dates on which premium, if any, will be paid;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any addition to or change in the &#8220;Events of Default&#8221; described in this prospectus or in the indenture with respect to the debt securities and any change in the acceleration provisions described in this prospectus or in the indenture with respect to the debt securities;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any addition to or change in the covenants described in the prospectus or in the indenture with respect to the debt securities;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our right, if any, to defer payment of interest and the maximum length of this deferral period; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">other specific terms, including any additional events of default or covenants.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may issue debt securities at a discount below their stated principal amount.  Even if we do not issue the debt securities below their stated principal amount, for United States federal income tax purposes the debt securities may be deemed to have been issued with a discount because of certain interest payment characteristics.  We will describe in any applicable prospectus supplement the United States federal income tax considerations applicable to debt securities issued at a discount or deemed to be issued at a discount, and will describe any special United States federal income tax considerations that may be applicable to the particular debt securities.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Senior Debt</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Senior debt securities will rank equally and</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;pari passu</font><font style="font-family:inherit;font-size:10pt;">&#32;with all of our other unsecured and unsubordinated debt from time to time outstanding.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subordinated Debt</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The indenture does not limit our ability to issue subordinated debt securities.  Any subordination provisions of a particular series of debt securities will be set forth in the supplemental indenture, board resolution or officers&#8217; certificate related to that series of debt securities and will be described in the relevant prospectus supplement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If this prospectus is being delivered in connection with a series of subordinated debt securities, the accompanying prospectus supplement or the information incorporated by reference in this prospectus will set forth the approximate amount of senior indebtedness outstanding as of the end of the most recent fiscal quarter.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Conversion or Exchange Rights</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt securities may be convertible into or exchangeable for our other securities or property.  The terms and conditions of conversion or exchange will be set forth in the supplemental indenture, board resolution or officers&#8217; certificate related to that series of debt securities and will be described in the relevant prospectus supplement.  The terms will include, among others, the following:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the conversion or exchange price;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the conversion or exchange period;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">provisions regarding our ability or the ability of the holder to convert or exchange the debt securities;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">events requiring adjustment to the conversion or exchange price; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">provisions affecting conversion or exchange in the event of our redemption of the debt securities.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Merger, Consolidation or Sale of Assets</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The indenture prohibits us from merging into or consolidating with any other person or selling, leasing or conveying substantially all of our assets and the assets of our subsidiaries, taken as a whole, to any person, unless:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">either we are the continuing corporation or the successor corporation or the person which acquires by sale, lease or conveyance substantially all our or our subsidiaries&#8217; assets is a corporation organized under the laws of the United States, any state thereof, or the District of Columbia, and expressly assumes the due and punctual payment of the principal of, and premium, if any, and interest, if any, on all the debt securities and the due performance of every covenant of the indenture to be performed or observed by us, by supplemental indenture satisfactory to the trustee, executed and delivered to the trustee by such corporation;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">immediately after giving effect to such transactions, no Event of Default described under the caption &#8220;Events of Default and Remedies&#8221; below or event which, after notice or lapse of time or both would become an Event of Default, has happened and is continuing; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we have delivered to the trustee an officers&#8217; certificate and an opinion of counsel each stating that such transaction and such supplemental indenture comply with the indenture provisions relating to merger, consolidation and sale of assets.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon any consolidation or merger with or into any other person or any sale, conveyance, lease, or other transfer of all or substantially all of our or our subsidiaries&#8217; assets to any person, the successor person shall succeed, and be substituted for, us under the indenture and each series of outstanding debt securities, and we shall be relieved of all obligations under the indenture and each series of outstanding debt securities to the extent we were the predecessor person.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Events of Default and Remedies</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When we use the term &#8220;Event of Default&#8221; in the indenture with respect to the debt securities of any series, we mean:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">default in paying interest on the debt securities when it becomes due and the default continues for a period of&#160;30&#160;days or more;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">default in paying principal, or premium, if any, on the debt securities when due;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">default is made in the payment of any sinking or purchase fund or analogous obligation when the same becomes due, and such default continues for&#160;30&#160;days or more;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">default in the performance, or breach, of any covenant or warranty in the indenture (other than defaults specified in clause&#160;(1), (2)&#160;or (3)&#160;above) and the default or breach continues for a period of&#160;60&#160;days or more after we receive written notice of such default from the trustee or we and the trustee receive notice from the holders of at least&#160;25% in aggregate principal amount of the outstanding debt securities of the series;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">certain events of bankruptcy, insolvency, reorganization, administration or similar proceedings with respect to us have occurred; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(6)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any other Event of Default provided with respect to debt securities of that series that is set forth in the applicable prospectus supplement accompanying this prospectus.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No Event of Default with respect to a particular series of debt securities (except as to certain events of bankruptcy, insolvency or reorganization) necessarily constitutes an Event of Default with respect to any other series of debt securities.  The occurrence of certain Events of Default or an acceleration under the indenture may constitute an event of default under certain of our other indebtedness that we may have outstanding from time to time.  Unless otherwise provided by the terms of an applicable series of debt securities, if an Event of Default under the indenture occurs with respect to the debt securities of any series and is continuing, then the trustee or the holders of not less than&#160;51% of the aggregate principal amount of the outstanding debt securities of that series may by written notice require us to repay immediately the entire principal amount of the outstanding debt securities of that series (or such lesser amount as may be provided in the terms of the securities), together with all accrued and unpaid interest and premium, if any.  In the case of an Event of Default resulting from certain events of bankruptcy, insolvency or reorganization, the principal (or such specified amount) of and accrued and unpaid interest, if any, on all outstanding debt securities will become and be immediately due and payable without any declaration or other act on the part of the trustee or any holder of outstanding debt securities.  We refer you to the prospectus supplement relating to any series of debt securities that are discount securities for the particular provisions relating to acceleration of a portion of the principal amount of such discount securities upon the occurrence of an Event of Default.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">After a declaration of acceleration, the holders of a majority in aggregate principal amount of outstanding debt securities of any series may rescind this accelerated payment requirement if all existing Events of Default, except for nonpayment of the principal on the debt securities of that series that has become due solely as a result of the accelerated payment requirement, have been cured or waived and if the rescission of acceleration would not conflict with any judgment or decree.  The holders of a majority in aggregate principal amount of the outstanding debt securities of any series also have the right to waive past defaults, except a default in paying principal or interest on any outstanding debt security, or in respect of a covenant or a provision that cannot be modified or amended without the consent of all holders of the debt securities of that series.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No holder of any debt security may seek to institute a proceeding with respect to the indenture unless such holder has previously given written notice to the trustee of a continuing Event of Default, the holders of not less than&#160;51% in aggregate principal amount of the outstanding debt securities of the series have made a written request to the trustee to institute proceedings in respect of the Event of Default, the holder or holders have offered reasonable indemnity to the trustee and the trustee has failed to institute such proceeding within&#160;60&#160;days after it received this notice.  In addition, within this&#160;60-day period the trustee must not have received directions inconsistent with this written request by holders of a majority in aggregate principal amount of the outstanding debt securities of that series.  These limitations do not apply, however, to a suit instituted by a holder of a debt security for the enforcement of the payment of principal, interest or any premium on or after the due dates for such payment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the existence of an Event of Default actually known to a responsible officer of the trustee, the trustee is required to exercise the rights and powers vested in it under the indenture and use the same degree of care and skill in its exercise as a prudent person would under the circumstances in the conduct of that person&#8217;s own affairs.  If an Event of Default has occurred and is continuing, the trustee is not under any obligation to exercise any of its rights or powers at the request or direction of any of the holders unless the holders have offered to the trustee security or indemnity reasonably satisfactory to the trustee.  Subject to certain provisions, the holders of a majority in aggregate principal amount of the outstanding debt securities of any series have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust, or power conferred on the trustee.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The trustee will, within&#160;90&#160;days after receiving notice of any default, give notice of the default to the holders of the debt securities of that series, unless the default was already cured or waived.  Unless there is a default in paying principal, interest or any premium when due, the trustee can withhold giving notice to the holders if it determines in good faith that the withholding of notice is in the interest of the holders.  In the case of a default specified in clause&#160;(4) above describing Events of Default, no notice of default to the holders of the debt securities of that series will be given until&#160;60&#160;days after the occurrence of the event of default.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The indenture requires us, within&#160;120&#160;days after the end of our fiscal year, to furnish to the trustee a statement as to compliance with the indenture.  The indenture provides that the trustee may withhold notice to the holders of debt securities of any series of any Event of Default (except in payment on any debt securities of that series) with respect to debt securities of that series if it in good faith determines that withholding notice is in the interest of the holders of those debt securities.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Modification and Waiver</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The indenture may be amended or modified without the consent of any holder of debt securities in order to:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">evidence a successor to the trustee;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">cure ambiguities, defects or inconsistencies;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">provide for the assumption of our obligations in the case of a merger or consolidation or transfer of all or substantially all of our assets that complies with the covenant described under &#8220;- Merger, Consolidation or Sale of Assets&#8221;;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">make any change that would provide any additional rights or benefits to the holders of the debt securities of a series;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">add guarantors or co-obligors with respect to the debt securities of any series;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">secure the debt securities of a series;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">establish the form or forms of debt securities of any series;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">add additional Events of Default with respect to the debt securities of any series;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">add additional provisions as may be expressly permitted by the Trust Indenture Act;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">maintain the qualification of the indenture under the Trust Indenture Act; or</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">make any change that does not adversely affect in any material respect the interests of any holder.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other amendments and modifications of the indenture or the debt securities issued may be made with the consent of the holders of not less than a majority in aggregate principal amount of the outstanding debt securities of each series affected by the amendment or modification.  However, no modification or amendment may, without the consent of the holder of each outstanding debt security affected:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">change the maturity date or the stated payment date of any payment of premium or interest payable on the debt securities;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reduce the principal amount, or extend the fixed maturity, of the debt securities;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">change the method of computing the amount of principal or any interest of any debt security;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">change or waive the redemption or repayment provisions of the debt securities;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">change the currency in which principal, any premium or interest is paid or the place of payment;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reduce the percentage in principal amount outstanding of debt securities of any series which must consent to an amendment, supplement or waiver or consent to take any action;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">impair the right to institute suit for the enforcement of any payment on the debt securities;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">waive a payment default with respect to the debt securities;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reduce the interest rate or extend the time for payment of interest on the debt securities;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adversely affect the ranking or priority of the debt securities of any series; or</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">release any guarantor or co-obligor from any of its obligations under its guarantee or the indenture, except in compliance with the terms of the indenture.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Satisfaction, Discharge and Covenant Defeasance</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may terminate our obligations under the indenture with respect to the outstanding debt securities of any series, when:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">either:</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">all debt securities of any series issued that have been authenticated and delivered have been delivered to the trustee for cancellation; or</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">all the debt securities of any series issued that have not been delivered to the trustee for cancellation have become due and payable, will become due and payable within one year, or are to be called for redemption within one year and we have made arrangements satisfactory to the trustee for the giving of notice of redemption by such trustee in our name and at our expense, and in each case, we have irrevocably deposited or caused to be deposited with the trustee sufficient funds to pay and discharge the entire indebtedness on the series of debt securities; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we have paid or caused to be paid all other sums then due and payable under the indenture; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we have delivered to the trustee an officers&#8217; certificate and an opinion of counsel, each stating that all conditions precedent under the indenture relating to the satisfaction and discharge of the indenture have been complied with.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may elect to have our obligations under the indenture discharged with respect to the outstanding debt securities of any series (&#8220;legal defeasance&#8221;).  Legal defeasance means that we will be deemed to have paid and discharged the entire indebtedness represented by the outstanding debt securities of such series under the indenture, except for:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the rights of holders of the debt securities to receive principal, interest and any premium when due;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our obligations with respect to the debt securities concerning issuing temporary debt securities, registration of transfer of debt securities, mutilated, destroyed, lost or stolen debt securities and the maintenance of an office or agency for payment for security payments held in trust;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the rights, powers, trusts, duties and immunities of the trustee; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the defeasance provisions of the indenture.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, we may elect to have our obligations released with respect to certain covenants in the indenture (&#8220;covenant defeasance&#8221;).  If we so elect, any failure to comply with these obligations will not constitute a default or an event of default with respect to the debt securities of any series.  In the event covenant defeasance occurs, certain events, not including non-payment, bankruptcy and insolvency events, described under &#8220;Events of Default and Remedies,&#8221; will no longer constitute an event of default for that series.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to exercise either legal defeasance or covenant defeasance with respect to outstanding debt securities of any series:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we must irrevocably have deposited or caused to be deposited with the trustee as trust funds for the purpose of making the following payments, specifically pledged as security for, and dedicated solely to the benefits of the holders of the debt securities of a series:</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">money in an amount; or</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S.&#160;government obligations (or equivalent government obligations in the case of debt securities denominated in other than U.S.&#160;dollars or a specified currency) that will provide, not later than one day before the due date of any payment, money in an amount; or</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a combination of money and U.S.&#160;government obligations (or equivalent government obligations, as applicable),</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">in each case sufficient, in the written opinion (with respect to U.S.&#160;or equivalent government obligations or a combination of money and U.S.&#160;or equivalent government obligations, as applicable) of a nationally recognized firm of independent public accountants to pay and discharge, and which shall be applied by the trustee to pay and discharge, all of the principal (including mandatory sinking fund payments), interest and any premium at due date or maturity;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">in the case of legal defeasance, we have delivered to the trustee an opinion of counsel stating that, under then applicable federal income tax law, the holders of the debt securities of that series will not recognize income, gain or loss for federal income tax purposes as a result of the deposit, defeasance and discharge to be effected and will be subject to the same federal income tax as would be the case if the deposit, defeasance and discharge did not occur;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">in the case of covenant defeasance, we have delivered to the trustee an opinion of counsel to the effect that the holders of the debt securities of that series will not recognize income, gain or loss for federal income tax purposes as a result of the deposit and covenant defeasance to be effected and will be subject to the same federal income tax as would be the case if the deposit and covenant defeasance did not occur;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">no event of default or default with respect to the outstanding debt securities of that series has occurred and is continuing at the time of such deposit after giving effect to the deposit or, in the case of legal defeasance, no default relating to bankruptcy or insolvency has occurred and is continuing at any time on or before the&#160;91st day after the date of such deposit, it being understood that this condition is not deemed satisfied until after the&#160;91st day;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the legal defeasance or covenant defeasance will not cause the trustee to have a conflicting interest within the meaning of the Trust Indenture Act, assuming all debt securities of a series were in default within the meaning of such Act;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the legal defeasance or covenant defeasance will not result in a breach or violation of, or constitute a default under, any other agreement or instrument to which we are a party;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if prior to the stated maturity date, notice shall have been given in accordance with the provisions of the indenture;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the legal defeasance or covenant defeasance will not result in the trust arising from such deposit constituting an investment company within the meaning of the Investment Company Act of&#160;1940, as amended, unless the trust is registered under such Act or exempt from registration; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we have delivered to the trustee an officers&#8217; certificate and an opinion of counsel stating that all conditions precedent with respect to the legal defeasance or covenant defeasance have been complied with.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Covenants</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will set forth in the applicable prospectus supplement any restrictive covenants applicable to any issue of debt securities.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Paying Agent and Registrar</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The trustee will initially act as paying agent and registrar for all debt securities.  We may change the paying agent or registrar for any series of debt securities without prior notice, and we or any of our subsidiaries may act as paying agent or registrar.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Form of Securities</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each debt security will be represented either by a certificate issued in definitive form to a particular investor or by one or more global securities representing the entire issuance of the series of debt securities.  Certificated securities will be issued in definitive form and global securities will be issued in registered form.  Definitive securities name you or your nominee as the owner of the security, and in order to transfer or exchange these securities or to receive payments other than interest or other interim payments, you or your nominee must physically deliver the securities to the trustee, registrar, paying agent or other agent, as applicable.  Global securities name a depositary or its nominee as the owner of the debt securities represented by these global securities.  The depositary maintains a computerized system that will reflect each investor&#8217;s beneficial ownership of the securities through an account maintained by the investor with its broker/dealer, bank, trust company or other representative, as we explain more fully below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Global Securities</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may issue the registered debt securities in the form of one or more fully registered global securities that will be deposited with a depositary or its custodian identified in the applicable prospectus supplement and registered in the name of that depositary or its nominee.  In those cases, one or more registered global securities will be issued in a denomination or aggregate denominations equal to the portion of the aggregate principal or face amount of the securities to be represented by registered global securities.  Unless and until it is exchanged in whole for securities in definitive registered form, a registered global security may not be transferred except as a whole by and among the depositary for the registered global security, the nominees of the depositary or any successors of the depositary or those nominees.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If not described below, any specific terms of the depositary arrangement with respect to any securities to be represented by a registered global security will be described in the prospectus supplement relating to those securities.  We anticipate that the following provisions will apply to all depositary arrangements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ownership of beneficial interests in a registered global security will be limited to persons, called participants, that have accounts with the depositary or persons that may hold interests through participants.  Upon the issuance of a registered global security, the depositary will credit, on its book-entry registration and transfer system, the participants&#8217; accounts with the respective principal or face amounts of the securities beneficially owned by the participants.  Any dealers, underwriters or agents participating in the distribution of the securities will designate the accounts to be credited.  Ownership of beneficial interests in a registered global security will be shown on, and the transfer of ownership interests will be effected only through, records maintained by the depositary, with respect to interests of participants, and on the records of participants, with respect to interests of persons holding through participants.  The laws of some states may require that some purchasers of securities take physical delivery of these securities in definitive form.  These laws may impair your ability to own, transfer or pledge beneficial interests in registered global securities.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">So long as the depositary, or its nominee, is the registered owner of a registered global security, that depositary or its nominee, as the case may be, will be considered the sole owner or holder of the securities represented by the registered global security for all purposes under the indenture.  Except as described below, owners of beneficial interests in a registered global security will not be entitled to have the securities represented by the registered global security registered in their names, will not receive or be entitled to receive physical delivery of the securities in definitive form and will not be considered the owners or holders of the securities under the indenture.  Accordingly, each person owning a beneficial interest in a registered global security must rely on the procedures of the depositary for that registered global security and, if that person is not a participant, on the procedures of the participant through which the person owns its interest, to exercise any rights of a holder under the indenture.  We understand that under existing industry practices, if we request any action of holders or if an owner of a beneficial interest in a registered global security desires to give or take any action that a holder is entitled to give or take under the indenture, the depositary for the registered global security would authorize the participants holding the relevant beneficial interests to give or take that action, and the participants would authorize beneficial owners owning through them to give or take that action or would otherwise act upon the instructions of beneficial owners holding through them.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal, premium, if any, and interest payments on debt securities represented by a registered global security registered in the name of a depositary or its nominee will be made to the depositary or its nominee, as the case may be, as the registered owner of the registered global security.  Neither we nor the trustee or any other agent of ours or the trustee will have any responsibility or liability for any aspect of the records relating to payments made on account of beneficial ownership interests in the registered global security or for maintaining, supervising or reviewing any records relating to those beneficial ownership interests.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect that the depositary for any of the securities represented by a registered global security, upon receipt of any payment of principal, premium, interest or other distribution of underlying securities or other property to holders on that registered global security, will immediately credit participants&#8217; accounts in amounts proportionate to their respective beneficial interests in that registered global security as shown on the records of the depositary.  We also expect that payments by participants to owners of beneficial interests in a registered global security held through participants will be governed by standing customer instructions and customary practices, as is now the case with the securities held for the accounts of customers in bearer form or registered in &#8220;street name,&#8221; and will be the responsibility of those participants.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the depositary for any of these securities represented by a registered global security is at any time unwilling or unable to continue as depositary or ceases to be a clearing agency registered under the Exchange Act, and a successor depositary registered as a clearing agency under the Exchange Act is not appointed by us within&#160;90&#160;days, we will issue securities in definitive form in exchange for the registered global security that had been held by the depositary.  Any securities issued in definitive form in exchange for a registered global security will be registered in the name or names that the depositary gives to the trustee or other relevant agent of ours or theirs.  It is expected that the depositary&#8217;s instructions will be based upon directions received by the depositary from participants with respect to ownership of beneficial interests in the registered global security that had been held by the depositary.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless we state otherwise in a prospectus supplement, the Depository Trust Company (&#8220;DTC&#8221;)&#160;will act as depositary for each series of debt securities issued as global securities.   DTC has advised us that DTC is a limited-purpose trust company created to hold securities for its participating organizations (collectively, the &#8220;Participants&#8221;) and to facilitate the clearance and settlement of transactions in those securities between Participants through electronic book-entry changes in accounts of its Participants.   The Participants include securities brokers and dealers, banks, trust companies, clearing corporations and certain other organizations.  Access to DTC&#8217;s system is also available to other entities such as banks, brokers, dealers and trust companies that clear through or maintain a custodial relationship with a Participant, either directly or indirectly (collectively, the &#8220;Indirect Participants&#8221;).  Persons who are not Participants may beneficially own securities held by or on behalf of DTC only through the Participants or the Indirect Participants.  The ownership interests in, and transfers of ownership interests in, each security held by or on behalf of DTC are recorded on the records of the Participants and the Indirect Participants.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Governing Law</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The indenture and each series of debt securities are governed by, and construed in accordance with, the laws of the State of New York.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;to the debt securities;</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any addition to or change in the covenants described in the prospectus or in the indenture with respect to the debt securities;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our right, if any, to defer payment of interest and the maximum length of this deferral period; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">other specific terms, including any additional events of default or covenants.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may issue debt securities at a discount below their stated principal amount. Even if we do not issue the debt securities below their stated principal amount, for United States federal income tax purposes the debt securities may be deemed to have been issued with a discount because of certain interest payment characteristics. We will describe in any applicable prospectus supplement the United States federal income tax considerations applicable to debt securities issued at a discount or deemed to be issued at a discount, and will describe any special United States federal income tax considerations that may be applicable to the particular debt securities.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Senior Debt</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Senior debt securities will rank equally and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">pari passu</font><font style="font-family:inherit;font-size:10pt;">&#32;with all of our other unsecured and unsubordinated debt from time to time outstanding.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subordinated Debt</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The indenture does not limit our ability to issue subordinated debt securities. Any subordination provisions of a particular series of debt securities will be set forth in the supplemental indenture, board resolution or officers' certificate related to that series of debt securities and will be described in the relevant prospectus supplement.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If this prospectus is being delivered in connection with a series of subordinated debt securities, the accompanying prospectus supplement or the information incorporated by reference in this prospectus will set forth the approximate amount of senior indebtedness outstanding as of the end of the most recent fiscal quarter.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Conversion or Exchange Rights</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt securities may be convertible into or exchangeable for our other securities or property. The terms and conditions of conversion or exchange will be set forth in the supplemental indenture, board resolution or officers' certificate related to that series of debt securities and will be described in the relevant prospectus supplement. The terms will include, among others, the following:</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the conversion or exchange price;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the conversion or exchange period;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">provisions regarding our ability or the ability of&#160;&#160;the holder to convert or exchange the debt securities;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">events requiring adjustment to the conversion or exchange price; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">provisions affecting conversion or exchange in the event of our redemption of the debt securities.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Merger, Consolidation or Sale of Assets</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The indenture prohibits us from merging into or consolidating with any other person or selling, leasing or conveying substantially all of our assets and the assets of our subsidiaries, taken as a whole, to any person, unless:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">either we are the continuing corporation or the successor corporation or the person which acquires by sale, lease or conveyance substantially all our or our subsidiaries' assets is a corporation organized under the laws of the United States, any state thereof, or the District of Columbia, and expressly assumes the due and punctual payment of the principal of, and premium, if any, and interest, if any, on all the debt securities and the due performance of every covenant of the indenture to be performed or observed by us, by supplemental indenture satisfactory to the trustee, executed and delivered to the trustee by such corporation;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">immediately after giving effect to such transactions, no Event of Default described under the caption &#8220;Events of Default and Remedies&#8221; below or event which, after notice or lapse of time or both would become an Event of Default, has happened and is continuing; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we have delivered to the trustee an officers' certificate and an opinion of counsel each stating that such transaction and such supplemental indenture comply with the indenture provisions relating to merger, consolidation and sale of assets.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon any consolidation or merger with or into any other person or any sale, conveyance, lease, or other transfer of all or substantially all of our or our subsidiaries' assets to any person, the successor person shall succeed, and be substituted for, us under the indenture and each series of outstanding debt securities, and we shall be relieved of all obligations under the indenture and each series of outstanding debt securities to the extent we were the predecessor person.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Events of Default and Remedies</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When we use the term &#8220;Event of Default&#8221; in the indenture with respect to the debt securities of any series, we mean:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">default in paying interest on the debt securities when it becomes due and the default continues for a period of 30 days or more;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">default in paying principal, or premium, if any, on the debt securities when due;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">default is made in the payment of any sinking or purchase fund or analogous obligation when the same becomes due, and such default continues for 30 days or more;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">default in the performance, or breach, of any covenant or warranty in the indenture (other than defaults specified in clause (1), (2) or (3) above) and the default or breach continues for a period of 60 days or more after we </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-left:96px;text-align:justify;"><font style="font-family:inherit;font-size:10pt;">receive written notice of such default from the trustee or we and the trustee receive notice from the holders of at least 25% in aggregate principal amount of the outstanding debt securities of the series;</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">certain events of bankruptcy, insolvency, reorganization, administration or similar proceedings with respect to us have occurred; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(6)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any other Event of Default provided with respect to debt securities of that series that is set forth in the applicable prospectus supplement accompanying this prospectus.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No Event of Default with respect to a particular series of debt securities (except as to certain events of bankruptcy, insolvency or reorganization) necessarily constitutes an Event of Default with respect to any other series of debt securities. The occurrence of certain Events of Default or an acceleration under the indenture may constitute an event of default under certain of our other indebtedness that we may have outstanding from time to time. Unless otherwise provided by the terms of an applicable series of debt securities, if an Event of Default under the indenture occurs with respect to the debt securities of any series and is continuing, then the trustee or the holders of not less than 51% of the aggregate principal amount of the outstanding debt securities of that series may by written notice require us to repay immediately the entire principal amount of the outstanding debt securities of that series (or such lesser amount as may be provided in the terms of the securities), together with all accrued and unpaid interest and premium, if any. In the case of an Event of Default resulting from certain events of bankruptcy, insolvency or reorganization, the principal (or such specified amount) of and accrued and unpaid interest, if any, on all outstanding debt securities will become and be immediately due and payable without any declaration or other act on the part of the trustee or any holder of outstanding debt securities. We refer you to the prospectus supplement relating to any series of debt securities that are discount securities for the particular provisions relating to acceleration of a portion of the principal amount of such discount securities upon the occurrence of an Event of Default.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">After a declaration of acceleration, the holders of a majority in aggregate principal amount of outstanding debt securities of any series may rescind this accelerated payment requirement if all existing Events of Default, except for nonpayment of the principal on the debt securities of that series that has become due solely as a result of the accelerated payment requirement, have been cured or waived and if the rescission of acceleration would not conflict with any judgment or decree. The holders of a majority in aggregate principal amount of the outstanding debt securities of any series also have the right to waive past defaults, except a default in paying principal or interest on any outstanding debt security, or in respect of a covenant or a provision that cannot be modified or amended without the consent of all holders of the debt securities of that series.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No holder of any debt security may seek to institute a proceeding with respect to the indenture unless such holder has previously given written notice to the trustee of a continuing Event of Default, the holders of not less than 51% in aggregate principal amount of the outstanding debt securities of the series have made a written request to the trustee to institute proceedings in respect of the Event of Default, the holder or holders have offered reasonable indemnity to the trustee and the trustee has failed to institute such proceeding within 60 days after it received this notice. In addition, within this 60-day period the trustee must not have received directions inconsistent with this written request by holders of a majority in aggregate principal amount of the outstanding debt securities of that series. These limitations do not apply, however, to a suit instituted by a holder of a debt security for the enforcement of the payment of principal, interest or any premium on or after the due dates for such payment.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the existence of an Event of Default actually known to a responsible officer of the trustee, the trustee is required to exercise the rights and powers vested in it under the indenture and use the same degree of care and skill in its exercise as a prudent person would under the circumstances in the conduct of that person's own affairs. If an Event of Default has occurred and is continuing, the trustee is not under any obligation to exercise any of its rights or powers at the request or direction of any of the holders unless the holders have offered to the trustee security or indemnity reasonably satisfactory to the trustee. Subject to certain provisions, the holders of a majority in aggregate principal amount of the outstanding debt securities of any series have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust, or power conferred on the trustee.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The trustee will, within 90 days after receiving notice of any default, give notice of the default to the holders of the debt securities of that series, unless the default was already cured or waived. Unless there is a default in paying principal, interest or any premium when due, the trustee can withhold giving notice to the holders if it determines in good faith that the withholding of notice is in the interest of the holders. In the case of a default specified in clause (4) above describing Events of Default, no notice of default to the holders of the debt securities of that series will be given until 60 days after the occurrence of the event of default.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The indenture requires us, within 120 days after the end of our fiscal year, to furnish to the trustee a statement as to compliance with the indenture. The indenture provides that the trustee may withhold notice to the holders of debt securities of any </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">series of any Event of Default (except in payment on any debt securities of that series) with respect to debt securities of that series if it in good faith determines that withholding notice is in the interest of the holders of those debt securities.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Modification and Waiver</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The indenture may be amended or modified without the consent of any holder of debt securities in order to:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">evidence a successor to the trustee;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">cure ambiguities, defects or inconsistencies;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">provide for the assumption of our obligations in the case of a merger or consolidation or transfer of all or substantially all of our assets that complies with the covenant described under &#8220;- Merger, Consolidation or Sale of Assets&#8221;;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">make any change that would provide any additional rights or benefits to the holders of the debt securities of a series;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">add guarantors or co-obligors with respect to the debt securities of any series;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">secure the debt securities of a series;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">establish the form or forms of debt securities of any series;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">add additional Events of Default with respect to the debt securities of any series;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">add additional provisions as may be expressly permitted by the Trust Indenture Act;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">maintain the qualification of the indenture under the Trust Indenture Act; or</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">make any change that does not adversely affect in any material respect the interests of any holder.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other amendments and modifications of the indenture or the debt securities issued may be made with the consent of the holders of not less than a majority in aggregate principal amount of the outstanding debt securities of each series affected by the amendment or modification. However, no modification or amendment may, without the consent of the holder of each outstanding debt security affected:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">change the maturity date or the stated payment date of any payment of premium or interest payable on the debt securities;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reduce the principal amount, or extend the fixed maturity, of the debt securities;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">change the method of computing the amount of principal or any interest of any debt security;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">change or waive the redemption or repayment provisions of the debt securities;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">change the currency in which principal, any premium or interest is paid or the place of payment;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reduce the percentage in principal amount outstanding of debt securities of any series which must consent to an amendment, supplement or waiver or consent to take any action;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">impair the right to institute suit for the enforcement of any payment on the debt securities;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">waive a payment default with respect to the debt securities;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reduce the interest rate or extend the time for payment of interest on the debt securities;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adversely affect the ranking or priority of the debt securities of any series; or</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">release any guarantor or co-obligor from any of its obligations under its guarantee or the indenture, except in compliance with the terms of the indenture.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Satisfaction, Discharge and Covenant Defeasance</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may terminate our obligations under the indenture with respect to the outstanding debt securities of any series, when:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">either:</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:justify;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:24px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">all debt securities of any series issued that have been authenticated and delivered have been delivered to the trustee for cancellation; or</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">all the debt securities of any series issued that have not been delivered to the trustee for cancellation have become due and payable, will become due and payable within one year, or are to be called for redemption within one year and we have made arrangements satisfactory to the trustee for the giving of notice of redemption by such trustee in our name and at our expense, and in each case, we have irrevocably deposited or caused to be deposited with the trustee sufficient funds to pay and discharge the entire indebtedness on the series of debt securities; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we have paid or caused to be paid all other sums then due and payable under the indenture; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we have delivered to the trustee an officers' certificate and an opinion of counsel, each stating that all conditions precedent under the indenture relating to the satisfaction and discharge of the indenture have been complied with.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may elect to have our obligations under the indenture discharged with respect to the outstanding debt securities of any series (&#8220;legal defeasance&#8221;). Legal defeasance means that we will be deemed to have paid and discharged the entire indebtedness represented by the outstanding debt securities of such series under the indenture, except for:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the rights of holders of the debt securities to receive principal, interest and any premium when due;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our obligations with respect to the debt securities concerning issuing temporary debt securities, registration of transfer of debt securities, mutilated, destroyed, lost or stolen debt securities and the maintenance of an office or agency for payment for security payments held in trust;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the rights, powers, trusts, duties and immunities of the trustee; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the defeasance provisions of the indenture.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, we may elect to have our obligations released with respect to certain covenants in the indenture (&#8220;covenant defeasance&#8221;). If we so elect, any failure to comply with these obligations will not constitute a default or an event of default with respect to the debt securities of any series. In the event covenant defeasance occurs, certain events, not including non-payment, bankruptcy and insolvency events, described under &#8220;Events of Default and Remedies,&#8221; will no longer constitute an event of default for that series.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to exercise either legal defeasance or covenant defeasance with respect to outstanding debt securities of any series:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we must irrevocably have deposited or caused to be deposited with the trustee as trust funds for the purpose of making the following payments, specifically pledged as security for, and dedicated solely to the benefits of the holders of the debt securities of a series:</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">money in an amount; or</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government obligations (or equivalent government obligations in the case of debt securities denominated in other than U.S. dollars or a specified currency) that will provide, not later than one day before the due date of any payment, money in an amount; or</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a combination of money and U.S. government obligations (or equivalent government obligations, as applicable),</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">in each case sufficient, in the written opinion (with respect to U.S. or equivalent government obligations or a combination of money and U.S. or equivalent government obligations, as applicable) of a nationally recognized firm of independent public accountants to pay and discharge, and which shall be applied by the trustee to pay and discharge, all of the principal (including mandatory sinking fund payments), interest and any premium at due date or maturity;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">in the case of legal defeasance, we have delivered to the trustee an opinion of counsel stating that, under then applicable federal income tax law, the holders of the debt securities of that series will not recognize income, gain or loss for federal income tax purposes as a result of the deposit, defeasance and discharge to be effected and will be subject to the same federal income tax as would be the case if the deposit, defeasance and discharge did not occur;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">in the case of covenant defeasance, we have delivered to the trustee an opinion of counsel to the effect that the holders of the debt securities of that series will not recognize income, gain or loss for federal income tax purposes as a result of the deposit and covenant defeasance to be effected and will be subject to the same federal income tax as would be the case if the deposit and covenant defeasance did not occur;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">no event of default or default with respect to the outstanding debt securities of that series has occurred and is continuing at the time of such deposit after giving effect to the deposit or, in the case of legal defeasance, no default relating to bankruptcy or insolvency has occurred and is continuing at any time on or before the 91st day after the date of such deposit, it being understood that this condition is not deemed satisfied until after the 91st day;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the legal defeasance or covenant defeasance will not cause the trustee to have a conflicting interest within the meaning of the Trust Indenture Act, assuming all debt securities of a series were in default within the meaning of such Act;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the legal defeasance or covenant defeasance will not result in a breach or violation of, or constitute a default under, any other agreement or instrument to which we are a party;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if prior to the stated maturity date, notice shall have been given in accordance with the provisions of the indenture;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the legal defeasance or covenant defeasance will not result in the trust arising from such deposit constituting an investment company within the meaning of the Investment Company Act of 1940, as amended, unless the trust is registered under such Act or exempt from registration; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we have delivered to the trustee an officers' certificate and an opinion of counsel stating that all conditions precedent with respect to the legal defeasance or covenant defeasance have been complied with.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Covenants</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will set forth in the applicable prospectus supplement any restrictive covenants applicable to any issue of debt securities.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Paying Agent and Registrar</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The trustee will initially act as paying agent and registrar for all debt securities. We may change the paying agent or registrar for any series of debt securities without prior notice, and we or any of our subsidiaries may act as paying agent or registrar.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Form of Securities</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each debt security will be represented either by a certificate issued in definitive form to a particular investor or by one or more global securities representing the entire issuance of the series of debt securities. Certificated securities will be issued in definitive form and global securities will be issued in registered form. Definitive securities name you or your nominee as the owner of the security, and in order to transfer or exchange these securities or to receive payments other than interest or other interim payments, you or your nominee must physically deliver the securities to the trustee, registrar, paying agent or other agent, as applicable. Global securities name a depositary or its nominee as the owner of the debt securities represented by these global securities. The depositary maintains a computerized system that will reflect each investor's beneficial ownership of the securities through an account maintained by the investor with its broker/dealer, bank, trust company or other representative, as we explain more fully below.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Global Securities</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may issue the registered debt securities in the form of one or more fully registered global securities that will be deposited with a depositary or its custodian identified in the applicable prospectus supplement and registered in the name of that depositary or its nominee. In those cases, one or more registered global securities will be issued in a denomination or aggregate denominations equal to the portion of the aggregate principal or face amount of the securities to be represented by registered global securities. Unless and until it is exchanged in whole for securities in definitive registered form, a registered global security may </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">not be transferred except as a whole by and among the depositary for the registered global security, the nominees of the depositary or any successors of the depositary or those nominees.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If not described below, any specific terms of the depositary arrangement with respect to any securities to be represented by a registered global security will be described in the prospectus supplement relating to those securities. We anticipate that the following provisions will apply to all depositary arrangements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ownership of beneficial interests in a registered global security will be limited to persons, called participants, that have accounts with the depositary or persons that may hold interests through participants. Upon the issuance of a registered global security, the depositary will credit, on its book-entry registration and transfer system, the participants' accounts with the respective principal or face amounts of the securities beneficially owned by the participants. Any dealers, underwriters or agents participating in the distribution of the securities will designate the accounts to be credited. Ownership of beneficial interests in a registered global security will be shown on, and the transfer of ownership interests will be effected only through, records maintained by the depositary, with respect to interests of participants, and on the records of participants, with respect to interests of persons holding through participants. The laws of some states may require that some purchasers of securities take physical delivery of these securities in definitive form. These laws may impair your ability to own, transfer or pledge beneficial interests in registered global securities.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">So long as the depositary, or its nominee, is the registered owner of a registered global security, that depositary or its nominee, as the case may be, will be considered the sole owner or holder of the securities represented by the registered global security for all purposes under the indenture. Except as described below, owners of beneficial interests in a registered global security will not be entitled to have the securities represented by the registered global security registered in their names, will not receive or be entitled to receive physical delivery of the securities in definitive form and will not be considered the owners or holders of the securities under the indenture. Accordingly, each person owning a beneficial interest in a registered global security must rely on the procedures of the depositary for that registered global security and, if that person is not a participant, on the procedures of the participant through which the person owns its interest, to exercise any rights of a holder under the indenture. We understand that under existing industry practices, if we request any action of holders or if an owner of a beneficial interest in a registered global security desires to give or take any action that a holder is entitled to give or take under the indenture, the depositary for the registered global security would authorize the participants holding the relevant beneficial interests to give or take that action, and the participants would authorize beneficial owners owning through them to give or take that action or would otherwise act upon the instructions of beneficial owners holding through them.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal, premium, if any, and interest payments on debt securities represented by a registered global security registered in the name of a depositary or its nominee will be made to the depositary or its nominee, as the case may be, as the registered owner of the registered global security. Neither we nor the trustee or any other agent of ours or the trustee will have any responsibility or liability for any aspect of the records relating to payments made on account of beneficial ownership interests in the registered global security or for maintaining, supervising or reviewing any records relating to those beneficial ownership interests.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect that the depositary for any of the securities represented by a registered global security, upon receipt of any payment of principal, premium, interest or other distribution of underlying securities or other property to holders on that registered global security, will immediately credit participants' accounts in amounts proportionate to their respective beneficial interests in that registered global security as shown on the records of the depositary. We also expect that payments by participants to owners of beneficial interests in a registered global security held through participants will be governed by standing customer instructions and customary practices, as is now the case with the securities held for the accounts of customers in bearer form or registered in &#8220;street name,&#8221; and will be the responsibility of those participants.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the depositary for any of these securities represented by a registered global security is at any time unwilling or unable to continue as depositary or ceases to be a clearing agency registered under the Exchange Act, and a successor depositary registered as a clearing agency under the Exchange Act is not appointed by us within 90 days, we will issue securities in definitive form in exchange for the registered global security that had been held by the depositary. Any securities issued in definitive form in exchange for a registered global security will be registered in the name or names that the depositary gives to the trustee or other relevant agent of ours or theirs. It is expected that the depositary's instructions will be based upon directions received by the depositary from participants with respect to ownership of beneficial interests in the registered global security that had been held by the depositary.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless we state otherwise in a prospectus supplement, the Depository Trust Company (&#8220;DTC&#8221;) will act as depositary for each series of debt securities issued as global securities.&#160;&#160;DTC has advised us that DTC is a limited-purpose trust company created to hold securities for its participating organizations (collectively, the &#8220;Participants&#8221;) and to facilitate the clearance and settlement of transactions in those securities between Participants through electronic book-entry changes in accounts of its Participants.&#160;&#160;The </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Participants include securities brokers and dealers, banks, trust companies, clearing corporations and certain other organizations. Access to DTC's system is also available to other entities such as banks, brokers, dealers and trust companies that clear through or maintain a custodial relationship with a Participant, either directly or indirectly (collectively, the &#8220;Indirect Participants&#8221;). Persons who are not Participants may beneficially own securities held by or on behalf of DTC only through the Participants or the Indirect Participants. The ownership interests in, and transfers of ownership interests in, each security held by or on behalf of DTC are recorded on the records of the Participants and the Indirect Participants.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Governing Law</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The indenture and each series of debt securities are governed by, and construed in accordance with, the laws of the State of New York.</font><font style="font-family:inherit;font-size:8pt;">&#160; </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s35B54A6EEBE67EBA464CCE26599D1FEB"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DESCRIPTION OF WARRANTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following description, together with the additional information we may include in any applicable prospectus supplements, summarizes the material terms and provisions of the warrants that we may offer under this prospectus and the related warrant agreements and warrant certificates.  While the terms summarized below will apply generally to any warrants that we may offer, we will describe the particular terms of any series of warrants in more detail in the applicable prospectus supplement.  If we indicate in the prospectus supplement, the terms of any warrants offered under that prospectus supplement may differ from the terms described below.  Specific warrant agreements will contain additional important terms and provisions and will be incorporated by reference as an exhibit to the registration statement that includes this prospectus.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">General</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may issue warrants for the purchase of common stock, preferred stock or debt securities in one or more series.  We may issue warrants independently or together with common stock, preferred stock and debt securities, and the warrants may be attached to or separate from these securities.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will evidence each series of warrants by warrant certificates that we will issue under a separate agreement.  We may enter into a warrant agreement with a warrant agent.  We will indicate the name and address of the warrant agent in the applicable prospectus supplement relating to a particular series of warrants.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium, if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture; or</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or, payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Additional Information</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will describe in the applicable prospectus supplement the terms of the series of warrants, including:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the offering price and aggregate number of warrants offered;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the currency for which the warrants may be purchased;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if applicable, the date on and after which the warrants and the related securities will be separately transferable;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one warrant and the price at, and currency in which, this principal amount of debt securities may be purchased upon such exercise;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which these shares may be purchased upon such exercise;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreement and the warrants;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the terms of any rights to redeem or call the warrants;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the dates on which the right to exercise the warrants will commence and expire;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the manner in which the warrant agreement and warrants may be modified;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a discussion on any material or special United States federal income tax consequences of holding or exercising the warrants;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the terms of the securities issuable upon exercise of the warrants; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any other specific terms, preferences, rights or limitations of or restrictions on the warrants.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise of Warrants</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable prospectus supplement.  Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to&#160;5 p.m., Eastern time, on the expiration date that we set forth in the applicable prospectus supplement.  After the close of business on the expiration date, unexercised warrants will become void.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Holders of the warrants may exercise the warrants by delivering the warrant certificate representing the warrants to be exercised together with specified information, and paying the required amount to the warrant agent in immediately available funds, as provided in the applicable prospectus supplement.  We will set forth on the reverse side of the warrant certificate and in the applicable prospectus supplement the information that the holder of the warrant will be required to deliver to the warrant agent.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon receipt of the required payment and the warrant certificate properly completed and duly executed at the corporate trust office of the warrant agent or any other office indicated in the applicable prospectus supplement, we will issue and deliver the securities purchasable upon such exercise.  If fewer than all of the warrants represented by the warrant certificate are exercised, then we will issue a new warrant certificate for the remaining amount of warrants.  If we so indicate in the applicable prospectus supplement, holders of the warrants may surrender securities as all or part of the exercise price for warrants.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Enforceability of Rights by Holders of Warrants</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each warrant agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any warrant.  A single bank or trust company may act as warrant agent for more than one issue of warrants.  A warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us.  Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, its warrants.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sADBD0914C3F91EFA8C03CE2659AAAFDF"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DESCRIPTION OF UNITS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may issue units comprised of one or more of the other securities described in this prospectus in any combination.  Each unit will be issued so that the holder of the unit is also the holder of each security included in the unit.  Thus, the holder of a unit will have the rights and obligations of a holder of each included security.  The unit agreement under which a unit is issued </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date.  The applicable prospectus supplement may describe:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the terms of the unit agreement governing the units;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States federal income tax considerations relevant to the units; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">whether the units will be issued in fully registered global form.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This summary of certain general terms of units and any summary description of units in the applicable prospectus supplement do not purport to be complete and are qualified in their entirety by reference to all provisions of the applicable unit agreement and, if applicable, collateral arrangements and depositary arrangements relating to such units.  The forms of the unit agreements and other documents relating to a particular issue of units will be filed with the SEC each time we issue units, and you should read those documents for provisions that may be important to you.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s3BF366E811167E9F533CCE2659B494FA"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PLAN OF DISTRIBUTION</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may sell the securities offered by this prospectus from time to time in one or more transactions, including without limitation:</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">directly to one or more purchasers;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">through agents;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">in "at the market offerings" to or through a market maker or into an existing trading market, or a securities exchange or otherwise;  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to or through underwriters, brokers or dealers; or  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">through a combination of any of these methods. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A distribution of the securities offered by this prospectus may also be effected through the issuance of derivative securities, including without limitation, warrants, subscriptions, exchangeable securities, forward delivery contracts and the writing of options. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the manner in which we may sell some or all of the securities covered by this prospectus includes, without limitation, through:</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a block trade in which a broker-dealer will attempt to sell as agent, but may position or resell a portion of the block, as principal, in order to facilitate the transaction;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">purchases by a broker-dealer, as principal, and resale by the broker-dealer for its account;  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ordinary brokerage transactions and transactions in which a broker solicits purchasers; or  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">privately negotiated transactions. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may also enter into hedging transactions. For example, we may:</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">enter into transactions with a broker-dealer or affiliate thereof in connection with which such broker-dealer or affiliate will engage in short sales of the Common Stock pursuant to this prospectus, in which case such broker-dealer or affiliate may use shares of Common Stock received from us to close out its short positions;  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">sell securities short and redeliver such shares to close out our short positions;  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">enter into option or other types of transactions that require us to deliver Common Stock to a broker-dealer or an affiliate thereof, who will then resell or transfer the Common Stock under this prospectus; or</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">loan or pledge the Common Stock to a broker-dealer or an affiliate thereof, who may sell the loaned shares or, in an event of default in the case of a pledge, sell the pledged shares pursuant to this prospectus. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, we may enter into derivative or hedging transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions.  In connection with such a transaction, the third parties may sell securities covered by and pursuant to this prospectus and an applicable prospectus supplement or other offering materials, as the case may be.  If so, the third party may use securities borrowed from us or others to settle such sales and may use securities received from us to close out any related short positions.  We may also loan or pledge securities covered by this prospectus and an applicable prospectus supplement to third parties, who may sell the loaned securities or, in an event of default in the case of a pledge, sell the pledged securities pursuant to this prospectus and the applicable prospectus supplement or other offering materials, as the case may be.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A prospectus supplement with respect to each offering of securities will state the terms of the offering of the securities, including:</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the terms of the offering; </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the name or names of any underwriters or agents and the amounts of securities underwritten or purchased by each of them, if any;  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the public offering price or purchase price of the securities and the net proceeds to be received by us from the sale;  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any delayed delivery arrangements;  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any underwriting discounts or agency fees and other items constituting underwriters' or agents' compensation; </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any discounts or concessions allowed or reallowed or paid to dealers; and </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any securities exchange or markets on which the securities may be listed. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The offer and sale of the securities described in this prospectus by us, the underwriters or the third parties described above may be effected from time to time in one or more transactions, including privately negotiated transactions, either:</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">at a fixed price or prices, which may be changed;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">at market prices prevailing at the time of sale, including in "at the market offerings"; </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">at prices related to the prevailing market prices; or  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">at negotiated prices. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">General </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any public offering price and any discounts, commissions, concessions or other items constituting compensation allowed or reallowed or paid to underwriters, dealers, agents or remarketing firms may be changed from time to time. Underwriters, dealers, agents and remarketing firms that participate in the distribution of the offered securities may be "underwriters" as defined in the Securities Act. Any discounts or commissions they receive from us and any profits they receive on the resale of the offered securities may be treated as underwriting discounts and commissions under the Securities Act. We will identify any underwriters, agents or dealers and describe their commissions, fees or discounts in the applicable prospectus supplement or other offering materials, as the case may be.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Underwriters and Agents </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If underwriters are used in a sale, they will acquire the offered securities for their own account. The underwriters may resell the offered securities in one or more transactions, including negotiated transactions. These sales may be made at a fixed public offering price or prices, which may be changed, at market prices prevailing at the time of the sale, at prices related to such prevailing market price or at negotiated prices. We may offer the securities to the public through an underwriting syndicate or through a single underwriter. The underwriters in any particular offering will be mentioned in the applicable prospectus supplement or other offering materials, as the case may be. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless otherwise specified in connection with any particular offering of securities, the obligations of the underwriters to purchase the offered securities will be subject to certain conditions contained in an underwriting agreement that we will enter into with the underwriters at the time of the sale to them. The underwriters will be obligated to purchase all of the securities of the series offered if any of the securities are purchased, unless otherwise specified in connection with any particular offering of securities. Any initial offering price and any discounts or concessions allowed, reallowed or paid to dealers may be changed from time to time. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may designate agents to sell the offered securities. Unless otherwise specified in connection with any particular offering of securities, the agents will agree to use their best efforts to solicit purchases for the period of their appointment. We may also sell the offered securities to one or more remarketing firms, acting as principals for their own accounts or as agents for us. These firms will remarket the offered securities upon purchasing them in accordance with a redemption or repayment pursuant to the terms of the offered securities. A prospectus supplement or other offering materials, as the case may be, will identify any remarketing firm and will describe the terms of its agreement, if any, with us and its compensation. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with offerings made through underwriters or agents, we may enter into agreements with such underwriters or agents pursuant to which we receive our outstanding securities in consideration for the securities being offered to the public for cash. In connection with these arrangements, the underwriters or agents may also sell securities covered by this prospectus to hedge their positions in these outstanding securities, including in short sale transactions. If so, the underwriters or agents may use the securities received from us under these arrangements to close out any related open borrowings of securities. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dealers</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may sell the offered securities to dealers as principals. We may negotiate and pay dealers' commissions, discounts or concessions for their services. The dealer may then resell such securities to the public either at varying prices to be determined by the dealer or at a fixed offering price agreed to with us at the time of resale. Dealers engaged by us may allow other dealers to participate in resales. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Direct Sales </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may choose to sell the offered securities directly to multiple purchasers or a single purchaser. In this case, no underwriters or agents would be involved. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Institutional Purchasers</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may authorize agents, dealers or underwriters to solicit certain institutional investors to purchase offered securities on a delayed delivery basis pursuant to delayed delivery contracts providing for payment and delivery on a specified future date. The applicable prospectus supplement or other offering materials, as the case may be, will provide the details of any such arrangement, including the offering price and commissions payable on the solicitations. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will enter into such delayed contracts only with institutional purchasers that we approve. These institutions may include commercial and savings banks, insurance companies, pension funds, investment companies and educational and charitable institutions. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Indemnification; Other Relationships </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may have agreements with agents, underwriters, dealers and remarketing firms to indemnify them against certain civil liabilities, including liabilities under the Securities Act. Agents, underwriters, dealers and remarketing firms, and their affiliates, may engage in transactions with, or perform services for, us in the ordinary course of business. This includes commercial banking and investment banking transactions. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Market-Making, Stabilization and Other Transactions </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There is currently no market for any of the offered securities, other than our Common Stock which is listed on The Nasdaq Capital Market.  If the offered securities are traded after their initial issuance, they may trade at a discount from their initial offering price, depending upon prevailing interest rates, the market for similar securities and other factors. While it is possible that an underwriter could inform us that it intends to make a market in the offered securities, such underwriter would not be obligated to do so, and any such market-making could be discontinued at any time without notice. Therefore, no assurance can be given as to whether an active trading market will develop for the offered securities. We have no current plans for listing of the debt securities or preferred stock on any securities exchange or quotation system; any such listing with respect to any particular debt securities or preferred stock will be described in the applicable prospectus supplement or other offering materials, as the case may be.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with any offering of Common Stock, the underwriters may purchase and sell shares of Common Stock in the open market. These transactions may include short sales, syndicate covering transactions and stabilizing transactions. Short sales involve syndicate sales of Common Stock in excess of the number of shares to be purchased by the underwriters in the offering, which creates a syndicate short position. "Covered" short sales are sales of shares made in an amount up to the number of shares represented by the underwriters' over-allotment option. In determining the source of shares to close out the covered syndicate short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through the over-allotment option. Transactions to close out the covered syndicate short involve either purchases of the Common Stock in the open market after the distribution has been completed or the exercise of the over-allotment option. The underwriters may also make "naked" short sales of shares in excess of the over-allotment option. The underwriters must close out any naked short position by purchasing shares of Common Stock in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the shares in the open market after pricing that could adversely affect investors who purchase in the offering. Stabilizing transactions consist of bids for or purchases of shares in the open market while the offering is in progress for the purpose of pegging, fixing or maintaining the price of the securities. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with any offering, the underwriters may also engage in penalty bids. Penalty bids permit the underwriters to reclaim a selling concession from a syndicate member when the securities originally sold by the syndicate member are purchased in a syndicate covering transaction to cover syndicate short positions. Stabilizing transactions, syndicate covering transactions and penalty bids may cause the price of the securities to be higher than it would be in the absence of these transactions. The underwriters may, if they commence these transactions, discontinue them at any time. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s70B8CEB53225FE292CA8CE2659D5DAD2"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LEGAL MATTERS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless otherwise specified in the applicable prospectus supplement, the validity of the securities offered hereby will be passed upon for us by Paul Hastings LLP. Certain other legal matters will also be passed upon for us by Paul Hastings LLP. If legal matters in connection with offerings made by this prospectus are passed on by counsel for the underwriters, dealers or agents, if any, that counsel will be named in the applicable prospectus supplement.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sCBEAD6294FCDF2870CFFCE2659F75A94"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXPERTS</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements of Caladrius Biosciences, Inc. as of December 31, 2014 and 2013, and for each of the years in the three year period ended December 31, 2014, and management&#8217;s assessment of the effectiveness of internal control over financial reporting as of December 31, 2014, incorporated by reference in this prospectus have been so incorporated by reference in reliance upon the reports of Grant Thornton LLP, independent registered public accountants, upon the authority of said firm as experts in accounting and auditing.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s1C79E160D21613661EA9CE265A297469"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We incorporate by reference into this prospectus the documents listed below (excluding any portions of such documents that have been "furnished" but not "filed" for purposes of the Exchange Act):</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Annual Report on Form 10-K for the fiscal year ended December 31, 2014, filed with the SEC on March 2, 2015;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:60px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Amended Annual Report on Form 10-K/A for the fiscal year ended December 31, 2014, filed with the SEC on April 30, 2015;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:60px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Quarterly Report on Form 10-Q for the quarter ended March 31, 2015, filed with the SEC on May 6, 2015;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:60px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, filed with the SEC on </font><font style="font-family:inherit;font-size:10pt;">August&#160;6, 2015</font><font style="font-family:inherit;font-size:10pt;">;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:60px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Current Reports on Form 8-K filed with the SEC on January 5, 2015, January 13, 2015, January 16, 2015, January 22, 2015, May 29, 2015, June 5, 2015 and July 15, 2015; and </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:60px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The description of our common stock set forth in our Registration Statement on Form 8-A, filed with the SEC on August 2, 2013 (including any amendment or report filed with the SEC for the purpose of updating such description).</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also incorporate by reference into this prospectus all documents (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that are related to such items) that are filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (i) after the date of the registration statement of which this prospectus forms a part and prior to effectiveness of the registration statement, and (ii) after the date of this prospectus but prior to the termination of the offering.  These documents include periodic reports, such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as proxy statements.  Any such filings shall be deemed to be incorporated by reference and to be a part of this prospectus from the respective dates of filing of those documents. The SEC file number for each document incorporated by reference is 1-33650.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will provide to each person, including any beneficial owner, to whom a prospectus is delivered, copies of these filings, excluding all exhibits unless an exhibit has been specifically incorporated by reference in such filings, at no cost, upon written or oral request made to:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Caladrius Biosciences, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">420 Lexington Avenue, Suite 350</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New York, NY&#160;10170</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(212) 584-4180</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s5C11D9F2D7F5A02F8F76CE265A4A4652"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WHERE YOU CAN FIND MORE INFORMATION</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have filed a registration statement on Form&#160;S-3 of which this prospectus is a part with the SEC under the Securities Act of&#160;1933.  This prospectus omits some information and exhibits included in the registration statement, copies of which may be obtained upon payment of a fee prescribed by the Commission or may be examined free of charge at the principal office of the SEC in Washington, DC.  You may also access our Form S-3 registration statement on the SEC&#8217;s website as discussed below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to the informational requirements of the Securities Exchange Act of&#160;1934 and in accordance therewith file reports, proxy statements and other information with the SEC.  The reports, proxy statements and other information filed by us with the SEC can be inspected and copied at the Public Reference Room maintained by the SEC at&#160;100 F Street, N.E., Washington, D.C. 20549.  Copies of filings can be obtained from the Public Reference Room maintained by the SEC by calling the SEC at&#160;1-800-SEC-0330.  In addition, the Commission maintains a website that contains reports, proxy and informational statements and other information filed electronically with the SEC at</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;http://www</font><font style="font-family:inherit;font-size:10pt;">.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">sec</font><font style="font-family:inherit;font-size:10pt;">.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">gov</font><font style="font-family:inherit;font-size:10pt;">&#32;.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">You may request, orally or in writing, a copy of these documents, which will be provided to you at no cost, by contacting Paige Cooperman, Esq., Associate General Counsel, Caladrius Biosciences, Inc., 420 Lexington Avenue, Suite 350, New York, NY&#160;10170, telephone (212) 584-4180.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">You should rely only on the information contained in this prospectus, including information incorporated by reference as described above, or any prospectus supplement that we have specifically referred you to.  We have not authorized anyone else to provide you with different information.  You should not assume that the information in this prospectus or any prospectus supplement is accurate as of any date other than the date on the front of those documents or that any document incorporated by reference is accurate as of any date other than its filing date.  You should not consider this prospectus to be an offer or solicitation relating to the securities in any jurisdiction in which such an offer or solicitation relating to the securities is not authorized.  Furthermore, you should not consider this prospectus to be an offer or solicitation relating to the securities if the person making the offer or solicitation is not qualified to do so, or if it is unlawful for you to receive such an offer or solicitation.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><a name="sA1B658B0235DA69C3872CE265A7DDD14"></a></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">847,458</font><font style="font-family:inherit;font-size:14pt;font-weight:bold;">&#32;Shares of Common Stock</font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;"><img src="caladriuslogoa03.jpg" alt="caladriuslogoa03.jpg" style="height:117px;width:300px;"></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PROSPECTUS SUPPLEMENT</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">September&#160;14, 2016</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>caladriuslogoa03.jpg
<TEXT>
begin 644 caladriuslogoa03.jpg
M_]C_X1*U17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    D    <@$R  (    4
M    EH=I  0    !    K    -@ +<;    G$  MQL   "<0061O8F4@4&AO
M=&]S:&]P($-#(#(P,30@*$UA8VEN=&]S:"D ,C Q-3HP-3HP,2 P.#HP-SHR
M.      #H $  P    $  0  H ( !     $   =3H , !     $   +?
M      8! P #     0 &   !&@ %     0   28!&P %     0   2X!*  #
M     0 "   " 0 $     0   38" @ $     0  $7<         2     $
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MU;-M?JW;[OTFS^:LV8OU/QK<GZJ?6O'IEUKJX:!J7%K+3MT_.LVJ[]7/JO\
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M=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M    0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M
M951%6%0    5 $, 80!N &\ ;@ @ $T 1@ X #( ,  P $, ( !3 &4 <@!I
M &4 <P      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @
M %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M
M#&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $
M  $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L
M  !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#
M8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
M    26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #
M %)D("!D;W5B0&_@            1W)N(&1O=6) ;^            !";" @
M9&]U8D!OX            $)R9%15;G1&(U)L=                $)L9"!5
M;G1&(U)L=                %)S;'15;G1&(U!X;$!RP           "G9E
M8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,
M3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M    4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O
M;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T
M;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T
M5&]P;&]N9P      .$))30/M       0 2P    !  $!+     $  3A"24T$
M)@      #@             _@   .$))300-       $    'CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))32<0       *  $
M         3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"A
MF9H !@       0 R     0!:    !@       0 U     0 M    !@
M 3A"24T#^       <   _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H   X0DE-!
M  (  #A"24T$ @       @  .$))300P       ! 0 X0DE-!"T       8
M 0    ,X0DE-! @      !     !   "0    D      .$))300>       $
M     #A"24T$&@     #50    8              M\   =3    $ !# &$
M; !A &0 <@!I '4 <P!? $P ;P!G &\ 7P!!     0
M       !              =3   "WP                     !
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M;&]N9P   M\     4F=H=&QO;F<   =3     W5R;%1%6%0    !
M;G5L;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$58
M5     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$58
M5     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@
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M &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !< 00!D &\ 8@!E "
M4 !H &\ = !O ', : !O '  ( !# $, (  R #  ,0 T     0 X0DE-! 8
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M<U)'0@               0  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K JMUJ^FL7*S0K42MN*XMKJ&O%J^+L "P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV ;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N W 7<BMT0W9;>'-ZB
MWRG?K^ VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9$
M   !_]L A  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! @$! 0$! 0("
M @(" @(" @(" @(" P,# P,# P,# P,# P,# 0$! 0$! 0(! 0(# @(" P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P/_P  1" +?!U,# 1$  A$! Q$!_]T ! #K_\0!H@    8" P$
M    !P@&!00) PH" 0 + 0  !@,! 0$            &!00#!P(( 0D "@L0
M  (! P0! P," P,# @8)=0$" P01!1(&(0<3(@ (,11!,B,5"5%"%F$D,Q=2
M<8$88I$E0Z&Q\"8T<@H9P=$U)^%3-H+QDJ)$5'-%1C='8RA55E<:LL+2XO)D
M@W23A&6CL\/3XRDX9O-U*CDZ2$E*6%E:9VAI:G9W>'EZA8:'B(F*E)66EYB9
MFJ2EIJ>HJ:JTM;:WN+FZQ,7&Q\C)RM35UM?8V=KDY>;GZ.GJ]/7V]_CY^A$
M @$# @0$ P4$! 0&!@5M 0(#$00A$@4Q!@ B$T%1!S)A%'$(0H$CD152H6(6
M,PFQ),'10W+P%^&"-"624QAC1/&BLB8U&50V160G"G.#DT9TPM+B\E5E=58W
MA(6CL\/3X_,I&I2DM,34Y/25I;7%U>7U*$=79CAVAI:FML;6YO9G=X>7I[?'
MU^?W2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H
M# ,!  (1 Q$ /P#?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U_]#?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]T$78/R!Z&ZE69^U>[>HNLUIP6G;L'LG9NS%@4"Y:8[
MCK:8*!_4V]GFU\L<R[V0-EVZYO*\/ @EEK]GAHW2"[W7:[#_ '.N8H:?[\D1
M/^/$=$EWQ_.:_E<=>F=<]\U^F*\TY82?W'R>7[-#:/KX&ZVH\L)?\/$6O^+^
MY#V[V"]Y-TI]-R]=K7_?RK;_ +?'>.GYTZ#=S[A\DVE?%W*$T_@)D_ZMAJ]%
M*W;_ ,*4?Y56W&E&'[/[.W\(R=#[2Z8WS1K46^AB&^H,*1?\>0+_ (V]CBQ^
MZ5[T78'CV=O;5_W[=PFGV^"9?Y5Z(9_>'D>'^SFDE_TL+C_CX3HN.XO^%6OP
M'Q[R1;<Z6^6&XG2X6>IVGU/@J&8_@QRR;PJ)P/\ %Z93_A[%=K]ROW,E :[W
M#;8J^0EN7(_[-5'[&/11-[X\K)B&VNG^U8E'_5TG^70+YC_A6MT/ [C ?#_M
MS)QC]#9CL79N#=N>-:45)D0./Z,?^)]B"#[D/,K#_&=]MD/]&"5_\+)T72>^
M^UC^RV^5OMD1?\ ;H/J[_A71MR-[8WX&9JKCN?77?)&AQ[VN;?MP;&JA_3^U
M_P ;-(_N-W1'ZW,J*?E8%O\ #>+_ (.DK>_4(/9M9/VW '_6$],S?\*[UU'3
M_+X)6YTEOE>%8K?@E1UJ;'_"Y_U_;X^XR:9YH_[IO_;_ --?Z_?_ $B?^SK_
M +=^I$/_  KMHF"_<?R_ZJ(ZK-X?E+%4 )?EE,G7<5S_ (<?Z_NK?<:D'P<S
M@_;MQ'_:\>K#W[7SVH_]E/\ UPZ6.,_X5P=9RZ?XS\)=]4%].O\ AG=FW\MI
MN?7I^ZV[17M^+VO_ (>T$WW'MW7_ ''YAA;_ $UHZ_X)WZ4)[\61_M-M<?9,
MI_PQCH5MO_\ "LCXA5.C^]/QI^2&&O;R?W?GZQW+H_KH_B.9Q.K_  OI]DMU
M]R7GI*_1;O82?Z<7$?\ QV*3I=%[Z[ ?[>SN%_TOAM_A=>A\VK_PJ&_EG[A,
M8R^/^26Q-=M3;JZKV_6"*_UU_P!R-PYDFW^T@^PS>_<Y]W;6O@-87/\ S3N7
M%?\ G-!%T:0>]7)LO]H+B+_31*?^.2/T:/97\_K^4UO=HX*;Y78[;E;(5!I-
MZ]9]P;46+5]/)E<K@$Q_^OIK#;\V%O8-W#[LGO;MP+/LC2J/.*XM9*_[59B_
M_&>CNV]T^1+G O@A]'CE7^933_/HY>P/YA?P0[3>"#8'S&^,^Y:^H*B'#T?=
M77T.?8OPE]O5M?%7+<\#53BYX^OL [G[7>Y.S MN>PW\*CBQM)RG^]A"G_&N
MA#:\V<L7U!:[A;N3Y":/5_O)8'^71ML=DL=EZ.#(XFOHLGCZI!+2U^.JH*VC
MJ8S])(*JF9D=?\58CV!Y898)#%.I1UXJP((^T'(Z/D=)%#H0P/ @U'[>IOMO
MJW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7_T=_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=!AVGW;TWT=@CN?NCM?KCJ;;H61ES?9&]MM[
M*QDIB%WCIZS<=33)(_( CC)8D@ $D#V<;-R]O_,=S]'R_93WTO\ !!%)*V?4
M1JQ ^9QTBO=RV_;8O&W&>.!/61U0?M8CJGOO/_A1A_*\Z9^\I,)VKN[O?.T7
MD23#])["R^7@:9>$6'=>]#@L'.C'GR4N3F '/)L#._+GW5/>/?\ 2]Q91;;&
MWX[N95-/G'%XTP/R:->@!N?NYR5MU5CG>Z8>4*$_\:?0A_)CU4!W/_PK7S4O
MW=#\>?A_BZ'3K^QW/W/V+5Y7R7XC-7L78]'1Z+?4Z-Q/>]A:US.NP?<AMUTR
M<T[ZS>L=K %_9-,SU_. = #<??>0U7:=O ]&FD)_:B ?]7.JJ^V_^%&_\T_M
M#[F'#=N[)Z:QM7K67&]2=7;4H],;?2.FS>_(]P9:"WX>'((_'+GF\T;']U'V
M8V>C7%C-N#KP:YN)#^U(3#&?L*$?+H#W_N[SO>U$=PEN#Y11J/YN'8?DU>JT
MNS_G-\SNZ?N$[6^5GR%WY1U6KRXC<7;V^JW;ZJ_ZXZ?;IKA00H?RD5.J_P"'
MN7-G]N>0.7Z'9=EL;9E_$EK"'_-]&LGYEB>@=>\S<Q;C7ZZ^GE!\FE<K_O.K
M2/R'16&9G9G=F=W8L[L2S,S&[,S'DDGDD^QF  *#HDX]=>]]:Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NEWL;M+LW
MK"O&5ZT[%WWUYE ZR#);&W=N#:5>)%_3(*S 5%/)J%A8ZK^RS<MFV?>(O W>
MTAND_AFB25?V.K#I5;7M[9/XEG,\+>J.RG]JD=6&]5?SJOYI'3[4HVU\R>U=
MP4U,5!H^TI<%W'%40KPT$]1VG1Y>HLPXU).KCZJZFQ$6[U]WWV;WT'ZO8+:(
MGSMP]K0^H%L\2_M!'J#T++'W&YVV^G@[C*X'E)IE_P"KH<_SKU:%T_\ \*K_
M )J;2-)2=Q]*]#=PXR I]Q68:GW7U=NVN4<2^;*T59E<4A(_28L$H!O<,+ 0
M[OOW+?;Z^#/L.X7E@YX!S'<1#[%*1R'\YC^70UV_WPYC@HNX6T%PH\QJC8_F
M"R_L3JVSI/\ X55?"K>GV=%W9T]W?T?DZ@QBHR&+I]O]L;+H+\2F?+XB;&9A
MPI-U\6WG) / -@8/YA^Y=[@[?JDY>O[3<4'!6+VTK?8K"2(?G..AWMOOARY<
MT7<K>:V8^8TRH/S!5_V1]7+=#?S/?Y?WR7^R@Z=^673F?S&1\8HMJ9S<T?7^
M^*IY.!'3[%[#3%9>0@D*WCHF )%SR+P'S+[/>Y_*.IM^V2ZBC3C(D?C0C[9H
M#)$/S?J0]KYTY5WF@V^_B=CP5FT.?]I)I?\ ET>X$$ @@@@$$&X(/(((]QMT
M)^N_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U_]+?X]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW13/DG\[/B!\0<?)
M6_([Y"=;=8U:TWW<&V,GFURF_<C3%-8GQ'7>W5K,[6(1;UTN.D476Y&H7&_*
M7MOSWSU*(^5-KGO%K0R*FF%3Z-.^F%3\F<'CZ=$6\<S[!L":MWNXX3QTEJN?
MLC6KG\E/6O!\F?\ A5OT-M3^(83XH]!;W[<RD?EIZ?>W:F1INM-EK*+^+(8_
M;N,&3S&0@/%X:O\ A4AN>18:LIN4/N5<RWNFXYUW.&Q0Y,-LIN):?PL[>'$A
M^:^,/\D3;S[Y;7!6/8[5[AOXY2(T^T*-3L/D=!ZU_P#Y&?\ "@7^9U\AOOJ"
M#NZ#HC:];Y!_=GX]X1.OI8%?TJ8-]5$M?NE&"FW[>=52?5I!M;)SE3[L/L_R
MMIE;;CN4R_Z)>OX]?MA 2W/YPD_/J*]W]U><]VJHN?I4/X8!X?\ QNK2?\;Z
MI[W;O/>&_P#.UFZ-][KW+O7<V1;7D-Q;MSN4W)G:Y[EM59E\S+-42FY)N\A^
MI]SO8[?8;9;+9[;!';PI\*1(L:#[%0!1^0ZC^>XN+J4SW4C2.>+,Q9C]I))/
M2:]K.F>O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NCH_'K^8M\X_BJ:*'H;Y/\ ;>QL-C_']IL]MRR[IZ^B\=@G_&.MY+D<
M$>!IN<>3;B]N/<?<T^U7MSSIJ;F79[:YD;C+X8CG/_-^+1-_QOH1[3S;S+L=
M!M=[+$HX)JU1_P#.-]2?\9ZOK^-G_"K/Y(;.^PP_RBZ)Z][JQ,7B@J-W==U]
M9U3ODQ\>7(9#'3)E<+6S#DB"EI,:C<#6OU.-/-OW+.4[_5/R=N4^WN<B*=1<
MP_)58&.5!\V:8_(]2AL_OCO%O2/>[6.Y7^.,F)_M([D)^0"#K89^+W\_S^6G
M\F?X?BI>Y).@]Z5QCC_NC\AJ"GZ^B$[ *PAW['/6;792_IB63-1S/<'PJ25&
M+?./W9/=SE#7,MA^\[=?]%L29S3YPZ5N.'&D14?Q'J6-E]T^3MYHAN/I9#^"
M<>'_ ,;J8_L[P3Z=7*XC,8C<&+H,W@<ICLWALI315N,R^(KJ;)8O(T<ZZX*N
M@KZ-GBFB<<K)&Y4CD'W <\$]K,UO<HT<B$AE8%64CB"IH01Y@BO4A1R1RH)(
MF#*PJ""""/4$8(Z<?;75^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z_]/?X]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW29WCO39W7FV\MO+?^[-M;'VA@:9JW.;JWAG<
M7MK;F&HT-FJLKF\S+#34\8) +RRJ/\?:RPV^_P!UNTL-L@DN9Y31(XD:21SZ
M*B LQ^0!Z9N+FWM(6N+J18HU%69V"J!ZDD@#\SUKU?,'_A3'\'>A/XIMKH*B
MW%\L=_T?FITGVB[[-ZFI*V.Z%*WL;/TTDU8H)5DDPF(KJ>5;@52'GWE'R)]T
M3W%YFT7?,S1[):M0TE_5N2/E C +\Q++&P_@/44<P>\G+6UZH=J#7TH_A[(@
M?G(PJ?\ :*P/\0ZU=?EG_P *!/YC?RD_B>%Q?:$'QTZ^KO-"-G= 0UNSLE+1
MMZ(TRG8]1/4;CED,9*5 I<E2TTMVO2J"%7,;DC[L/M1R;HN)K,[K=+0^+>D2
MJ#_1@ 6 "N5U1NZ_QGB84WWW4YNWO5&D_P!)$?P050T^<E3(?G1E!_AZI7R>
M3R6:R%;E\SD*[+97)5,M9D<GDZNHK\A7UE0YDGJJVMJF>261V)9W=BQ/)-_>
M04,,-O$L$"!$0 *J@*J@<  *  >0'4=.[R.9)"68Y))J2?4D\>H/MWJG7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1L?C1\Z?EW\/<HF2^-_?_8G6%/]U]Y5
M;9QF8.4V%E:G5J,^;Z\W"M7@ZUSR/)58^1@"=+"Y]@CF[VXY&Y[A,7-FV07A
MI02,FF91Z).FF9!\E<#H]V;F;?\ E]]>T74D(K4J#5#]L;50_FIZV8_B'_PJ
MUW5BSC-L?-OHJDW11*8J>H[6Z&:+#;@CC6R?=9GK'=%3]A62L3KFFH,Q0HH!
M$=&Q( Q$YY^Y793:[SV\W(PMDBVO*NGV)<1KK4#@ \4A/G(.IEV#WQG33#S)
M:AQ_OV##?:8V.DGU*NOR7K:3^)W\Q#X:_-O%I5_''O;9^]LVM+]WD=@UE1-M
MCLS#1HEZA\GU]N5*7*"&)KHU;#324K$'Q3R+9CAMSM[6<_>WDWA\U[;+;QUH
MLP DMW]-,\9:.IXZ"P<>:@XZFO8N;>7N9$U;1=)(U*E#VR#[8VHU!Z@%?0GH
MZGN/NA'U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=?_]3?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!#W;W]TI\;M
MC5_97?/:&R^J-CXZZ2[@WKG*/#TU35",R1XW$T\[>>NK9 #X:&BBEJ)3Z8XV
M/'L]Y>Y9YAYLW%=HY:LY;VY?@D2%B!_$Q&$0>;N54>9'2#<MUV[9[8WFZ3I!
M$/Q.P )]!YL?0 $GR'6JA\W?^%4>T<)_%]D_ WJQ]YY!?/1IW?W-0U^'VM&>
M8Q7[1ZQI)(,G6J5(D@J,S54!C=;2X^9#8YI>WGW,;ZX\/</<J]^G7!^DM2&D
M_P!++<$&-/0K$LM0>V53U!W,GO=!'JMN5X/$/#QI@0OVI&*,?D7*T/%".M3?
MY/?-GY5?,K<O]Y_DIW=O?M"HAJ9*O%8/*Y%<?LK;LLH*L=K["PB4V&QI*G0S
M45#&[C_.,YY]YM<G^WO)?(-I]'REMT-F"*,ZKJE?_FI,Y:63U&MR!Y =07O7
M,F^<PS>-O%R\Y!J%)HB_Z5!1%_)17SZ*S[&?1'U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=.6&S.8V[E<?G=OY;)8+.
M8BKAK\5F<-756,RN,KJ9Q)3UN/R-$Z30S1L R21N&4\@@^V;BW@NH6MKI%DC
M<%61P&5@>(92""#Y@BAZO'))"XEB8JRFH()!!]01D'K8"^%'_"D#YR?&8XK:
MO=592_+;JZC,-.]%V5DI\=VOC:&.P88;MNEBJ*FJD^K,VX:3)NW"))"O(QB]
MPONG^W/-X>]Y>4['>-4U@4-;,?Z=L2JJ/^:#0@<2&ZE7ESW>YEV;3!N)%_ /
M*0TE ^4H!)_YN!_M'6X1\'/YS_P6^=PQ>WMA]DKUKV_D!#">E>WVQ^T-ZU=?
M)Z/M=HUK3RXO/ZF#F*+$UTU5XQY)Z6"^D8(^XOL![C^VVNZW*T^KL5J?J[75
M+$!ZRB@DA\JF5%2N%=N/4_\ +7N)RSS/IBM9O!N#_H,M$<GT4U*O\@I+4R5'
M5K_N%.ASU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU__5W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=(+LWM/K;I;96;[([;WWM3K;86W*<U6;W=
MO3.X_;V!QT9XB2;(9.2.,RRM:."%29)7(2-6=@I,]GV;=N8-PCVG8[:2[N93
M1(HD9W;[%4$T'$G@!DD#/26]OK/;K9KR_E6&),EG8*H_,^?H.).!UJ6?/K_A
M4CMG!'-]=?R_=D)N[)H:B@?Y!=IXFLH=KT[<Q&NV!UK.8*VN-CKIZS/-2HDB
MVDQM3$03F[[9_<VO+GP]U]S[CP$PWT5LP,A^4UP*HGHR0ZR0<3(W4$\T^]D,
M6JTY5B\1N'CR@A?M2/!/R+Z17BC#K4%[_P#DOWY\I]]579/R&[8WIVSO*H\R
MQ9/=N6EJZ;$4L\GE?&;:PL(CH,51:O4M#C::"G4\K&#[SIY8Y1Y9Y,VT;3RM
M8Q6-N*56):%B,:I'-7D?^G(S,?,]0%NN\[IO=R;S=IWGD/FQK0>BCX5']%0!
M\N@.]B/HLZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZY([1LKHS(Z,KHZ,59&4W5E8<@@
M\@CWH@$4/6^&1U?!\"O^%!GS8^'38;9G8>9D^4G25"8*4[+[3S5:^^=OXV.R
M>'9':TB5.0IPB*D<-)EH\A211J(Z>"GOK&-GN7]U_P!O>?!)?[5'^YMQ:I\6
MW0>"[>LUM54:IJ2T9B<DU9FX=2=RO[K<Q\OZ;>[;ZVV&-$A.M1_0ERP^0;6H
M& !UNS? _P#FV?#+^8-C:2AZB[!3;':XHS4YCHOL=J+;79E"8(O)6S86@\TE
M+G*2( NU7A:FI$:%34K3NWC'/7W*]D.?_:^9I-]M?&LJT6\@K);FO .:!H6/
M#3*J5-=!<"O61_+'/?+O-:!;"71/3,,E%D'K05(<?-":#C0XZLS]Q#T,NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__UM_CW[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO==,RHK.[
M!54%F9B%5547+,3] /R??@"30=>ZUS_YCG_"BWXR?$M\_P!8_'&/$_)_OJ@-
M3CZJ;#94CI78>5BO$Z;HWIC&+9BIIWL9,7@F925D@J,A13*5]Y6>U'W5>;^=
MQ%O'-A;9]L:C .O^-S+Q_3B;^R5APDFH<AEBD4UZB/F[W;V;8M5EM%+VZ&#0
M_HH?Z3CXR/X4^8+J>M'+Y>_._P"4WSHWNV]_DCVMG-Z&EJ:B?;6S:>0X?KK9
M$,]T^UV=LB@*T-&1'IBDJS&]7.JJ:JHG<:ST5Y%]MN3/;C;OW=RG9);Z@!)*
M>^>8CSEF;O;.0M0BDG0BC'6-6_\ ,^]\S7/U.\3M)0]J<(T^2(,#TKEC^(D]
M%"]COH@Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J?BLKE
M,%D\?FL'DJ_#9G$UE-D<5EL565&.R>,R%',*BCK\?7TC)+#-%(JO'+&X96 *
MD$7]M300W,+6]PBR1N"K*P#*RD4(934$$8((H1U=)'B<21$JRFH(-"".!!&0
M1Z];/G\NG_A2[WOT0<%UC\UL?F?D9U33_;X^E[/H9:5>]]HT2VC$V3JZYXJ7
M=<,:CD9&6GR!):1\C4:4@.'GNK]T;EOF3Q-X]O63:KTU8VY!^CE/HH +6Q/]
M -%P B6I;J:.4?>/<]LTV7,8-W ,"04\9!\R:"4?Z8A_,N>'6[9\:OE5\?OE
M_P!;T':_QT[/VWV;LVL\457/AJEXLQMW(R1>8X/=^VZY8LAB:]5]34>0IHI"
MI$BJT;*[<\^;N2^:.1=V;9.:[.2SN%J0'%5=:TUQ2"J2)_21F%<&A!'61^S[
MYM6_V8OMHF6:,\:<5/\ "ZFC*WR8 ^?#HPGL+]&W7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U__U]_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW1/_F3\[?C)\#>N'[)^1W8E#M>GJXZI-J;-QHCR_8G
M8&1I4#/BMD[1A=9ZMPS1I-52&*CIBZ-5U-/&P?V.^0?;;F_W*W8;3RI:F8K3
MQ)6[8(5/XII2"%'$A1JD>A"(Q%.@_P P\S[-RO9_6;O,$!KI09D<CR1>)^9P
MHKW$#K0<_F6_SYOE%\[IL]UQU_59'X\?&BL-10'KK:F8D&[]_8MB8Q)VIO2B
M$4M3'.A)DPE#XL>JL(YUKGC6I/3#VC^[5R;[;+%NVZ!=UW=:-X\B_I0M_P N
MT1J%(/"5]4II53&"4ZQ=YQ]T-[YG+6=J3:69J/#4][C_ (:XH37^!:)Y'52O
M5$_O)'J,>O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[H?_C=\I>__ (B]D8_MCXZ]G[EZQWI0^.*HJ\'5*^*S
M^/243-A-V;=KEEQ^6H'8!FHLC331:@'"AU5E#'-G)O+'/.TMLG-5G'>6[9 <
M=R-2FN-Q1XW'DZ,K4Q6A(Z-=GWO==@O!?;1,T,@\U.&'HRFJLOR8$>?'K>G_
M )8__"BWHGY4G;W4'RQ7;WQU[_JS28K&[GEK'H^D^S,I+:*)<5FLI([[=R$[
MW5<;EJAZ=VT+3U\LTJ4J<X?>#[JO,G)?B[[R3KW7;%JS1@5N[=>)U(H G11_
MHD2A@*EX@JESDSR9[M[9OFBPWW3:71H U:0R'Y$_V;'^%C0^3DG3ULJ A@""
M"" 00;@@\@@CWB1U,77?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO_T-_CW[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UK9_P U;_A0GT_\
M0FW'TA\5FVYWK\DJ4U>)SFX!4G)=1]/Y*(F"IBSU?C9$.<S-.]T.(H)UAIY
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MM(WN7[<*:-S!MH^V^M?^MO3HY7YF/#;KH_\ 4/+_ - ==R_ GYT0(9)OA?\
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M152P4T<LR#'D;D/F;W%WZ/E[E:W,TSY=CB*%*T,LST(1%]<LQHJ*SE5)+O\
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MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$
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MB%#41QK1IIW ^"&.H+GA4FB)4%W5<]'_ "]RUO',]Z+':(BYQJ8X2,'\3MP
M]!EFI103CKZ$/\L?^29\9OY>&-Q6^*VFI.ZODU)1#^+=S;HQ4*TVU:BH@\=;
MC.I=MU!E3#4X5GB?(,\F1J%:025$<$@I(^7GN_\ >%YO]TY7VZ,G;]G![;6-
MC60 X:YD%#*W A*")2!12PUG*WDSVXV;E-%N6 N;VF9F&%]1$N= \M67.:D
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M*"4&QCB<3BL#C,?A<'C,?AL-B:.GQ^+Q.)HZ;'8S&T%)$(:6AQ]!1JD4,,2
M)'%&@55    ]C)55%"J* < . ZZ#VMK:V-M'9V4:PPQ*%1$4(B*HHJJJ@*J@
M8    P.G#WOI_KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z_
M_]'?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=:'G_  HN_FTGN[>>7^!OQ]W*9.G^N,^L??6[,/5G[7LOLG 5
M@:/8='44YM-A=N54=ZNY*564CN%\>/@FGZ3_ '5/9'^KNWI[E<T0TO[M/\3C
M89MX'']L0>$LZGM\TA/&LK*N,/NWSW^\KAN5]J?_ !>%OUV!Q)(I^ 'S2,\?
MXG'H@)U1_>:O4&]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U>=_*A_D@]W?S#L
MGC>SM^/F.F?BA15^G(=CU- J;H[*^RJ#%D,#U%C,BACGLRM3U&=J8VH:636J
M+6U$,M(,<?>O[Q/+OM9"^S[;IW#>V7M@!_3@J*J]TRFHP=2PJ1(XH28U8/U)
MG(WMMN7-CB]NJV]B#F2G=)3BL0/'T+GM4_Q$%>OH7_&GXO=%_$+JG!=+_'SK
M[#=>[$P:B5J7'1M-E<_EGB2*LW)NS.U):KR>2J0B^>MK)7D*JD:E8HXXTY<<
MW<X\R<];U)S!S1=/=7,F*MA46I(CC0=L<:U-$4 5))JQ).5^S;+MFP6*[=M,
M0BB7R'%CYLS'+,?,DD^7  =#][#'1KU6'\YOYI/1GPXI<AM*AF@[2[S^W(I.
MML!D(EI=N3S1:Z>L[#SL(D3&QV*R+1(LE9*I0B&.&05"D>Z;[:[<#&/U)?X1
MY?Z8^7V<?EY]8U^]GWFN2?:*.3:H2-SWNG;:1.-,1(J&NI141#@1& TS BB*
MC>(-0;Y._+_OGY=;P.[.Y]Y5.6@I)IWVYL[&>7&;&V?3SFQIMM[<1VCC8KI2
M2KG:6JF"KYYY=(M'M]N-WN$GB7+5] ,*/L'^7CZGKDY[D^[///NONW[UYPO#
M*JD^%;I5+: 'RABJ0#3!=BTK@#6[4'18_:'J-NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NC2_%+X>]V_,7?R;(ZBVZ9Z.B>FDW=O?+B>CV9LC'5#D)6Y_+
M(C_N.%?[:BITDJ9RK>*)E21T76&W76XR^%;KPXL>"CYG_)Q/4F^UWM)SG[N;
MZ-EY4M]2(09[EZK;VR'\4KT.30Z(U#2/0Z5(#$;FOPF_EX]&_"?;B-M2@7>'
M:N3H5IMV=M[@HH!N#("0!JK&;=I09$Q&,+BXHZ9V>0!#53U+HC+)&V;/:[8G
MZ8U2'BYX_8/0?+]I/78#V9]@>2O9K;P=K3ZO=)%I/?2J/%>OQ)$,B"&O^AH2
MS4'BO(5!!]_9MU.?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=?_2W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]UKU?S^?YJ)^#W1J=#=-[@6E^47?F!KX,9D,?4A<CU
M)UA4O)B<WV(6B/D@R5:ZSX[;K#25F2IK5<-0+'-E']V7V8_UQ>8SS+O\6K9M
ML<%E8=MS<"C)!G!C04DGXU4I&120E8H]T^=_ZM;9^Z]O>E[=*:$',4? R?)C
ME8_GJ:O;0_.;=WD=I)&9W=F=W=BSN['4S,S<DD\DGWU8  %!@#K$?CD]<?>^
MM=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7@"2  22; #DDGZ #WKK?6W5_)P_P"$\^3[+&UO
ME#\^=LU^"Z[D%'GNM_CCE4J<9N'?<; 5./W'VU!=)\=AV&F2GP9T55;PU9]O
M2#P5V#?OU]Z2+:#-R=[9S+)="J3WZT9(?)H[8Y5Y?)ILI'PCU/W1SU[?>T[W
MFC>N:4*PX:.W.&?S#2^:IZ)\3?BHN&W?\-AL1MW$8O ;?Q6-P6"PF/H\3A<)
MAJ&EQF(Q&*Q].M)08S%XVB5(:>G@B1(H88D5$10J@  >^=L]Q/=3O=73M))(
MQ9W8EF9F-69F-2S$DDDDDG)ZR2CCCAC6*)0JJ      ,  #  & !PZXYO-X;
M;6'R>X=Q9;&X' X6AJ<GF,UF:ZFQF)Q6-HHC/5U^1R%:R10PQ(I>261PJ@$D
M@>V&944NY  R2< #IF]O;/;K22_W"5(((5+R22,$1$459G=B%55&220 ./6L
M'_,$_G8Y3/29OJ#X:Y&IPN"'W&,W#WN89:7.9<&\-33=9TE2JO04Y%U&8G05
M3DEJ6.FT1U,H'W?F9GK;[::#@7\S_I?3[>/I3CUS5]^?OE7-\TW*?M#(88,I
M+N5"LDGD19J0#$OE]0P$AXQ+'19&UQZRLK,C6560R%54UU?75,]975U9/+55
ME9654IGJ:JJJ9RSR22.S.[NQ9F))))]@XDL:G)/7/:::6XE:>=B\CDLS,269
MB:EF)J2234DY)R>HWO73?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5I7\O
M7^6'V7\T<Q3;RW&V2Z\^/F+KS%F=]24H3+;OEI)M%;M[KNFK%,<\P(,51DI$
M:EI6U7$\Z&F8]VC8Y]R;Q'JD(XMYGY+_ )^ ^9QUDU[!_=LYC]XKM=WW#7M^
MPQ-22Y*]\Y4]T5H&%&;\+S$&*(UP[KX9W,NF.DNK_CYU_ANL>H=HXS9NSL)'
M^S08^,M4U]:Z*E5F,WDIBU16UT^E3/5U,CR/8 MI50)(MK6"SA$%NH51_JJ3
MYGYGKK]R?R9RUR%L,/+7*=HEG:0C"J,LV-4DCFK22-0:G<EC@5H  *OM_H4=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7_T]_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW19?F'\J^M/A5\=.R_D?VM5Z-M=?X22IH<-!/%!EMY;JK6^RVKLG B0-JK
M,G6O%31MI*PH7J)=,$,KJ+^0^2]W]P>:[3E/95_6NGH7(JL48S)*_P#1C0%C
MYL:*M68 DW,&^6?+FT3;O?'LB&!YNQPJ+\V-!\LDX!Z^4[\I/DIVA\O>^NR/
MD/W!ECE=\=D9^?+544+2C%X#%1**/;^T]OP3,S0X[%44<%#11EF;QQJTC/*S
MNW:;DWE+9^1>6K3E;8DT6UH@4$TU.QR\KD<7D<EW/"IH   !@[O>\7N_[I-N
MVX-JEF:I]%'!57T5110/09SGH /8GZ*NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J;C<;D<SD
M:#$8B@K<KELK6TN-Q>+QM+/79')9&NG6EHJ"@HJ56EFFFE98XHHU+.Q"J"2!
M[;EEBMXFGG8(B LS,0%50*EF)H  !4DX R>KHCR.(XP69B  !4DG   R23P'
M6]A_)7_D#XCHV+:/RP^;NV:+.]V$46XNK^C<Q#!7X+J"0Z:K&[GW[2/KAKMS
MIZ9:6A;53XIK2.)<B$-!S>^\%]YJ?F,S\D^W<QCV_*7%XI*O=>31PG!2W/!G
MPTPP-,5?%R:]N?:V/;!'OO,B!KG#1PG*Q>89QP,GHO!..7^':^]X4=3GT#?>
M_?O5/QKZYS':7<.ZJ/:VU<2/%&TI\^5SF4EC9Z/ ;<Q49\U;75&EO%!"#90T
MDA2&.21$UW=V]E"9[EM*C]I/H!YG_5PZ"'/'/?*_MUR]-S-S;=+:VL6!7+R.
M02L4*#NDD:AHJ^0+,5168:8WS\_F:=M?-3-5.VJ$UW7?0N-KO+@.MJ*M_P J
MSS4LNNDS_8==2D+75EPLD-&I-)2'2(EDF5JJ6-]VWNXW-M [(AP7U^;>I^7
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MVX/O/CI\:<WD\-3SXZI\F*[%[A@#XG>&]]<)\=328W]W"X63UKH6LJX9#%D
M%ZJ_=;]HQR'RE_6G>8M.Z[NBL0P[H+4T:*'.5:3$LHP:^&C"L6<2?=CG'^L&
M\?NFR>MI9DC'"27@[_,+E$^6I@:/UKO^\I^HEZ][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NG7!
M8+-[HS>(VUMK$9/<&XMP9.@PN!P.%H*K*9C-9C*52T6-Q6*QM$KS5%343.D4
M$$2,[NP5020/;%S<V]G;R7=W(L442EW=R%5%459F8T"JH!))(  J>G(HI)Y%
MAA4N[D!5 )))-  !DDG  X]?0,_DE?R-L%\.<7@/D[\I<'BMR?*S+425VTMH
MU7VF7P/Q]Q]=!=8Z5U\D%5NN2-BE;DHF:.B!:EHF)\U54<POO#?>,N>?9I>3
M^3)&AV5#26455[U@?/@5M@<I&:&3#R#X47*KVX]M(N7T3>M[4/?,*JAH5@!]
M/(R^K<%^%?-CLM>\1^IBZ*+\Q/FAT_\ "[K>7>_9.0^_S^32JI]A]=XNI@&Z
M-\YB",$T]#$^K[>BA+(:[)3(8J=646DGDA@E+]QW*VVV'Q9C4GX5'%C_ )O4
M^7VT'44>[GO#RE[.\NG>N8I-<\H86UHA'C7,@'!0:Z(UJ/%F8:(P1\3LB/I&
M_++Y?]R?,?L>??\ VMFR:.D:II]F[(Q<D\.T=BX>>0/_  [!8^1C>60*AJZZ
M;545#*ID?0D4<<8[AN-SN,WC7!X<%'!1Z#_*>)ZXQ^Z?NSS?[N\PMOO-$W8E
M1;VR$B"VC)^")2>)H-<C5DD(&HT"JI6O:'J,NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>ZV%?Y5?\IUNT?[O_ "3^3FWY(NM U+F>L^K\K"T4O8EB
M*BBW7NZDDLRX']+T=$X!R/$DH%!I6N%^P[!X]+V^'9Q53^+YG^CZ#S^SCGS]
MV#[K1YF\#W%]R;<C;NV2SLG%#=^:SSJ<BVX&.,YN/B;]"@FVMX((:6&&FIH8
MJ>GIXHX*>G@C2*&"&)!'%##%& JJJ@*JJ  !8>QZ  *#KJ*B)$@CC 55   %
M  ,  #  ' =9??NK=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T6?M'YH_$+I+[A
M.W?E!T#US54NL2XO=_;>Q<+FVD3]<-/@JRN6LFD%C^W# S\'CCV+]F]O^>N8
M:'8]FO;M3^**VF=/M+A- 'S) Z)KWF+8-MJ+^]@A(\GE0'_>2U3]@'5</:/_
M  H<_E3]9_<04G?^7[/RE-J#XKJ[K+?^<\A7Z"GS^;H,;AI=7-C'DB/R; @F
M5]F^ZU[T[O1GVQ;-#^*XN(4_:B/)*/SCZ"%[[L<CV=0MT9F'E'&[?\:*JA_W
MKJN+M'_A6A\=L1]Q'TQ\4.Y-_.FI*>?LG>.R^JJ>1AP)BFVEW?)HOR%(5B/K
MH)XE?9ON1\U3T/,&]VMMZB"*6Y/V?J?2BO[1]O01O??;:8ZC;K&67_FHZ1?\
M=\7K8/\ @#\H<G\T/B!TK\G<QM&@V'D>V</N#,3[1QF5J,Y181<1O7)[7IZ:
M'+54-/).6CH4E=V@3U,0%  ]XO>YW)T/M_SUN')\$YN4L711*RA"^J*.0DJ"
MP7+D 5.!QZE;E7>GYBV"VWJ2,1&<,= .H"CLO$@5^&O ='$]@/H0=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0:=A]T=
M.]149R';';'6G6% (S,:[L/?>UME48A'UE-3N2JIDT_[5JM[-]JY?W[?)/"V
M2RN+QN%((9)37[(U8]([O<=OL%UWT\<(]9'5!^UB.J[.T?YX?\J[J7[B+._,
M'K[<U9!J6.BZNQV[NVONY5^D5/D^N<=DJ 7_ !)+5I'_ +7]/<J;-]W7WGWR
MAMMAGA4^=PT5M3YE9WC?\@I/RZ"5[[E<D6%1+N$;D>48>6OYQJR_SIU7%VC_
M ,*J_@OM?[FEZOZA^1':M?#J\%96879G7^UZNW">/)93+5F26_YUX86%OJ;@
M2OLWW+O<>\H^\7UC9*>(#RSR#_:K$L9_*7H(7OOARS!5;*WGG/J0D:G\RQ;_
M (QT;;^4=_.)R/\ -+WS\@,)_H$HND\!TY@M@97$G_2)/V!F,])O'(Y:BF_B
M,_\ !L-#3B)<<CK''%)R[ NP4$@CWQ]AXO9K;MKN/WF=PEOWF5OT! J>$L9&
MD>+*6KXA%21PX9Z/N0_<!^=KJZB^E%LENJ$?J:RVLL,]B 4T^AX\>KQ?>.G4
ME=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_5W^/?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5#_\_?\ F,M\'_B7
M5=?==9XX[Y$?)*FS.Q]A2T%3X\MLG924ZT_8/9*-$1)!+3T]0F-Q,P9'6MJD
MJ8BXHI@,D_NR^U(]Q>=QNFZQ:]JVDI-,&';-+6L$&<$,RF209!C0HU/$7J,/
M=+F[^K6PFTM&I=WE42ARB?Z))\B =*G^)@1\)Z^;)[ZT=8?=>][Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW4S'8[(9?(4.)Q-#693*Y2LI<=C,9CJ6>MR&1R%;.M-1T-#1TRM)--
M-(RQQ11J6=B%4$D#VW++%!$T\[!$0%F9B JJ!4DDX  R2< 9/5D1Y'$<8+,Q
M   J23@  <2?(=?02_D:_P DK%_#O X+Y3_)[;]'E?E7N3%_=;/VA7I#64/Q
M\P.7HRCTR+ZHY-U5<$C1Y*L6XHHV:BIC<U4U1S ^\9]X:;GRYDY,Y/E*;+$U
M)95J#>NIX^HME(K&G^B$"1_P*N5?MI[;IR_$N][T@:^<51#D0*1P_P":I'Q'
M\([5_$3LN^\1NICZ(A\[_GKUC\'^NAF<^8-T=H;EI:I.N.LJ6L6&OSE5$#$V
M:S<J:FHL/326%15E2TC?LP*\A.@JW7=8-KAU/W2-\*^OS/H!Z_D.H/\ ?#WR
MY;]EN7_J[ZESN=RK"TLU:C2,,>)(<F.!#\;TJQ[$!:M-(+OKOSM'Y*]EY[MC
MMW<E1N/=><DT(/5!B<%BHI&:@V[MO&:F2CH*4.RPP(222TDC23222/&-W=SW
MLQN+AM3']@'H!Y ?ZL]<7N>>>N9O<;F.?FGFNX-Q=3G[$B0$Z8H4J1'$E>U1
MYDLQ9V9B#7M-T$.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZV!_Y3
M'\K3_2[/@ODW\C-O'_152319+K'KO+TY4=EUE/)JI]T[CHYA<X"%QJI:9Q;(
MN-3@T*Z:P7<O[%]01?7@_3XJI_%\S_1]!Y_9QSR^ZO\ =D_K6\'N3[@V_P#N
MK0A[.TD'^YC XFE4_P#$53E$/^Y!%6_0%)ML>...*-(HD2.*-%CCCC4)''&@
MTHB(M@  + #Z>Q]UU-5550JB@& !P ZY^_=;Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ^:U\F?Y]G\TK<W8?8NT,3\D'ZZVOA=Y[KP./Q/6_7_7FVJB&AQ6<J,=1VW.
M^,J,R'$2*"PR0N?5:_/OK9RA]VGV:M-JM+Z?:?JYI(HW9IYIY 2R*Q_3\18J
M5/\ OOY=8>[S[H<[37<UO'>>"BNR@1I&N Q [M)?A_2ZJN[1^6_RH[N^X7N+
MY(]Z]H056ORT6^^U]\[HQ@1_U0PXO,5TM-''S811Q*@' 4#W,^S<C\F<NT.P
M[39V97@8;:&-OM+*@8GYDD] >]W[>]RK^\+R:<'R>5V'["Q%/E3HO7L4]%/7
MO?NO=>]^Z]U]1#^11_VZ<^&W_AF;U_\ ?N;A]\<OO(?]/MW_ /YJQ?\ :-!U
MFI[9?\J+M_\ I'_ZNR=6U^X0Z'G7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW6GG_ #]_YMGSE^&/RTP'0'QI[/PG6FR\IT9LW?M=D(NO
M=C[IW1+G=P[IS^'R'CRF]J')111>#'4XC6&G1T;4P>Y!&=_W9?9#VYY_Y(EY
MGYNLWO+A+R6$*9YHXPB1PLO;"\9)K(U:L0<"G6/_ +I<]\R\N[ZFU;/,(8VA
M1R?#1FU,S@Y=6H**. _/K5M[1_F5?S .Y_N(^QOF-\B,Y05>K[G!T?:.Z=L[
M8GU_7R;4VK44.-/]!_DO N!8'WF3LWM)[8[!0[3L-C&R\'-O')(/^;DBO)_Q
MKJ%+WG'FK<:B[W"=@>*B1E7_ 'E2%_ET2RNKZ[*5E1D,E6U>1KZN0S55=75$
MU765,S?JEJ*FH+.['\LS$^Y CCCA010J%5<    #T &!T'&9G8NY))XDY)_/
MJ+[<ZKU[W[KW6X5_PD>_YF)\W_\ PR^C/_=YN?W@A]^+_DE<N_\ -6\_XY;]
M9 >PW^Y>Y?Z2'_CTG6[C[YY=9(=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=?_UM_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=)[=V[-M["VKN;?&\LS0;<VCLW 9C=.Z=P9284^-P>W=OX^3*YK+Y"<\)
M#34T4DTK?A5)]JK&RN]RO8=NL(S+/<.L<:**L[NP5%4>99B /F>FIYX;6![F
MX8)'&I9F/!545)/R %3U\I[^9C\W=R_S ?E_V;W_ )1Z^DV?/6#:'4&V:YSJ
MVGU/MJHE@VIC6@U,L535^2;+9)48K]]5U)0Z- ':7VB]N[3VQY%L^6(=+3@>
M+=2#_1+F0 R-7S5:"*.N?#1*YKU@[SES)-S5O\VZO41DZ(E/X8EKI'R)RS?T
MF/ET0;W)O06Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWO77NM[3^0)_)8CZ5Q.V/G!\L-HC_3+G*.
M#,]$]7;BH?W.I<'70>2D["W3C:H>C<U;$X?'4LJZL7 PDD R,NC'\W?O-_>"
M/,,\WMWR3/\ [KXR4O+A#_N2X.8(V'&W0BCL#29A0?I+67)SVL]NAMT:<R[[
M'_C#"L,;#^R4\)&!_P!$(^$?@&3WGLVQ_>$W4Z=$,^>_SQZ\^#_6+9S*_:;E
M[3W13U=-UEUPM5XZC-5\2^.3.YSPGR4V'HG*FJG%FE;33PGR/JC*MVW6':X-
M;=TC?"OK\S\AY_L'4'>^GOAL'LMRU];=:;G=+D,+.TU4,C#!EDIE+>,TUMQ8
MTC3N-5T<^YNYNQ_D!V/N3M;M;<E9NC>>Z*LU%=75)T4])3)Z:+$8BB3]NEH:
M6.T5+2P@)&@  N23%]S<S7<S3SMJ9O\ 50>@'D.N*W.'.',//G,-QS1S1<-<
MWERU68\%'X8XUX)&@[41:!1^9Z"WVQT&>O>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>ZNJ_E/\ \M.H^46YJ7O'N7$3P?'K9^5(QN(JTD@;MW<V,F_<
MPM,38G"T<JZ<K4J;3.#10DM]R],)=@V4WS_57(_14X'\9'E_I1Y^O#UIF/\
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MZ$<)9%/ZK#^SC.@=[DQSQ[4>WWUTB<T;TGZ*&L$;#^T8'^T8?P*?@'XF%?A
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MHX8UAA4*B !5 H  *  #  & !PZ";Y$_('KCXP]2[I[C[1RO\.VWMNF IZ.
MQOE]R9RI5EP^U]O4DC+YZZLD&B)+A44/-,T<$4LB%]Y=PV-NUS.:*O[2?(#Y
MG_9X= _W Y]Y>]M>5;KF[F:7P[>W&%%#)-(?[.&)21JDD. , "KN5168:'/R
MW^5?9/S"[CSG;78E28$G+8W9^TJ6HEFPNQMI03M)C=NXD.%U%=1EJZDHK5$[
M23,JZE1(KW"_GW&Y-Q-]@'DH\@/\I\SGKAW[J^Z',7NWS=/S5S VD-V00*28
M[: $E(DK2M*ZG>@,CEG(%0H+%[0]1MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW0Y?''X^=@_*'N':/3/6M *G/[HK?\ *LC.DAQ6V<!2D2YO=.=F
MC!\='10WD>WJD?1#$'FEC1E5G:37UPMM ,M^P#S)^0_V./0U]O.0M^]R^;;3
MD_EQ-4]RW<YKHAB7,DTI'".-<GS8T10795._'\9OCGUY\5>G-J=,];47BP^W
MJ8S93,5$429?=NYJM%.;W7GI8_UU59(H-KE88EBIXM,,,:+*]E9PV%LMM#P'
M$^9/F3\S_L==T?;?V]V#VPY0M>3^74I#;BKR$#7/,U/$GE(XO(1]B*%C6B(H
M ^>U?0ZZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z^.CW7_S.7MO
M_P 2;OW_ -ZJK]]Y.7O^2!8_\\\/_5M>N?FY?\E&X_YJ/_QX]!E[..D77O?N
MO=>]^Z]U[W[KW7U$/Y%'_;ISX;?^&9O7_P!^YN'WQR^\A_T^W?\ _FK%_P!H
MT'6:GME_RHNW_P"D?_J[)U;7[A#H>=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=?/+_X5,?]O)-H_P#BJ_6/_O>[N]]2?N:?].FG_P"E
MC<?]6;;K$_WM_P"5PC_YYH_^/R]:W'O+/J'^O>_=>Z][]U[KWOW7NMPK_A(]
M_P S$^;_ /X9?1G_ +O-S^\$/OQ?\DKEW_FK>?\ '+?K(#V&_P!R]R_TD/\
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M (5P;]KVR_PEZP@GDCQD&.[LW[DZ96'BK*^JJ=N;>P<\B?ZJFCAR"H?Z3O\
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M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZZ9592K ,K
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M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7T)O\
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M[3CW3]RH4W&/7M6UZ;J\J*JX5OT;<^7Z\@[E\X4FH:@=;T( 4!5 55 "J
M +  #W*/7;,  4'6K1_PIJ_F$OTET3A/A-UMF_MNROD9BWS/:=105&BMVUT7
M1U[49Q$IC*O&^ZLA!+1$@D-04>0AE334QM[S+^Z%[7#F'F23W"W:.MIM3:+<
M$8DO"*ZAY$6Z$/\ *22)@:H>H2]Y>:SMNV+RY9M2:[%9:<5A!I3_ )NL"/\
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MQ\^8K(8_#'D]QY=M=;E*S1Z#6Y&IGG*V!D( 'O&?F;F[F;G+<#NO--]-?3\
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MM;>]CT;EN5+N\J*,KR*/"@/F/ BTHRUH)3*P^+H\7:O9VR^E>M-_=N]C9B'
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M_BEG\=MW)?9=G=U-6];;',$WBK\9CZVCOO?==-I(=?L,?(8(9XR&BJZJD<<
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MU[W[KW7O?NO=;A7_  D>_P"9B?-__P ,OHS_ -WFY_>"'WXO^25R[_S5O/\
MCEOUD![#?[E[E_I(?^/2=;N/OGEUDAU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=(7+]H=9[?9TS_8FQ<&\9*R+E]W8#&M&R_4.M;4(01^;^S*#
M9MWNA6VM9I*_PQ.W^!3TFDO;.+$LR+]K*/\ ">DT/D)T&9#".\.H#,JZVB'9
M>S#($)L'*?>WM_C;VK_JOS-35^[KJGK]/+_T!TQ^]MKK3ZF+_G(G^?I4XCLO
MKC<+1I@-_P"R<X\MO$F(W5@LDTFK]/C6BG<F_P"+>T<^T;M:@FYM9HZ?Q1NO
M^%1T_'>6<N(I4;[&4_X#TMO9=TIZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[H%^Q_DC\=^G,U2;;[=[[Z7ZKW%D,7%G*# ]C]I;'V/FJW"SU<U!!E
MZ3%[FKJ6>2E>>FJ(4J$C,9DBD0-J1@!!M/*?-6_6[7>Q;9=WL2L49X+>:9 X
M 8J6C1@& 925)K0@TH1T77F\;3M\@AO[J&!R*A9)$0D5(J S TJ"*\*@^G0?
M?[/5\(O^\Q_BM_Z4+U)_]=_9I_K;^XG_ $8-Q_[(;G_K5TD_K/RW_P!'"V_Y
MSQ?]!]>_V>KX1?\ >8_Q6_\ 2A>I/_KO[]_K;^XG_1@W'_LAN?\ K5U[^L_+
M?_1PMO\ G/%_T'T(N\/D7\?.O,!M#=>_^]NF]C[6[!QZY;8.Y=X=G[)VS@-[
MXIZ*GR29/:&8S5=!3Y.G-/5TM0)J*21#'-$]],B$E5ARIS1NMU/9;9MMU<S6
MK:9HXK>:1X6JRZ951"T;:E9:. :JPX@]++C=]IM(HY[JZBB2451GD15<4!JA
M+ ,*$&HK@@^?0A[3W=M/?NW<5O#8VY]O;SVEGJ;[S![HVGFL;N+;N9HQ*T)J
ML5F\/+-35$>M'37#*RZE(O<'V57MC>[9=O8;E"]O/$:/'(C1R(>-&1@&4T(-
M"!TJ@N(+J%;BV=9(VRK*0RD>H()!_(]*'VEZ>Z [;GR=^->\=\IUAM'Y"]';
MI[*DKLOC(^O-N=L["SF^9,EM^FGK,_CTVEC,A+7F>AAI:J6LB%/JA2&5I JQ
MN0([OD_FVPVW]\7VUWD-H K>/);3)#I<@(WBL@2CEE"G51BP K4=%D.];/<7
M/T5O=PO-4CPUE1GJM2PTABU5 )(IBAKPZ''V'.C/KWOW7NO>_=>Z][]U[K__
MTM_CW[KW7O?NO=>]^Z]U[W[KW6J?_P *O^Y_[L?%3XZ=%TE5X*WMONG+;XKX
MHWL]7MSJ+:CT=523)_QR.0W-C)^1^N!;'@^\TON4;!]9SINO,CK5;&T6%3Z2
M74@((^>BWD'V,>H.]\]Q\'8[3;%-#/,7/S6):$?9JD4_:.M#3WTJZQ@Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NC.
M_"_XU[@^8/RHZ,^-NVS4PU7:V_L3@<MD:1!)/@=H4I;,[ZW,L; AOX9A::OR
M&DBS>'3^?8.]P.;;7D3DS<N;;NA6RA9U4\'E/9#'_P W)61/EJKT=<N[/+S!
MO=ML\/&=PI(_"@R[?[5 S?EU];S:&T]O;"VGM?8VT<738/:>R]NX3:>V,)1*
M4H\/M[;N-BP^%Q=(A)(BIZ:&*&,$\*H]\/KZ]NMSOIMROG,D]P[R2.>+/(Q9
MV/S9B2?MZSPMX(K6!+:W4+'&H50. 50  /D  .B:_P R'Y+?[*Q\2.R]_P"-
MKOLM[Y^C7KOK5DD\=2N]MX4\M)29*D/_ !TQE&E;EP#P?M=)_5;V0;S>_0;>
M\RFC'M7_ $Q\_P A4_EU"_WA_<;_ %L?:G<M]MWT7LZ_26F:'ZB<,JNOSAC$
MD_S\*GGUH-DEB68EF8DDDDDDFY))]Q1UPM))-3UU[]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZV7/^$^O0"SUO<WR:S%%J%"E+T]L:HE
MCU**FI6GW3ORJAUCATB_@T$<J<Z9:B.X!8$:\HVE3)?,.'8O^%O\G\^NC7W"
M^1 \V\>Y%VGP!;"V)'F=,URPKY@?3J&'DTB^HZV=?8WZZ3=?-<_X41?+!_DI
M_,8W[L[#9/[W8'QCQM/T7MN*&752/NG#3OD^T\D802JU(SL]3B97!]<6.I[V
MM8=:_NL<DCE'VIMK^X33=;PQO)*C/AN MLM?X?!"R@>32MUA[[L[Z=XYNEMX
MVK%9#P5]-0S*?MUDJ?D@ZHG]Y(]1CU[W[KW1ZOY86R/](G\Q3X2[5:'[BGJ/
MDYT[F,A3E=2SXG:N]J3=>8A<?ZEJ6BF5C^ 2?<;^\.X_NKVKYAO0:$;?=*I]
M&DA:-3^3..A/R7;?5\V[;!2H-Q$3]BN&/\@>OK(^^)?6=/7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO= ]W#\A>B/CW@QN7O7N3K+J#!NDCTV0[&WOMW:$5>8OU
M0XM,Y40O5RD^E8:97D9K*JDD#V?;#RMS)S1<_2<MV%Q?R#BL$+RT^;:%(4?-
MJ <2>B_<-VVO:8O&W.XCMU]9'5*_9J(J?D*GJF?N_P#X4H_RQNIC64FS]Y=E
M]_Y>E,D/VG4O762IL9]VOI5'W%V;)MVDDAO8M44+U*Z>4$A]/N?.7?NE>\&]
MZ7O[>WVR-LUN9U+4_P!);B=@?Z+A#7C3J/-R]X>3+"JV\DETP\HHS2O^FD\,
M4^8K\J]5,=N?\*V=V5'W5)T/\.=NXC3K%%N#MSLW);C\U[^-ZK9^S<=BO%;@
MLJ9R2_T#"US-VQ_<@L4TOS+OSR>J6UNL=/LEE>2OYPC[.@+?^^\YJNU[>J^C
M2R%OVHBK3_>SU6CV;_PI/_FG[_:H&W>R>L>G:>H+ TO6?4.TZI8HG^L4%7VB
MNYJE.. ZSZQ]0X//N7=H^Z5[,;8!]5:7%^1YW%U(/S(M_IU/V4I\N@;>^\/.
M]U7P9H[<'RCB4_SD\0_SKT1/?7\UG^9+V*\[;E^;OR2CCJ2WGI=J]H[DV!CY
M5;]4;XW84V-IRA_XY^+3_A[DC;?97VEVH#Z3EVP)' R6\<S#_;3"1J_.M>@Q
M<\\<X7=?&W*XSY+(R#]B%1_+HJFZ.]^\-\/))O3N7M;=[RZO*^Z.Q-W[@>35
M^KR-EJR8F_YO[&EGRURYMP V_;[:"G^^X(D_XZHZ(Y]SW*YS<W$LG^FD=O\
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M(=#SKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z(-\@OYH_\
M+[^+LU=0=S_*WJ?!;@QK21UVSMNYJ7L7?5%.G IZ_9/7,65RE,S'TK]S21K>
M_( )$F<K^S?NASBJR[!LMS)$_"5T$$)'JLTYCC;_ &K'H+;KSMRILI*[C?1*
MXXHI\1Q]J1AF'Y@=4U=U?\*K_AELYZJAZ3Z4[O[KKZ<N(LEFQMOJ;:%=;B-J
M3)Y";+Y8 _VO/@8R 18,;@3YR_\ <MY_OP).8=PM-O4_A3Q+F4?:JB*+]DQZ
MCW<??#EVW)7;;::Y(\SIB0_826;]J#JK'MK_ (5=_,'<K5%/TY\?^A>JJ"<N
M(JG=<V].U-Q4:']!ILC%5[?QY<?EIL2ZG_4#W,VR?<IY$M*-OVZ7EZP\HQ%;
M(?M4K.]/LD!^?0(O_?+F":HV^U@@!_BURL/SK&O[5/5='8O\_'^:[V.U3'5?
M*O+[0QTY;QXSKK8?66R5I%?ZI39G#8=,H?\  RY!V'X/N5MJ^[/[*;2 4V59
MW'XIYKB6OVH\IC_8@Z"5W[H\\WE0U\8P?*-(TI^835_QKHEN\OGW\YNPVE.]
MOF-\G]RQ3:M5%E.]NS9\8@;]208H9,4T:G\K'$H_P]R!8>V7MSM8'[NV';X2
M/-;.W#?FWAZC^9Z#EQS3S-=_[D[A<O7R,TE/V:J?RZ+=G]Y[PW7(9=T;KW+N
M25G\C29_.Y3,2,][ZR^1ED)/^-_8LMMOL+(:;.".$?T$5?\ CH'11+<7$YK/
M(S_Z9B?\)Z37M9TQU[W[KW7O?NO=/.%W%N#;54*[;N=S. K1:U9A<G6XJJ&D
MW6U10O&_!^G/M/<6EK=IX=W&DJ^CJ&'["".G8YI86U0L4/J"0?Y=&MZ\_F'?
M/'JF2F/7_P Q?DKMRFI"IAQ$/<V_:W;WH_0)MM92NGQ\H'T DIF%KCZ$^P5N
MGM9[:[T#^]-AL)2W%C:PA_RD5 X_)AT>6G-G,]B1]+N%P@'EXSE?]Y+%?Y=6
M4=,_\*2_YH?5DM-'NKL'KCO?%4Y1!CNVNL<##/\ ;"P>,9SK [;KY)"+E9JJ
MHF8'EM0&GW$F_P#W2_9S>@396L^VN?Q6UPY%?])<>.@'R55'I3CT,-N]X.=;
M$@3RQW2CREC7_#'X;?F2>KM/C9_PJ[Z.W1/C\)\J/CQO7J:JE\=/4;XZJS=)
MV9M7S,1Y*_([8RT>)RM!3#F\=))E)>!8-<Z<>N;?N4\QV:M<<F;K%? 9$-RA
MMY*?PK(IDC=OFPA7[/.2-G]\MLG(CWRT> _QQ$2+]I4Z64?9K/6QU\:OFC\5
MOF%MX[D^-G>>P>UJ:&FCK,CB,%EOM=X8&"5@D;[GV)F5ILUC-3,%7[^@AU']
M-_>*/-WM_P Z<B77TG-NVS61)HK.M8G/_"YDU12?[1VIY]2[L_,6Q\P1>-L]
MRDXI4A31U_TR&CK_ +91T9_V#NCKKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J#D\IC,
M)CJ[,9G(T.(Q.,I9Z[)93)U=/08['T5-&9:FLKJVJ9(HHHT!9Y)&"J 22![<
MAAFN)5@MT+NY 55!9F)P  *DDG@!D]5=TC0R2$*JBI)-  /,DX ZI*^4_P#P
MH4_EM_&B7(X3#=F9/Y&;XH'EIWVU\?\ '4V[,1%4HQCC-7V/DYZ';C0ZP1(V
M/R=7*@!/@8E0V0W)GW7/=GFX)<7%FNU6S9\2]8Q,1\H%5YZTX:XT4_Q<:1OO
M?NOR?LQ,<<QNY1^& :A^<A(CI_I68CTZH)[Y_P"%7_R3W+/6T/QS^.G5'5.(
MD\D%-FNRLMN+M?=8C%Q'74T.)?;N-II6X;PSTM:B<KJDX;WDSRU]RCE*T59.
M:]UN;UQDI;JEM']A+">1A\PT9/&@X=1;NGOGO$Q*[1:10+ZR%I6^T4\-0?D0
MP^WJIOM+^>)_-0[::H7.?,#L#;%',S^*@ZMQVTNIUHXF-Q!3Y'KS'8ZO8+]
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M^Q3_ ,!U[O?Q6/\ V4O_ -:>BG_7JY-]+C_G$O\ T'U[_H*$_EF_\J?R/_\
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MHZ*EB!^K22.J*/ZGVS//%;0/<SMI2-2S$\ JBI)^P"O5XT>5UBC%68@ >I.
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M\TTJ%R[FK%69BE2<GLTY-2?7JS3W$/0RZ][]U[K3T_X5C?\ =.W_ ,//O_\
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M;_FWT7;);'VWUC_PJ+^'76VS:!,5M#KWXUP;'VKBX[%,=MS:GPPWM@<'0(0
M+0TU/%&.!]/8JAW&[WC[G&_;M?MKGNK\S2-_%))NMH[M^;,3T4O;0V7O5M]G
M;C3'%;Z%'HJVDRJ/R '6X)[P3ZG[KWOW7NO>_=>Z][]U[K__U-_CW[KW7O?N
MO=>]^Z]U[W[KW7RV/YW/9P[8_FG_ #(W!'4>>FV_V52]8TRJ^J*F/46U,=UC
M74\0'"_Y7B:AY /]V,Y/)/OLG]WC9_W)[,;!:D4,MN;@_/ZF1[A2?]K(H'R
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MNO=>]^Z]U[W[KW7O?NO=?'1[K_YG+VW_ .)-W[_[U57[[R<O?\D"Q_YYX?\
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M/M+NO[Z]L-@W(FK26%J&/]-(E23_ (VK=8)\X6GT/-6XVH% MQ+3_2LY9?\
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M?4>]>]^Z]U[W[KW7O?NO=;YG_"3?_LD7Y,?^+'TW_OLL/[YJ_?:_Y7G:/^>
M_P#:1+UD_P"Q7_)!O/\ GH'_ %;3K:O]X6]3CU[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:$O_  K%_P"RS/CE_P"*
MQP?^_4W#[Z6_<F_Y4'=O^E@?^T:#K%[WT_Y6*S_YYO\ K+)UJO>\S^H0Z][]
MU[KWOW7NO>_=>ZVN_P#A)G_V55\H?_%?<1_[\?'^\*/OM_\ *E[-_P ]K?\
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MTY4\?0,5Y^ND?3V#KO[\6Y.3]#RY%'Z>)>-)_P =MX^CN'V&M1_N1N3-_I8
MO^&1NA<Q_P#PDU^)L2*,K\G?D16R '6^/Q_6N,1C^"L=3BZLC_8L?9'+]]KG
M8G]#9[%1_2:X;_!(O2Y/8K8@.^]G/V",?\^GI1P?\)/_ (/*I%3\@?E9*^@
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M\]W<1VEJC22RLJ(B@LS,Q 55 R68D  9)-!U222.&-II6"H@)8DT  %223P
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MKK*N>6JJZNJEDJ*FJJ:B0RSU%1/*2SN[$L[L222222??8M$2-!'& JJ   *
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M>BI=[[UR<14Z=:X]\#C)5L3'+1RJ3<LJ]2ON?\FIL/MJ_,TR4N-YF9ZTS]/
M6AB7[-8FD'JLBGT/6)_O/O;;AS.NUH?T[% M/+Q) '<_[SH7Y%3UK=^\LNH?
MZ][]U[KWOW7NO>_=>Z'?XT_&SN#Y;]T;+Z$Z+VK/NSL/?%?]K04H<TV+Q&.I
MU\^7W+N3*%62BQF/@#5%95.#I1=*+)*T<;AKF[FW8N1^7[CF;F.806MLM6/%
MF8X6.->+R.:*BCB34D $@TV?9]PW[<8]KVQ/$EE- /(#S9CY*HR3_A-!U]$C
M^6W_ "+?BA\$<+M[>6[\!A>__DM##2UV4[7WMAH*_![2S 42/3=2[1R0EI\7
M'3MZ8LK,DF2E];^>"*04L7+#W9^\?SM[DW$MA8ROMFT$D+;1.5>5?6YE6C2%
MO.,$0C TLPUG+/D_VSV+EB-+BX075Y@F5Q4*?2)34+3R8U<^H!TB[SWCOU)/
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=)7>>Q=D]C[=K]H=A[.VK
MOW:>53Q93:^\]O8C=&W<E'8CQU^%SD,]-,MB1:2(CGVMV_<MQVFZ6^VJ>2VG
M3X9(G:-U_P!*Z$,/R/3%Q;6UY";>[C66-N*NH93]H8$']G5%WRR_X3A?R\_D
M3%D<SUGMS._%;?U4LTL&8Z@G6?8DU<]_$V6ZKS[2XY:9+_\  ;!S8HFPO)];
MY'<D_>O]TN562WW>5-ZM5H"MT*3 >>FY2CZC_%,)OLZC/??:'E/=@9+-&L93
MYQ?!7YQ-5:?)"GV]"K_)>_E<[L_EB=?_ "&VGOW>FT.PMR=H=LXO)X/=NSZ;
M*T,.3ZTVGM2&EVC_ !S%Y>-9*'(KD*_.F>BBGJH8U:-HZJ7R-I)??_WDL?>#
M<]KO=LMY;6*SMF5XI2I*W$DA,NAE-'30D-'(1B:@HM,KO;ODJ?DNUNX+J1)7
MGE!5D!%8U4!=0/!M3/458#%&->KIO>/W4B]>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]#?X]^Z]U[W[KW7
MO?NO=4B_\**-P-A/Y2?R0I$D,4FYLYTCM]&4Z69?].&WLW/&I'^JBHI%8?E2
M1]/>0_W5K47'O?M+D5$*7;_]FDZ#^;C\^HW]VI?#Y#O%'XVA7_JM&W^ =?,^
M]]=>L-^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z4.TMKYC>^Z]L;+V[3&MW!N_<.%VO@J,:KU>8S^2BQ.,IAI!/[D\J+P">
M?I[27UY!MUE-N%T=,4"/(Y]%12S'\@#T];P27,Z6T0J\C!5'J6-!_,]?86ZA
MZWPG3G4_6/46VE"[=ZLZ]V9UU@5"",##;)VY3;:QG[8O;]FF3B_OA'ON[7&_
M;W>;Y=_VM[/+._\ III&D;^;'K/^PLX]OL8;"'X((TC7[$4*/Y#HI?\ ,][6
M/3_P6^0FX:>J--E-P;./7.&T/XZB2M[)KX=EU+4C\$204=;5588$%1$67D#V
M%-\G^GVJ9QQ(TC_;=O\ @)/4+?>4YH_JE[);_N"-IEGM_I(Z8):[9;<Z?FL<
MCO7B I(R.M";W%/7#/KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[HP?Q-Z_7M3Y/?'[KR:'[BBW9W!U]BLM'IUC^!2;GII<_(4_(2B2
M=R#];6]J]OA\>^AA\F=0?LJ*_P NA[[6;".9_<K8=@<:DNK^U1Q_PLS(93^4
M88_EU]$[W,/7T!]:RG_"J+M9]H? KK3K&CJO#7=O_(3;<>0IM5ON]J;"VME=
MRY$:1]=&4;!MSP/]>WO+W[F.RB^]R[O>)%JMA92:3Z2321QK^V/QNH:][K[Z
M?E>&R4YN)UK\U168_P#&M'7S[_?3_K%3KWOW7NO>_=>Z][]U[K8;_P"$Q6:_
MA?\ ,\H:'5I_O)T%VUA;7_7X),7N+3_ZH:O]A[Q9^^#;^-[/-)_OF]MG_;XB
M?\_]2S[,2:.= O\ '!*/^.M_S[U]&#WRIZRWZ][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[HD?S_ /@CT]_,)^/.Y>C.UJ&&DR#Q5&7ZT["IZ**IW#UA
MOV&E:+$[IPS,4:2(DB#)4/E1*RE:2%F1C'+%(?MC[D[][7<TP\Q[*Q9:A;B
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MO?NO=>]^Z]U[W[KW7U$/Y%'_ &Z<^&W_ (9F]?\ W[FX??'+[R'_ $^W?_\
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M;/'X5K9Q)%&OGI04JQ\V;+.W%F)8Y)ZP3W'<+K=;^;<KUM4L[%V/S)K0>@'
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M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW55O\PK^3_\
M$/\ F'X7(Y/?NU(NN^\!0F';_?VP,?0T&]J>H@@\>/I]Y4@$=/N/'QD(K4N2
M_>2(,E'5T;.9/<S^UWOKSS[67"0[9.;K;JU>RF8F$@GN,1RT#G/='VDT,B2
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M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NOEW_SU_\ M['\R?\
MP]-E?^^DV][[&?=O_P"G);!_S2E_[29^L*_<W_E>MP_TZ?\ 5I.JE/<X= /K
MWOW7NO>_=>Z][]U[K?E_X2??]D1_(3_Q:C*_^^DVK[YF_?8_Z>'M?_2N7_M)
MN>LI/8S_ )5N[_YZ3_U:BZVEO>&O4V=>]^Z]U[W[KW7O?NO=?,5_X4"?]O>/
ME]_U&]*?_ X[/]]@?NP_].,V+[+O_M.NNL,?=7_E?MP^V'_M'BZIN]SWU'O7
MO?NO=>]^Z]U[W[KW6^9_PDW_ .R1?DQ_XL?3?^^RP_OFK]]K_E>=H_YX#_VD
M2]9/^Q7_ "0;S_GH'_5M.MJ_WA;U./7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UH2_\*Q?^RS/CE_XK'!_[]3</OI;
M]R;_ )4'=O\ I8'_ +1H.L7O?3_E8K/_ )YO^LLG6J][S/ZA#KWOW7NO>_=>
MZ][]U[K:[_X29_\ 957RA_\ %?<1_P"_'Q_O"C[[?_*E[-_SVM_U8?J<_8K_
M )+E[_S0'_5Q>M\#WS:ZR=Z][]U[KWOW7NNB0H))  !))-@ .223[]U[KY W
MRP[>J._OD_\ (7NVHJ6J_P#2KW/V3ONDD+%DCQ6Y-W5>3PU)!JN1%3TDD$$*
MW],:*/Q[[J<D[$O+')^U\O(-/T5K!"?]-'$JN3\V8$GU)/6 N^WYW7>KO<B:
M^/-(X^QF) ^P"@'RZ+][%'13U[W[KW7O?NO=>]^Z]U]!G_A,M\(L%TI\0JGY
M9[DPT#=L?*"LR/\ !<G54Z_Q#;O2VU,W+A]OX2C:0%H1E\E2569JFC8+4P?P
MW6MZ9#[Y>_>]]Q+GF'GH<D6DA^BV<+K4'M>[D0,[GU\*-EB6N4;QJ'O/65GL
MURW%MVP'?9E_7O2:$\5A4D*!Z:V!<^HT>G6S%[Q%ZF3KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
M_]'?X]^Z]U[W[KW7O?NO=:\7_"G?+-COY8E91JY49[O[J7$NH_W8L,.5S@0\
M_P"JH@W^P]Y2_<^@$OO LA_T*RN6_:8T_P"?^HF]YY-')97^*>(?\>;_ "=?
M.A]]5^L2.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>ZM+_DI=.)WA_-#^'^U:FF^YQNV^S!VQE"Z>2FB@Z:P59VC1?=K8@QS5
MN)I::S"S-*JGAO<,_>#WX\N^SF^WJ&CRV_TR^I-TZVYI\PDC-\@"?+H;^W.W
M_O+G7;X"*A)/%/\ S94R"OVE0/SZ^IA[XT]9L]:]/_"A'LS^$],]$=1T]1HF
MWOV)G=\U\,;V=\?U]@!B((JD+_NN2HSZR(&X9X;BY3@(<W3Z;:*W'XF+?[R*
M?\_?RZP%^_OS)]+R?L?*D;4-[=RW+ ?P6L7A@'Y%KH$5XE*_AZU1/8"ZY<]>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=6H_P F+92[
MP_F ]4ULT/GI-BX+L'>M3&5N@:EV;5X#'3-_3QUN1II5/^J5?9[RW%XF[1D_
M@#-_(@?S(ZR=^Y]LPW;WXVN9QJ2RCNK@C_2V[Q(?RDE0CY@=;P'N3^NT?6CW
M_P *V.R6K^W?ASU!'467:G7'9O9-72*U@[=@;FQ^V,?43(/KI&V:I8B?IJDM
M]3[Z)_<@VD1;'OV^D?VT]O #_P T8WD8#_LH6OV#K&SWWO-5_M^W@_!')(1_
MIV51_P!6S3\^M0CWG3U 77O?NO=>]^Z]U[W[KW5T7_">_=7]U_YM?Q<627Q4
MFY8^X-JUAN1K_BG2&XY,=%;\ZJV&E%C_ +W[Q^^]%9?6>R&\D"K0_2R#_:W<
M&K_C!;J1?:F?P.?+*O!_%4_G#)3^8'7TV??(3K,OKWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>ZU ?^%4'PBHL[U]UG\\=EXA(]P;%K\;T_P!U
MS4<(5LALO<%5))UQNK(L@"WQN5DEP[S-JDD&2HX[^.F4#.K[F7N));;I>>VN
MX25BN5:ZM 3\,J >/&O_ #4C E P!X4AXN>H"][N6UEM(>9[9>^(B*:GFC']
M-C_I6JE>)UJ. ZT@O?1+K&SKWOW7NO>_=>Z][]U[I<=8[\S'5?9/7O9^WF*9
M_KC?&T]^8-PYC*9C:&>I]PXQA(MRMIZ=#<#CZ^RW>-M@WK:;K9[K,5W#)"_^
MEE1D;^3'I5974EC>17L7QPNKK]J,&'\QU]B?;&XL7N_;6WMV8.?[G"[HP>)W
M%B*D6M48O-T$>2Q\_I)'KBE1N"?K[X/7EK-8W<ME<"DD+LC#T9&*L/R(/70&
M&9+B%)XC574,/L(J/Y'I\]ING>O>_=>Z][]U[KWOW7NOCH]U_P#,Y>V__$F[
M]_\ >JJ_?>3E[_D@6/\ SSP_]6UZY^;E_P E&X_YJ/\ \>/09>SCI%U[W[KW
M7O?NO=>]^Z]U]1#^11_VZ<^&W_AF;U_]^YN'WQR^\A_T^W?_ /FK%_VC0=9J
M>V7_ "HNW_Z1_P#J[)U;7[A#H>=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW3=F,1BMP8G*8'.XZBS&$S>.K<1F,3DJ:*LQV4Q62
MIFHLACJ^CJ T<L,\+O%+&ZE65BI!!/MV">:UG2YMG,<D;!E920RLIJK*1D$$
M @C(/5)(TEC:*4!E8$$'(((H01Y@C!Z^4Q_-$^',_P %/FYW5T#2052['H<W
M'O#J:MJFEE:OZKWK&<YM&/[J8EYY,<CRX:KG:WDJJ.=@ "/?:?V<Y]7W(]O-
MOYG<CZED\*Y _#<Q=DN!@!R!*J^22*.L'>=>7SRSS)<[4H/A ZXB?.)^Y,^9
M7X"?-E/5?GN4.@IU[W[KW7O?NO=>]^Z]UM3_ /"4+MZ3;?RX^0_2L]3X,=VK
MT51;S@B9[+5[CZFWG34F.IDC_+B@W+EI@?PL;?U]X7_?7V(7?(^U<P**O97A
MB)]([F)BQ^S7!&/M(ZG#V,OS#OUWMQ-!/"'^UHG '_&9&/Y=;ZGOFGUE!U[W
M[KW7O?NO=>]^Z]U[W[KW6EC_ ,*L/F3+/DNE/@OM/)E::A@A[Y[@CI9O3-6U
M7W6W.K=MU;1$$&&(9;*5-++<-YL=. "B-[Z!_<MY""P[A[CWR98FSM:C@!ID
MN)!7U/A1JPX:95\SUCK[X\PDO;<LP-@?KRT]358U/V#4Q!]4/6FE[SYZQYZ]
M[]U[KWOW7NO>_=>Z][]U[K>F_P"$W_\ *DH.M=C8;^8%WSME)NS.PL7+)\<]
MN9JC#/L/KO)P-3R]GM3U(NF4W%"S+BY H,&*;S([?Q)EAYP_>P]ZI=WW&3VP
MY:FI:6K?X](A_MIU-1;U'&. _P!H/Q3#20/"JV3/M#R,EG;+S5NB?K2C_%U(
M^",_Z)_II!\/HF1\>-M7WA#U._7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U\\O_A4Q_P!O)-H_^*K]8_\ O>[N]]2?
MN:?].FG_ .EC<?\ 5FVZQ/\ >W_E<(_^>:/_ (_+UK<>\L^H?Z][]U[KWOW7
MNO>_=>ZW"O\ A(]_S,3YO_\ AE]&?^[S<_O!#[\7_)*Y=_YJWG_'+?K(#V&_
MW+W+_20_\>DZW<??/+K)#KWOW7NO>_=>Z][]U[JA+_A2C_VZJ[._\2=TQ_[W
M,'O)?[I7_3Z+/_GGN_\ JRW47>\/_*CS?\U(?^/CKYN/OK+UB!U[W[KW7O?N
MO=>]^Z]T<_\ EO\ _;P_X%_^+G_%S_W^&"]Q_P"['_3K.9?^E5N/_:)-T(N4
M/^5LVO\ YZ[;_J\G7UK/?$/K.[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z^7?_/7_P"WL?S)
M_P##TV5_[Z3;WOL9]V__ *<EL'_-*7_M)GZPK]S?^5ZW#_3I_P!6DZJ4]SAT
M ^O>_=>Z][]U[KWOW7NM^7_A)]_V1'\A/_%J,K_[Z3:OOF;]]C_IX>U_]*Y?
M^TFYZRD]C/\ E6[O_GI/_5J+K:6]X:]39U[W[KW7O?NO=>]^Z]U\Q7_A0)_V
M]X^7W_4;TI_\#CL_WV!^[#_TXS8OLN_^TZZZPQ]U?^5^W#[8?^T>+JF[W/?4
M>]>]^Z]U[W[KW7O?NO=;YG_"3?\ [)%^3'_BQ]-_[[+#^^:OWVO^5YVC_G@/
M_:1+UD_[%?\ )!O/^>@?]6TZVK_>%O4X]>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6A+_PK%_[+,^.7_BL<'_OU-P^
M^EOW)O\ E0=V_P"E@?\ M&@ZQ>]]/^5BL_\ GF_ZRR=:KWO,_J$.O>_=>Z][
M]U[KWOW7NMKO_A)G_P!E5?*'_P 5]Q'_ +\?'^\*/OM_\J7LW_/:W_5A^IS]
MBO\ DN7O_- ?]7%ZWP/?-KK)WKWOW7NO>_=>Z!KY&[FFV7\>N]]XTTCPU&T^
MFNT-S031FSQ38'9%=E(I$/\ 56B!'L_Y4LUW#FC;;!Q43W5O&1ZAYD4_X>B[
M=YC;;3=7 XQPR-_O*,?\G7QZ??=WK #KWOW7NO>_=>Z][]U[KWOW7NOKG_!+
M:N.V/\)?B#M'%1Q1T.W_ (R=%XV(Q* L[P=98P5-8Q %WGEUS2.1=G8L>2??
M#CW(O9=Q]P]]OIS5I=PO&-?*MQ)0?8!0 >0%.L].6($MN6[""/@EO"/^J:Y_
M,YZ-9[!71YU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__]+?X]^Z]U[W[KW7O?NO=:TW_"J:KDI_
MY<O6\*$!:_Y==;4DW^,:=5;YK@!_R'"I]Y<?<P0/[K7;'\.V3D?]E-F/\!/4
M.^][$<HPCUNHQ_U2F/\ DZ^>[[ZB=8H]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UM'_ /"4SJA=S_-+O#MNKI_/1]4] 5&#
MHI"EQ1[E[+WECZ>@J1)^&..Q.7A _(D8_CG#;[Z>]FS]O]NV-#1KV]#GYQV\
M3EA_SDEB/Y=39['6/C<Q7-^PJ((-(^32.M/^,JX_/K?L]\S.LI.M.S^?9V'_
M 'G^8.V-CT\^NCZRZAVY0U--JU"#<&ZLM7;GKI;?V3)038L6^OI!^A%HZYKF
MU[BL0X(@_:23_@IUR/\ OS;_ /O+W:MMEC:J;;81*1Z2SO),Q_.)H?V=4@^P
MQUA?U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U?[_P
MGPVHM=\B^[=ZO%K&VNFH-NQR$7$,^[]Z4%>K+?Z,4P\B@_726'T)]BSE&.MY
M++_"E/VL/\W6=OW"=K$_N#O.\D5^FV\1 ^AGN(F_;2 C[*];:GN0.NJ?7SD?
M^%-6^SN[^:'N';YG,HZMZ1ZAV*(]6K[89&AK.S#"!^+_ -XO);_:K_GWU;^Z
M%MOT/LY%=4I]9=W4WVZ2MO7_ *H4_+K$7WENOJ.=7BK_ &$,2?M!D_ZR=:^7
MO*'J*>O>_=>Z][]U[KWOW7NC\_RL-\CKG^8_\(]T/,*> ?)3JG;E;4$Z4@QV
M]]U4^R<G/(?PB4^1E9_]I!]QE[S[;^]?:?F*S J?H+F0#U:&-IE'VED%/GT*
M>2+GZ3F_;9N ^HB4_8[!#_)CU]8+WQ0ZSGZ][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NBM_-SH2B^4/Q$^1G0-721UD_9_4F\MOX%9461:7>2
MXE\EL7**C<%Z+,P4%7&/]5$/8R]O.9I.3N>=JYG1M(L[F)W^<6H+,OV/$74_
M(]$G,FUKO6P7>U,*F:)U7Y/2J'\G"G\NOD4LK(S(ZLCHQ5T8%65E-F5E/((/
M!!]]R0014=8%]=>]]:Z][]U[KWOW7NO>_=>Z^L%_*QW^_9O\N+X3[MFF-35R
M?&_J[;V0J6;7)4Y39&V8=D96IE;\O)4XZ5W_ -J)]\3_ 'FVP;1[K\PV*BBB
M_N'4>BS2&90/D%< ?+K.?DBZ-[RAMLYR?IXU/VHH0_S4]'Y]QGT*>O>_=>Z]
M[]U[KWOW7NOCH]U_\SE[;_\ $F[]_P#>JJ_?>3E[_D@6/_//#_U;7KGYN7_)
M1N/^:C_\>/09>SCI%U[W[KW7O?NO=>]^Z]U]1#^11_VZ<^&W_AF;U_\ ?N;A
M]\<OO(?]/MW_ /YJQ?\ :-!UFI[9?\J+M_\ I'_ZNR=6U^X0Z'G7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6FC_PK1Z!I
M&Q?Q/^4F.HECK8,ANWH/=^1$8UU=-5TS=A]=4;2@7 @:#=#@$F_FXM8WSY^Y
M'S,XFWODV5JJ5BO8E]"#X$Y_VU;<?[7K'KWVVI=%CO:#(+0.?4']2,?E23]O
M6EE[Z!]8Z=>]^Z]U[W[KW7O?NO=7)_R M_2; _FP_%J5IC%C]WUG9&P<F@;3
M]Q'NKJG-T>)A)_H,FM!)8_73;ZV(@/[SFV#<_9/>0!5H!!,OR\.YB+'_ )QZ
MQ^?4A>UET;7GJR/E(9$/^VB<#_C6GKZ='OC_ -9G=>]^Z]U[W[KW7O?NO=1:
MZNH\915F2R-53T./Q]+45U?6U<J04M'1TD)J*JJJ9Y"%2.-%9W=B  "3Q[O'
M')-(L,2EF<@  5))-  /,DX ZJS*BEW- !4D\ !Q/7R1_GG\ELC\P/F'\A?D
M76U-344/9/9&<K=IQU8=9\?U[AW7;G7&(D22Q5J3!4>/IW]*W=&;2"2/?<#V
MUY1BY$Y#VOE2, -:0():<&G;]2=O]M,SL/D0.L$.:-X??^8+O=V-1-(Q6OE&
M.V,?D@4=%&]CGH@Z][]U[KWOW7NO>_=>ZM"_E ?!67Y_?-OKKJG-T51/U+L\
M/VEWA51^:*,]<[3K8//MT5,)4I+G:^:BPJ,CK)&E3+4)?[=O<.>^ON0/;'V\
MN]ZMV OI_P#%[08/Z\@-)*'B(4#RFHH2BH?B'0UY Y9/-/,D-C(*P1_J3'_A
M:D=M?5V(3U )(X=?4NQ^/H,304.*Q=%28W&8RDIL?CL=04\-)0T%!1PK34=%
M14E.%CBBBC58XXT4*J@   #WQJEEDGE::9B[N2S,226)-223DDG))R3UFRB+
M&H1  JB@ P !P 'D!U+]M]6Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NOGE_\ "IC_ +>2;1_\57ZQ_P#>]W=[ZD_<
MT_Z=-/\ ]+&X_P"K-MUB?[V_\KA'_P \T?\ Q^7K6X]Y9]0_U[W[KW7O?NO=
M>]^Z]UN%?\)'O^9B?-__ ,,OHS_W>;G]X(??B_Y)7+O_ #5O/^.6_60'L-_N
M7N7^DA_X])UNX^^>762'7O?NO=>]^Z]U[W[KW5"7_"E'_MU5V=_XD[IC_P![
MF#WDO]TK_I]%G_SSW?\ U9;J+O>'_E1YO^:D/_'QU\W'WUEZQ Z][]U[KWOW
M7NO>_=>Z.?\ RW_^WA_P+_\ %S_BY_[_  P7N/\ W8_Z=9S+_P!*K<?^T2;H
M1<H?\K9M?_/7;?\ 5Y.OK6>^(?6=W7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U\N_^>O_ -O8
M_F3_ .'ILK_WTFWO?8S[M_\ TY+8/^:4O_:3/UA7[F_\KUN'^G3_ *M)U4I[
MG#H!]>]^Z]U[W[KW7O?NO=;\O_"3[_LB/Y"?^+497_WTFU??,W[['_3P]K_Z
M5R_]I-SUE)[&?\JW=_\ /2?^K476TM[PUZFSKWOW7NO>_=>Z][]U[KYBO_"@
M3_M[Q\OO^HWI3_X''9_OL#]V'_IQFQ?9=_\ :===88^ZO_*_;A]L/_:/%U3=
M[GOJ/>O>_=>Z][]U[KWOW7NM\S_A)O\ ]DB_)C_Q8^F_]]EA_?-7[[7_ "O.
MT?\ / ?^TB7K)_V*_P"2#>?\] _ZMIUM7^\+>IQZ][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM"7_A6+_V69\<O_%8X
M/_?J;A]]+?N3?\J#NW_2P/\ VC0=8O>^G_*Q6?\ SS?]99.M5[WF?U"'7O?N
MO=>]^Z]U[W[KW6UW_P ),_\ LJKY0_\ BON(_P#?CX_WA1]]O_E2]F_Y[6_Z
ML/U.?L5_R7+W_F@/^KB];X'OFUUD[U[W[KW7O?NO=%K^9U--6_#WY74=.NN>
MK^-?>M-"G)U33]7Y2*-;*">20.![%O(#K'SWLCMP6_LR?L%Q'T3\Q*6Y?OE'
M$V\P_P"J;=?(8]]S^L!^O>_=>Z][]U[KWOW7NO>_=>Z^LG_+&[*QW;?\O+X7
M[YQM1'4K6?'#JK Y.2)@\:[DV3M2GV1NVG4C_CEE,=61$'D%;'D>^)7O!M$N
MQ^Z7,&W2BFF_N76O^^Y9&FB/YQNI_/K.KDR\2_Y3VZY0UK;Q*?\ 3(H1OV,I
M'1Z/<<=";KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[K__T]_CW[KW7O?NO=>]^Z]UK(_\*M_^W>'3
M7_BY_7G_ +X_L7WE]]RO_IZ=_P#]*J?_ +2['J&??+_E4[?_ )ZX_P#JS<=?
M/R]]/NL5>O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>ZWIO^$EO6BXOX[_ "S[A,-I-\=S[,ZW6H*<O%U;L@[F\:.?P&W>2;?G
MZ_3WSA^^[NYFYJV38:XMK26>GSN)O#_[5>LF?8FST;3?[A3^UF2/_G&FK_K+
MUMJ^\(>IWZT$?YE6^O\ 2)\[OD[N#S>=*'L[);*BDU:E\/6]'!UY&(S]--L7
MZ2.#]1]?<3[U+XVZSOZ,5_WGM_R=<*?O%[W_ %@][^9;^NH)>/;@_*T5;44^
M7Z/1'/97U"O7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW6T-_PG;VZ(=L_*?=C1W.2SO5&W892/TC"8_/9*IC1O]J_B$)8?X+_3V..3
MTHD\GJ4'[-1_R]=+O[O_ &_1MO,^Z$?VDMC$#_S36Y<C\_%6OV#K9+]C3KHE
MU\M?^=WN[^^W\U;YGYGR^;[+LO%[1UZM6G^X&P\1L3Q7_P!H_ANBWXM;WV4^
M[O8_N_V6Y?MZ4U6[2_\ .::6;^?B5ZPG]R9_J>>-QDXTD"_[PB)_S[U59[FC
MH#]>]^Z]U[W[KW7O?NO=+'KO>-;UYV!L7?\ C5+9'8V\=L;QH%5M#-6[9S<&
M:I55_P $O MC^/9?NMA'NNUW.V2_!<Q21-]DB%#_ "/2BTN&M+J*Z3C$ZN/M
M4@C_  =?8XPV7Q^?Q&*SN)J%J\7F\;0Y?&U2?HJ<?DJ5:RCJ$_P>-U8?Z_O@
MQ<02VL[VTXTO&Q5AZ,I((_(CKH+'(LL:RH:JP!!^1%1TY>VNK]>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7R-/GAUM#T]\V/EKUA24HH\;LC
MY&]R8'"4X70J[=I-_P!?_=QT0?17H#3NH_ ('ON-[;;LV_>WNQ[PYU/<6-J[
MG^F84\3]CZAU@9S/9C;^8[^R44$=Q*H_TH=M/_&:=%/]C;HBZ][]U[KWOW7N
MO>_=>Z^FK_PGKW(^XOY2/Q<2:1I:G;\_<VVYW8D^C']Z[EFQ\8O^$I)J=!_K
M?[#WR$^]':"U]\-Y*B@E%K(/]M9VX;]K!CUF7[43>-R'95XIXR_LFDI_(CJZ
M;WC]U(O7O?NO=>]^Z]U[W[KW7QT>Z_\ F<O;?_B3=^_^]55^^\G+W_) L?\
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M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZW-?Y$6/\
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MU[K<*_X2/?\ ,Q/F_P#^&7T9_P"[S<_O!#[\7_)*Y=_YJWG_ !RWZR ]AO\
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M^Z]U\Q7_ (4"?]O>/E]_U&]*?_ X[/\ ?8'[L/\ TXS8OLN_^TZZZPQ]U?\
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MPI(9MC?(WOC9<U/8P2[3[>[!VY) 1]#"^'R$)6W^TD>P_>\F<G[F"NY;39W
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MWOW7NO>_=>Z][]U[KZB'\BC_ +=.?#;_ ,,S>O\ []S</OCE]Y#_ *?;O_\
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MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U\\O_A4Q_P!O)-H_^*K]8_\
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M7:"FJJJ)5B&8Q!=*#-4RA2LP2H2,4M52O)V5]G/=+;/=?D^+>[8K'>14CO(
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M^Z]U\='NO_F<O;?_ (DW?O\ [U57[[R<O?\ ) L?^>>'_JVO7/S<O^2C<?\
M-1_^/'H,O9QTBZ][]U[KWOW7NO>_=>Z^HA_(H_[=.?#;_P ,S>O_ +]S</OC
ME]Y#_I]N_P#_ #5B_P"T:#K-3VR_Y47;_P#2/_U=DZMK]PAT/.O>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JG_\ F!?SM/A?\ CEMG[@W-+W
M'WO0Q.D?2/5U70Y',8FNT_M0]A[G<MCMO*"4,L%2\N0$;++%CYD-_<[>V'W>
MO<#W-T7]K"+#;6_XEW *JP\S!'\<_P BH$511I5/0 YJ]Q^7>5M5O*_U%T/]
M!C()!_X8WPQ_,&KTR$/6F9\SO^%!/\P'Y93Y; ;4WS_LL755<TL,&Q^D*VNP
MNY*J@>ZI%N;M=BF<JI"A:.=<?+CZ2939Z/WGUR!]V#VPY)5+F]MOWQ>K0F:[
M >,-_P +MLPJ*Y76)74\).L>>8O=7FK?2T4$OT4!_!"2&(_I2_&?GI**?X>J
M0:ZNK<G6561R5959#(5]1-65U=75$M765E742&6HJJJJG+/))(Y+.[L2Q)))
M/O(B...&-8HE"JH      P  ,  < .HV9F=B[DDG))R2?4GJ+[<ZKU[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=&!^)G_95/QG_P#%@>F?_?C8WV%^=_\ E2]W_P">*Z_ZL2=&
MVQ?\ERS_ .:\/_5Q>OK]>^%?6?77O?NO=>]^Z]U[W[KW7R8OYE^?DW-_,2^<
M^7DD\H?Y:?(&@II+WU4&&[1R>%QQ!/\ TST\?'X^GOMQ[16PL_:OER "G^ZV
MR8_Z9[>-V_XTQZP4YRE,W-NYR'_E*G'Y"1@/Y#HD/N1.@UU[W[KW7O?NO=>]
M^Z]UM^_\)(=M)5=J?-;>!CO)@NO^FMM++;]";LW'GLI)'?\ VHX53;_:?\/>
M"GWX;LILO+UA7$D]U)3_ )IQPK_UE_GU/WL/#JOMQN/X8XE_WIG/_/G6[][Y
MW=9)=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U\\O\ X5,?]O)-H_\ BJ_6/_O>[N]]2?N:?].FG_Z6
M-Q_U9MNL3_>W_E<(_P#GFC_X_+UK<>\L^H?Z][]U[KWOW7NO>_=>ZW"O^$CW
M_,Q/F_\ ^&7T9_[O-S^\$/OQ?\DKEW_FK>?\<M^L@/8;_<O<O])#_P >DZW<
M??/+K)#KWOW7NO>_=>Z][]U[JA+_ (4H_P#;JKL[_P 2=TQ_[W,'O)?[I7_3
MZ+/_ )Y[O_JRW47>\/\ RH\W_-2'_CXZ^;C[ZR]8@=>]^Z]U[W[KW7O?NO='
M/_EO_P#;P_X%_P#BY_Q<_P#?X8+W'_NQ_P!.LYE_Z56X_P#:)-T(N4/^5LVO
M_GKMO^KR=?6L]\0^L[NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KY=_\ /7_[>Q_,G_P]-E?^
M^DV][[&?=O\ ^G);!_S2E_[29^L*_<W_ )7K</\ 3I_U:3JI3W.'0#Z][]U[
MKWOW7NO>_=>ZWY?^$GW_ &1'\A/_ !:C*_\ OI-J^^9OWV/^GA[7_P!*Y?\
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M$.O>_=>Z][]U[KWOW7NMKO\ X29_]E5?*'_Q7W$?^_'Q_O"C[[?_ "I>S?\
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MWM_Y7"/_ )YH_P#C\O6MQ[RSZA_KWOW7NO>_=>Z][]U[K<*_X2/?\S$^;_\
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MH%L/M'Y*X['?*[K6E-/229;.U$6UNZ,30):+R4>^Z"%Z;+&-2TC+G*":IJ&
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MF8@  5))P  ,DD\!UIF"@LQH!DD^77SP/YZ?\Y7-?-;?F8^-7Q[W)5XWXD;
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M#HJ"*^B3/=/U;RY,S, 6,>"FRJ(O+RI]!G7R!]ZKVTYRT6>[R'9+QJ#1=,/
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MI[9?\J+M_P#I'_ZNR=6U^X0Z'G7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJK?\
M"ES^916=']58WX,]0Y]Z'LSO;;SYGN?+8V<K6;5Z3JII<=#M1)X2#%5;IGAG
MAJ!JU+C(*B.2/1D(9!FA]T;VDCYBWI_<;?8M5GMKZ;56&)+L ,9*'BMNI!7R
M,S*0:Q,.H0]X^<6VVQ'+-@])KI:S$<5A-1I^1E((/] $$=X/6A;[Z6=8O=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW1T?BG_ "\/F9\UZY8?CAT)O7?>$2K-'7;\
MGIJ;;'6N*GB<+4PY#L+=,E'B1/$+N]'%5O4D Z(7:P,?<Z^Z?(/M['JYLW.*
MVDI40@F2X8>16",-+0\ Q4)ZL.A'L?*?,/,;4VBU>5:T+_#&/6LC46H] 2WH
M.MB/H/\ X2:]L9FGHLI\F/E+LK81<1S56T>GMHY7L/(&-^6HYMW[JEP5-2SH
M.':'&UL>H$*SK9SBQS-]]K9+=FAY1V:6Y\A+=2K OVB*,3,P/E62,TX@''4L
M[5[%7T@#[S>I%ZI$ID/V:V* '[%8=6D]??\ "73^6]M.& [NSGR*[2K $-4=
MR]CX' 8V60?K%-1[$PF+GBC/X5ZR1A_QT/N&]T^^/[L7K'Z&.QLU\O#@=V'V
MF:60$_8H'RZ&UI[*<H0 ?4-<3GSU2*H_((BD?M/V]&UVQ_((_E*;56,TOQ'Q
M.7J$ #U6Y^T>[=RM.P&DO)29?<DM,"?Z1P*OYM?V![S[S7O?>DZ]\9 ?*.WM
M(Z?FL ;]I)Z/H?:WD2#X; ,?5I)F_D9"/Y=#!0_R=OY8&.C$5/\ "3HF15*D
M&NVQ)E)/3]+S9.>9S_C=N?S?V12>_'O%*:MS%>#[)-/\E '2]?;_ )+04&VP
M_FM?\)/4FH_E _RQ:G4)/A#T NMM1^WV7!2V-[V4TKII'^"V'^'NB^^OO G#
MF*]_.4G_  @]6/(')AX[;!_O%/\ !T@\U_(Z_E29^.2.N^&77D"R@ACA=P=C
M[;D /U\<NW<W2LA_H4(M^/9E;_>*]ZK8@Q[_ #FG\:02?RDB8'\^DLGMKR-*
M*-MT8^QI%_XZXZ+KO;_A-G_*GW7%)'@NJ.Q^M7DU:9]D]T=@5TL1;Z&->Q:O
M/Q\?C4A_QO[%>W?>T]Z;(@W-[!=T\IK2 5_YP+"?Y]%%S[/\CSBD4$D/^DF<
M_P#5POT07MO_ (27]#96*KEZ+^6';.QZFS24=%VIL[:/9U(S_J6FEKMJ-M.2
M-"?2)?#*RCDI(18R9L?WW.9865>9-DMKD>9MI9;<_:!)]2"?E4 ^HZ"]_P"Q
M.UN"=LOI8CY"5$D'V57POVT/Y]49_-'_ (3Y?/'X=[*WCVS]MUYW=T_L7#Y3
M=&ZMY=9;E>ER^UMJ8:D>NR>>W+LO>4..K%CIXHWEG&*;("-!K9P@<KD;[?\
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MVB7 DSFSNB-R(FJS,FU<UNG&2.$_(4YE03^+C^OO!#[\5H7VSER^\HY;R/\
MYR);M_UBZR ]AI@MUN5O_$D+?[R9!_S_ -;MWOGEUDAU[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7SR
M_P#A4Q_V\DVC_P"*K]8_^][N[WU)^YI_TZ:?_I8W'_5FVZQ/][?^5PC_ .>:
M/_C\O6MQ[RSZA_KWOW7NO>_=>Z][]U[K<*_X2/?\S$^;_P#X9?1G_N\W/[P0
M^_%_R2N7?^:MY_QRWZR ]AO]R]R_TD/_ !Z3K=Q]\\NLD.O>_=>Z][]U[KWO
MW7NJ$O\ A2C_ -NJNSO_ !)W3'_O<P>\E_NE?]/HL_\ GGN_^K+=1=[P_P#*
MCS?\U(?^/CKYN/OK+UB!U[W[KW7O?NO=>]^Z]T<_^6__ -O#_@7_ .+G_%S_
M -_A@O<?^['_ $ZSF7_I5;C_ -HDW0BY0_Y6S:_^>NV_ZO)U]:SWQ#ZSNZ][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NOEW_P ]?_M['\R?_#TV5_[Z3;WOL9]V_P#Z<EL'_-*7
M_M)GZPK]S?\ E>MP_P!.G_5I.JE/<X= /KWOW7NO>_=>Z][]U[K?E_X2??\
M9$?R$_\ %J,K_P"^DVK[YF_?8_Z>'M?_ $KE_P"TFYZRD]C/^5;N_P#GI/\
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MW7NO>_=>Z4VRLH,'O+:6;9@JX?<V!RA8@$*,?E8JLL0>#;1[1[A#]383V_\
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M*-Q_S4?_ (\>@R]G'2+KWOW7NO>_=>Z][]U[KZB'\BC_ +=.?#;_ ,,S>O\
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M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HBO\ ,_\ ^W<7SM_\5*[_ /\
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M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7SR_^%3'_;R3:/\
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MPK]S?^5ZW#_3I_U:3JI3W.'0#Z][]U[KWOW7NO>_=>ZWY?\ A)]_V1'\A/\
MQ:C*_P#OI-J^^9OWV/\ IX>U_P#2N7_M)N>LI/8S_E6[O_GI/_5J+K:6]X:]
M39U[W[KW7O?NO=>]^Z]U\R#_ (4'TKTO\WKY;A@=-0W1=5$QL-:3_&W9Q8BW
MX#ZEY_I[Z^_=></[%['3R^L'[+^Z_P G6&?NLNGGZ_\ GX)_[-XNJ8_<_P#4
M=]>]^Z]U[W[KW7O?NO=;N_\ PD?SJU'6GS;VR) 7Q&^NDLZT-^47<6 W'CTD
M(_VLXLC_ )!]\[_OPVQ7=^7KRG]I#=I7_2/ W\O$_GUDE[#RUL]RA_A>%O\
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M^HW_ +N%WUAG[K_\K_?_ /-C_M&AZI@]S_U'?7O?NO=>]^Z]U[W[KW7T=/\
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M*]>]^Z]U[W[KW7O?NO=&!^)G_95/QG_\6!Z9_P#?C8WV%^=_^5+W?_GBNO\
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M]U[KWOW7NO>_=>Z][]U[KYY?_"IC_MY)M'_Q5?K'_P![W=WOJ3]S3_ITT_\
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M52?QK']?>#/WW[ R<O[!NE,0W%Q%7_FM'&]/S\#^74]^Q%QIW'<+3^..)_\
M>&8?]9.MXWWSIZR5Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NM"7_A6+_V69\<O_%8X/\ WZFX??2W[DW_ "H.[?\
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MVYC7J@VUA91"N%%O42_MN#,WV$#-.LSO:_9TVCDVUQ22Y'CN?7Q,I^R,(/\
MB^KDO<"=2%U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7S(_^%"G_ &]_^7?_ )0+_P"!@V5[Z^_=<_Z<5L7_ %&_]W"[ZPS]
MU_\ E?[_ /YL?]HT/5,'N?\ J.^O>_=>Z][]U[KWOW7NOHZ?\)FO^W7&U?\
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M9?\ :1'T&>=/^50W/_GEG_ZMMU\F[WVUZP5Z][]U[KWOW7NO>_=>Z,#\3/\
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M_A6+_P!EF?'+_P 5C@_]^IN'WTM^Y-_RH.[?]+ _]HT'6+WOI_RL5G_SS?\
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M\R4 Z^4][[3=8.]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UML_\
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MK=9=^S?_ "I,?_-:7_".M@?WC!U*O7O?NO=>]^Z]U[W[KW7QT>Z_^9R]M_\
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M# Y2[44N(W1"1*\Y.N2A&IUD+(PJ-('#%7:_<CG)=^BO9+N28/(H:$G])@S
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M('O'O[T>U+N?LINSTJ]J;>=?D4N(E8_\XW?J1_:B[-KSS9BM!*)8S^<;$?\
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M7B(@@_U.F$%3]"+$<>X;NXO!NI(?X'8?L)'7ST\];/\ U>YVWC8*:?HKVZ@
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M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z^9'_PH4_[>_\
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M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZV;?\
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ME943U=95SRU-555,LD]34U,\AEGJ*B>4EG=V)9W8DDDDF_OK^B)&@CC 55
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M_P#*_P!__P V/^T:'JF#W/\ U'?7O?NO=>]^Z]U[W[KW7T=/^$S7_;KC:O\
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M?78V_@</M7 X3:^WJ"GQ6 VWB,;@<'BZ12E+C</AZ),?C*"F0WM'##&D:"_
M ]\-KJYGO;F2\NF+RRLSNQXLS$LS'YDDD]9ZQ11P1+!$-*( J@<  * ?D.G?
MVQTYU[W[KW7O?NO=>]^Z]T17^9__ -NXOG;_ .*E=_\ _OL<E[D?V>_Z>ORW
M_P!+*R_[2(^@SSI_RJ&Y_P#/+/\ ]6VZ^3=[[:]8*]>]^Z]U[W[KW7O?NO=&
M!^)G_95/QG_\6!Z9_P#?C8WV%^=_^5+W?_GBNO\ JQ)T;;%_R7+/_FO#_P!7
M%Z^OU[X5]9]=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6O-_PH'_ )7T_P V>@*?
MOCI[;HR/R8^/.'R-;08['4VO+=H]4(SY7<FP(HX1Y*G(4$ADRN B]3-*:NCB
M0RUZLF4GW8/>)?;WF<\M;]+HVC=&4%F/;;W.%CF-<*CBD<QP -$C&D1!B?W5
MY*/,FU#=-O2MY: D <9(N+)\V7+(/74H%7Z^<\05)5@0P)!!%B".""#[ZK\<
MCK$CKKWOK77O?NO=>]^Z]U[W[KW7O?NO=6]?RW_YS_RN_ETUE'M7;^13M[X^
M2UK5&6Z)WWDZP8G'"IJ#45U=UMN-5GJ-N5DK-([B"*:AE=WEJ*&>;3(D%^['
ML!R5[JQM>W2?0[H!1;R%1J:@H!/'A9U& *E9% "I(JU!'W*'N)OG*+""(_46
ME<PN30>IC;)C)^0*DFI4G/6\]\'OYT?P4^<]+B,+LWLVDZN[>R @IYNE>X*G
M&[0WE/DY%"M2;1KYIFQF?#OK,*XJLEJ3&NN>EIR= YR>XOW?_<CVX>2XO[,W
MEBM2+NU#2Q!?650/$AH*5\10E<*[<>LF.6O<7ECF95CMYA!<'_092$>OHIKI
M?Y:26IDJ.K8_<)=#KKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z^>7_PJ8_[>2;1_P#%5^L?_>]W=[ZD_<T_Z=-/_P!+&X_ZLVW6)_O;_P K
MA'_SS1_\?EZUN/>6?4/]>]^Z]U[W[KW7O?NO=;A7_"1[_F8GS?\ _#+Z,_\
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M^Z]U[W[KW7O?NO=>]^Z]UH2_\*Q?^RS/CE_XK'!_[]3</OI;]R;_ )4'=O\
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M2\-7E]V9.'?>^UI96%EFH:;%X)7(]6BNMPK,#@C]]KFE(MKV;DN%N^:1[R4
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MEH>SL<9E 0U W#3UV1>-0"D-=3W'J#-UP^ZYSJ.;_:BTM)WU7.T$V4E3G1&
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MK_A6=\9L5%4CJ'XK]Y;ZJ$5A3?Z1-R[#ZNI9Y0+*9)=N3;ND1"?SXBUOJH/
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MW<MA:CS\2XD8_D(H) 3_ +8#Y]%-S[U\GP_V*7$Q_HQJ!_QN13_+JJ;YO_\
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M?B'X&-?A/;J:>\V^H)Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>]=>ZLR^,O\
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M7NMKO_A)G_V55\H?_%?<1_[\?'^\*/OM_P#*E[-_SVM_U8?J<_8K_DN7O_-
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MU_\ M['\R?\ P]-E?^^DV][[&?=O_P"G);!_S2E_[29^L*_<W_E>MP_TZ?\
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M7NO>_=>Z][]U[KWOW7NMKO\ X29_]E5?*'_Q7W$?^_'Q_O"C[[?_ "I>S?\
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M-@R,/FK $?,=3'<00W4#VMPH:.12K*>!5@00?D02.ODJ_.+XN;C^&'RO[O\
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M Z][]U[KWOW7NO>_=>Z.?_+?_P"WA_P+_P#%S_BY_P"_PP7N/_=C_IUG,O\
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M.S-^=08O:>U)MWY';5+G\GG(MY4F:GI9]GTU;+EZ,)3Q,[25]%"A-E4LUP,
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M]^Z]U__7W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UI3?\
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M2?P![T2%&IC0#K8!)H.ACVM\<OD+OGQ_W*Z'[FWAYK>+^ZW5^]]P>6_T\?\
M":&;5_L/9!>\U\K;=7]X;E:P4X^)<0I_QYQT80;1NUS_ +C6LTG^EC=O\"GH
MR^T/Y57\R7?)C_@/P=^34*3%?%/N7J3=NR:60-^EUJ]Z4^/B*'ZZ]>FW-[>P
MC?>]'M+MU?J>8]O-.(CN8IC^R)G-?E2O1S;\C\X7/]EMMQ_MHF0?M<*.C4[.
M_P"$]G\VC=YADD^,=/M*BF*VK]X]N],XH1ZOJ9L72Y^IR"V^IO1_ZUS<>P7?
M_>B]D;&H&\&=AY16MTW[&,*I_P :Z/+?VHY[N,FR\,>KRPC^0<M_+HX.QO\
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M[N.*.9#&C!&)E0H#5@1BM3CH)<[<N3<U[!)L\$HA9V1M3 D=K5I09SUJ[_\
M0)1WO_WF!U)_Z+K>/_U9[S%_X-[EO_HQ7/\ SGB_Z!ZA7_6(W/\ Z.$7_.-_
M\_7O^@2CO?\ [S ZD_\ 1=;Q_P#JSW[_ (-[EO\ Z,5S_P YXO\ H'KW^L1N
M?_1PB_YQO_GZ]_T"4=[_ />8'4G_ *+K>/\ ]6>_?\&]RW_T8KG_ )SQ?] ]
M>_UB-S_Z.$7_ #C?_/U[_H$H[W_[S ZD_P#1=;Q_^K/?O^#>Y;_Z,5S_ ,YX
MO^@>O?ZQ&Y_]'"+_ )QO_GZ'/XO_ /"8/NCH'Y+?'CO?*_*CJ_<.,Z4[SZE[
M;R. Q^PMUT=?G*#KC?V/WC68>BJZFJ:.*:ICHF@CDD4JK,&8$ CV'.<?OA<O
M\S\H[KRW#LMQ$^X6=S;*[31E4:>%X@Q 6I"EZD#) Z,]E]E]QVK>;3<WOHW6
MVFBE*A&!81NKD UP32G6Y-[P)ZR$Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM3#^8+_PG'[=
M^9WS%[P^3FW?DMUQLC#=L9W!9>AVMFMD[GRF3Q$>(V;C=KR0U=?0U*12%WH6
ME!1  K@'D'WFY[7_ 'KMCY Y#V[D^ZVB>XDLD=3(DT:JVJ622H4J2*!Z9/EU
M!/-?M%?\Q<P7.\PWD<:SLI"E&)%$5<D&GX:]$U_Z!*.]_P#O,#J3_P!%UO'_
M .K/8]_X-[EO_HQ7/_.>+_H'H/?ZQ&Y_]'"+_G&_^?KW_0)1WO\ ]Y@=2?\
MHNMX_P#U9[]_P;W+?_1BN?\ G/%_T#U[_6(W/_HX1?\ .-_\_7O^@2CO?_O,
M#J3_ -%UO'_ZL]^_X-[EO_HQ7/\ SGB_Z!Z]_K$;G_T<(O\ G&_^?KW_ $"4
M=[_]Y@=2?^BZWC_]6>_?\&]RW_T8KG_G/%_T#U[_ %B-S_Z.$7_.-_\ /UL5
M?R>/Y;N[_P"65T+V3T_O/LW;?:60WUV[6=E4V9VQ@\I@J.@HZG9F(VNN,GIL
MK+*[RA\:\ID5@NEU%K@^\5O?CW9L?=[F6TWVPLY+);:U%N4D=7+$2RR:@5
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M\8MSW;=-[O7W+>;F6[N),M+-(TDC?:[DL?S/4JVMI:6,"VUE$D,:\%10JC[
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M]MW,W_'G/2!N2.3WR=LMORA0?X .FZ'^4U_+0@+%/@W\:FU  ^;J[;E0./\
M4BHB:W^P]NM[V^[K<>8[_P#*XD'^ ]4'(G)H_P"69;_\XU_S=/-'_*X_EO4%
MO!\%/BB^FUOO.BNNLC]"2+_Q#'RW^O-_K^?H/;$GO)[L2?%S)N0^R\G7_CKC
MIU>2N4%X;9:_G#&?\*GI=8KX!?!'!:#A/A5\2L0T?Z&QGQQZ>H74WN2'IL,I
MN3R3>Y//LMG]SO<FY_W(YAW*2O\ %?71_P ,O2F/E;EB+^SVZU7[+>(?\^="
M_M_H7HS:9C;:O2_4^V6A(,3;?ZZV?AC$5_28SCJ./3;\6]D5US+S'?5%[N%S
M-7CKGE?_ (\QZ,(MKVR#^PMXDI_#&@_P#H58XTB1(XD2..-0B1QJ$1$46545
M>  . ![)2234Y)Z7  "@ZY^]=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NF;.;=V_N>A?%[E
MP6&W#C);^3'9S&466H9+BQUTE>DD9XXY7VHMKNZLY!-:2/$X_$C%3^U2#TW+
M#%,NB90X]& (_8>BU;I^!_P?WNSR;Q^'/Q:W/-(26J<[T!U3DZL,?JZ5E7B6
ME5O]J5P?\?8ML_<KW$V[%AOVXPCT2]N5'[!)3^71-/RQRU<YN-OMG/JT$1/[
M2M>@0S'\H3^6-G'9ZWX0?'V!FO<8?9%)MY!<W],> :F4?[ #V(H/?3W@MA2/
MF*]/^FF+_P#']71;)R#R9+EMM@'V(%_X[3I"U'\D#^5/52&67X8=;JQ_%/F>
MP:./ZWXAI,RB?\F^S)?O$>]*"@Y@G_-8#_,Q$])F]MN1V-3MT?Y&0?X'Z;H_
MY%?\IV-U=?AKLDLM["3>/;$J<BWJCEW 5/\ L1[=/WC_ 'L(H=_F_P"<5L/^
ML/5![9<BC/[O3_>Y?^@^E)C/Y*W\K'$,KTOPKZDE*<@9,;HS:GD'U)F<C4!O
MI_:!_P!Y]I)OO!>\TXH_,%R/]+X:?\<1>GD]NN2(_AVZ+\]1_P +'H9=L?RS
M_P"7AL]TEP'P?^*E/416,596=$=;9FOA(X#0Y#-8ZHG0_P!2L@)_/L@O/=WW
M3OQINN8MQ(/$"\G13]JHZ@_LZ,(>3>4[?,6VVP/J88R?VE2>C3[.ZQZUZZ@^
MUZ^Z]V/L6F\?B^WV=M/ ;8@\7_'/PX2G@73P.+6]@R_WC=]U;7NEU-<GC665
MY#^UV/1Y;V5G:#3:Q)$/Z"JO^ #I<>R[I3U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U__1W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW6J__ ,*9/Y=#]V=+8OYP]78+[GLSX_89L1V[1XZFU5FZ>CVJ
MWK%W!*D0+23;5JYI:J1M(MCJFMEE?11PI[S-^Z)[K#E[F!_;K>9:6>Z/JMBQ
MQ'=T T"O 7*@*/\ AJ1A161CU"/O)RB=RVY>9;):S6@I* ,M#6NK[8B2?](6
M)/:.M"3WTOZQ=Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z7?5O9&Z^G>R^
MO^VMB9 XK>O66]-L[]VGD1J(H]P[2S,.=Q$\B(5+()X$\B7 9;J>"?99O.TV
M6_;1=;)N2Z[>\BDAD7U25"C#Y&A-#Y'/2JRO)]OO(K^U.F2%U=3Z,I##^8Z^
MN5\8N_=H_*7X]]/?(;8LBG;/;FPL!O*DI!.M1+AJ[(T@7.[:K9D 4U6*KTJL
M;5VX$T$@'T]\.N<.6;[DSFB_Y6W+^VL9GB)I0.%/9(!_#(A61?Z+#K//9=TM
M][VFWW:U^"X17 ]"1W*?FK54_,'J-\INB,+\F/C]VGTCF_!$F^MK5E%A\A4(
M7CPVZJ%ERNT<Z0H+6H\G!2U#JO+(C)>S'V$+ZU6]M)+5_P 8Q\CQ!_(TZ"_N
M;R/9^X_(>Y\F7M +Z%EC8\(YUH\$GK^G,J.0.(!'GU\\C<FW<UM#<6?VGN3'
MSXG<6U\UE-NY[%52A:K&9K"5TF-RF/J5%[20SQ21N+_4'W$#HT;F-Q0J2"/0
MC!ZX#;CM]YM.X3[5N,9BN+:1XI4;BDD;%'4_-6!!^8Z9/=>D?7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=.N#S>7VUFL/N/
M9&KQ&=P&4Q^;PF6H)FIZ[%Y?%5:5V-R-%.G*2P31I+&XY#*"/I[LK,C!T-"#
M4'T(X=*;*]N]NO(MPL)&BG@=9(W4T9)$8,CJ?)E8 @^1'6_I\#OE9AOF'\<-
ME]K4\M)#N^GA&UNS\)2E4_@G8.%IXUS*I3K?QT]:KQ9*B6YM3U$:,Q=' EC:
MK]=QLEG'Q<&'HPX_D>(^1Z[L^QWNC9^[?MY9\T1E1=J/!O(Q_H=U&!XF/))
M5FC&:1R*"=0:AK-S[9V_O7;6X=G;MP]!N':N[,'EMM;EP&5ITJ\7F\!G:"3%
MYC$9&EDNLL%33RR0S1L+,C$'Z^SNSO+K;[N*_L9&BF@=9(W4T9'0AE93Y%6
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M6AF#2-+)2M15DFDU84=BO8;W4A]U.1XK^Y8?O*STPWJ"@/B =LP7R2=1K&
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M?Y:G_"E+N+H6/ =1_-VEW!W]U-3?:XS%]M4,L-5W?LFB6T*-GY:]XXMUT<0
M+-63Q9)07<UE85BIO>&_NW]TG8>93+OGMVR;9?&K-;&HM)CQ[-()MF/]$-"<
M#PXZE^IKY.]X=PVL)8<R!KJ 4 E&9D']*N)0/F0_$ZFP.MW/X]?);H?Y6==8
MWM;X]=G[5[2V-D@B?Q7;==Y*K$UKQ"9L/N7"52Q5V*KXU93+09*F@J$!!:,
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MG&J*1:/$_P#2C96IBM,=&NS[WNNPW8O=HG:"0<2IPP]&4U5E^3 CK<U_E_\
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M"^]5_P"TW,/A7A:;9KQ@+J$9*'@+F(?[\0?$H_M8QH/<(V2/?<'D:WYPVW7
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M=Z?)/IS$Y6E=HZO$0[YPF9S-'(ALT59B,'+4U,+<?IDB4_X>T$NZ;= =,LR
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ME3<(AJA99/E6A_GC^?0-YI^XU[J;/ UUR]=6>[A1_9J[6\[?Z59E$/[;@'R
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M.*H:W)Y.LI,=C<=25%?D,A7U$-)0T%#1PFHJZRLJZ@K'%%%&K/)([!54$D@
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MR4L#T=/E<-+<5,D*"8DA#3:5WBTW*.R8O&"<J<J5&6I6HX8J/.G19[$V7O\
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M?[1?\)ZY _??_P"GU+_TKK7_ (_/UM'_  >_[(Q^)G_BMW2?_ON,=['6U_\
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M;*6DD<T 'D .+,QHJ(H+.Q"J"Q Z7;=MU[NU['M^W1F6:4T55XGYGR  R2:
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M%%0*BJH'#VJZ&G7O?NO=>]^Z]UCBBB@BC@@CCAAAC2*&&)%CBBBC4)'''&@
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MNT)X=K8PQP1+Z)&H1:^I(%6/$DDG)Z67MSHWZ][]U[KWOW7NO>_=>ZU8?^%
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M*0U_4B 4CSH,!OF"*5^?6;/W6/=K9?<'VVL=A,RKNVS01VUQ 2-;1PJ(H;A
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M9:JB)U>"9:FB9Y&I3+)QX]\/:._]IN;7L%#2;9=%I+.8YU1US$YX>+#4*_\
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M09KAQY(I^%!C7*U$0'S8JC"CE;E+=^;;[Z3;4HBT\25JZ(P?,GS8_A0=S?(
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M/-,VV]_4 1-=1Y-K9CQU%1'#])*JA\].#])C<>Q=9[I8WX_Q:0$_PG#?L/\
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M:#=?^29<?\TW_P".GJ+O>_\ Z<YS3_TJK_\ [1I.M7G^1#_V7)4?^(5[ _\
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M>Z1K66SD8%\<7@;'C1>I #I_HB+52V)7.7(&\<GSEY1XUHQHDZC'R609T/\
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M6YA-585^SU!^8.#UV5Y(YRV3G_E6RYOY>D\2UO8PZUIJ1N#Q.!6DD3AHW%2
MRFA(H3J3?SWO^RY*?_Q"O7__ +M,O[C_ )J_Y*G^T7_">N5?WW_^GU+_ -*Z
MU_X_/UM'_![_ +(Q^)G_ (K=TG_[[C'>QUM?_)-M_P#FFG_'1UTQ]EO^G/<J
M_P#2IV[_ +1(NC2>UW4F]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6D1_.HQ$V-_
MF$=KULL>A-P;9ZMR],W_ !UAAZZQV!:0<#Z24,B_GZ?7\",>95T[O(?4*?\
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M^O'OW[@VC_? _:W^?KW_  +?L)_TSD/_ #FN_P#MHZ]_PU#_ "]_^\:ML_\
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M_P#M&DZU>?Y$/_9<E1_XA7L#_P!VF(]@;E7_ )*G^T;_  CKFE]R#_I]3?\
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M=SYR6)FQFU]M4#LIJ:ZK=2L: A44/-,T<$4LB);R\@L8&N+@T _:3Y >I/\
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MO&Q:!?C'<O\ IA_G%1^?4*^__M@/=CVSO>6[<#ZZ*ES9DT%+F$-I2IP!,C/
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MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JP;X2?RO\
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MZ]U[W[KW09=U_P#,FNV__$9;]_\ >5J_;%S_ +C2?Z5O\!Z#?.7_ "J&Z_\
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M8NE7"=8]8XBNE DE(NF,P],0B"6JJ934U1C17DJ9@@(<9MTWVY\Y#Z#"J/\
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MG *#ZF$+%=*/5D[89J#A_8L<EG8]0MS+[*;9>EKGEN7Z60Y\)ZM$3\FRZ?\
M&QY!0.M1?Y<?RYOF5\'LM/1_(KH_=>U-OBL^TQO8^*IQNCJW.-))HI?X9O\
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MV&*VE;\=H\EI0GB?#@=(2?\ 31'HKF0_D)_"6MG:6FW#WYB8V?4*7'[ZVG)
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M/:69H=LQS^:IZ^W"W]YNOJW6_DJ%.V,J7BI7E/\ G:G'-35!X'F'LPLMUOK
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MFIH9:BHJ)8X(*>"-Y9IYI6"10PQ1@LS,Q 55!)/ ]^ )-!U9$>5Q'&"S,0
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M]2/:B"TNKDTMXV?[ 2/V\.A;RYR%SOS>X3E?:+R_J::H+>61!_IG52BCU+,
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M$/["_D[_  "W^T]1'TY4[%R-1JU9#KW>.ZL L>KZ>#"5-558J.Q^FF@']#<
M#V53<N[3-GP]!_HDC^52/Y=0?O\ ]TCV)WTM(NT&QD;\=K<3Q4^R,N\ _*+H
ME.^/^$]/261,S=<=_P#:&T6?4T2;RV_M7?T,)/(6V&&W791]!=[V^I)Y]EDO
M*%JW]C,R_: W^#3U#>]?<&Y,N*GE[?KVTKP^HB@N@/\ G'](2/SK\^BE;O\
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M4B#XW?(FJ-J;H3NFI-R+0=6[YF-P-1'[="?H.?>Q97AX1/\ [RW^;IQ/;OW
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0W7O?NO=>]^Z]U[W[KW7_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
